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Abstract
Français
Ce travail de thèse s’articule autour de trois parties distinctes abordant chacune un thème précis lié à
l’épidémiologie. La première partie de ces travaux s’inscrit dans le cadre de la propagation de virus via
l’utilisation de modèles épidémiques. Dans cette partie, sont analysés diﬀérentes méthodes d’estimations
paramétriques et y sont étudiés la qualité de ces estimateurs. Une application à des virus informatiques
est proposée. La deuxième partie de cette thèse propose une méthode d’estimation de la prévalence
actuelle du virus de l’hépatite C en France par l’intermédiaire d’un modèle de rétro-calcul associé à
un modèle de Markov modélisant l’histoire naturelle de la maladie. Cette méthode et les résultats qui
en découlent sont comparés avec les résultats obtenus via l’approche de référence en France. Enﬁn, la
dernière partie s’intéresse à l’étude de l’impact des nouvelles thérapeutiques anti-hépatite C susceptible
d’éradiquer le virus à moyen terme. En assimilant la population d’intérêt à un groupement de graphes
aléatoires, la propagation du virus est modélisée à partir d’un modèle de métapopulation construit sur la
base de données migratoires où les dynamiques de chaque sous-population sont régies par un ensemble
d’équations diﬀérentielles déterministes. Ce travail doctoral a été réalisé dans le cadre dune convention
CIFRE avec les laboratoires Bristol-Myers Squibb.
Mots clé : modélisation, modèles compartimentaux, statistique, hépatite C, modèles dynamiques,
épidémiologie.
English
The works undertaken in this doctoral thesis are conducted in three parts, each one dealing with a speciﬁc
epidemiology-related domain. The ﬁrst part of this work deals with the propagation of viruses by using
well-known epidemic models. It is mainly focused on the analyze of diﬀerent estimation methods and on
their performance. An application on computer virus is proposed. The second part of this thesis gives
an estimation method of the hepatitis C virus prevalence in France based on a back-calculation model in
association with a Markov model of the disease’s natural history. This method and its results are com-
pared with those generated by the reference approach in France. The last part is focused on the study
of the recent anti-hepatitis C therapeutics impact on the population since is has been stated that those
could eradicate the virus at middle term. In that optic, based on published migration data and assuming
that the population of interest is organized into a set of speciﬁc contact networks, a metapopulation is
computed in which the dynamics of each sub-population is governed by a set of deterministic diﬀerential
equations. This doctoral research has been conducted through a CIFRE industrial research agreement
with the Bristol-Myers Squibb pharmaceutical company.
Keywords: modeling, compartmental models, statistics, hepatitis C, dynamic models, epidemiology.
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Introduction
Introduction
From time immemorial, mankind has been struck by a countless number of deadly infectious diseases
devastating the population at the time. Indeed, history is littered with example of epidemics responsible
for the annihilation of a non-negligible proportion of the civilization. For example, the Plague of Justinian
resulted in the death of an estimated 25 to 50 million people between 541 and 542, the Black Death wiped
out an estimated 75 to 200 million people between 1346 and 1353, the Spanish ﬂu killed an estimated 50
to 100 million people between 1918 and 1920 and, more recently, it has been estimated that the human
immunodeﬁciency virus (HIV) epidemic has contributed to the death of about 34 million people since
1981.
To better understand the mechanisms of epidemics, such as vector identiﬁcation or transmission rate
estimation, and to anticipate their evolution, epidemiologists have constantly called upon mathematical
modeling, improving the methodology at the same time. Hence, epidemic mathematical models have
become the main tool for describing the spread of communicable disease through populations and for
evaluating strategies to control the epidemic.
Though Daniel Bernoulli was considered the ﬁrst to provide an epidemic model for the spread of
smallpox in 1766, most of the existing work in this area was conduct during the past century. Indeed,
one of the most signiﬁcant breakthrough into epidemic modeling is the introduction of compartmental
models in the early 1900s by Kermack and McKendrick (1927). Compartmental models assume that the
population of interest can be stratiﬁed into several compartments, typically infected and non-infected,
interacting with each other over time. The most well-known compartmental model is the SI model where
people can enter two successive health sates: susceptible (usually denoted by the capital letter S) which
corresponds to the people susceptible to the infection and infected (denoted by the capital letter I) which
represents the infected population. Several adaptations of the SI model such as SIR (where R stands for
recovery) or SEIR (where E stands for exposed) have been developed ever since including more complex
dynamics.
Widely used for the spread of biological pathogens, epidemic models have also been used to describe
the propagation of malicious software on Internet. In 2002, Zou et al. (2002) proposed an adaptation
of the classic compartmental model developed by Kermack and McKendrick (1927) to the outbreak of
version 2 of the Code Red worm (CRv2) on July 19, 2001.
Going back to biological viruses, the main subject of this doctoral thesis focuses on the spread of
hepatitis C virus (HCV). Hepatitis C virus is a blood-borne virus which slowly destruct the liver in a
process called ﬁbrosis. With an estimated number of chronic carriers reaching 80 million worldwide, the
management of HCV has become a major challenge since the end of the 1900s. In France and in all other
developed countries, the population at risk is injecting drug users (IDU). For European countries, the
proportion of new HCV infections in the population of IDU has been estimated to 76.5% in 2012 (see
European Centre for Disease Prevention and Control (2012)).
With the arrival of new therapeutics (second-generation direct-acting antivirals or 2nd-gen DAAs)
on the market, it is expected that the prevalence of HCV should signiﬁcantly decrease since those new
therapeutics admit very high sustained virology response (SVR) rates whatever the genotype of the dis-
ease or the patient health state. With an estimated infected population of about 200,000 individuals in
France, it is highly necessary to measure the impact of the 2nd-gen DAAs on the infected population and
to answer the question: "Are we able to deﬁnitively eradicate hepatitis C virus and, if so, when?".
This doctoral thesis, conducted through a CIFRE industrial research agreement with the Bristol-Myers
Squibb pharmaceutical company, proposes to explore three diﬀerent problematics, each one dealing with
a speciﬁc epidemiology-related domain. The problematics considered in this work are not necessarily
directly connected with each other but are closely related to the mathematical modeling of epidemics.
Those three parts are preceded by some reminders of the diﬀerent mathematical tools used in the thesis
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(models, estimation methods, etc) and a review of diﬀerent epidemic models based on the compartmental
SIR framework originally introduced by Kermack and McKendrick (1927). Starting with the determin-
istic compartmental model, we review its stochastic counterpart as well as Markov models. We ﬁnally
review some extensions of the deterministic compartmental model on contact networks.
The second part deals with the propagation of viruses by using well-known epidemic models. Based
on a logistic model, Staniford et al. (2002) introduced the random constant scanning (RCS) model to
describe the propagation of Internet worms assuming a scanning rate (worm’s contact rate) constant over
time. Few years later, Kirmani and Hood (2010) proposed to remove this limitation and develop a more
realistic model by introducing the nonhomogeneous random scanning (NHRS) model where the expected
number of hosts infected during [0,t] is given by:
I(t) =
N
1 + ψ exp
(
− ∫ t0 β(u) du)
with N being the size of the population considered and β the scanning rate. Similarly, Kirmani and
Hood (2010) oﬀered an analytic expression for the cumulative distribution function (cdf) of the time
until infection of an initially uninfected host (T ) for their NHRS model. The objective of this work is to
tackle some problems of estimation of β(t) and the cdf of T by studying various estimation methods, such
as the least squares, maximum likelihood, and Kaplan-Meier methods and analyzing their performance.
An application on the datasets of the outbreak of version 2 of the Code Red worm (CRv2) and of the
outbreak of HIV in France since 1982 is proposed. The work undertaken in this part is currently under
minor revision for Communications in Statistics - Simulation and Computation.
The third part of the thesis is focused on the estimation of the prevalence of HCV in France. As
new therapeutics emerge, establishing successful strategies to eliminate the virus requires an accurate
estimation of the size of the infected population. Hence, we propose to estimate this prevalence by ﬁrst
estimating the past incidence of the disease in France. To do this, Deuﬃc-Burban et al. (1999) used a back-
calculation method based on the weighted least squares method and associated with a Markov model
of the diseases natural history. Using a dataset of the annual number of death due to hepatocellular
carcinoma (HCC), a direct consequence of HCV, Deuﬃc-Burban et al. (1999) proposed a parametric
model for the past incidence of HCV such as:
f(t;α, β, γ) =
⎧⎪⎪⎨⎪⎪⎩
exp(a(t − t0))
b + β−1 exp(a(t − t0)), for t < 1990
0.6 × exp(a(t − t0))
b + β−1 exp(a(t − t0)), otherwise
with a = 4 × α × β−1 and b = β−1 × exp(a(γ − t0)) where α is the slope of the curve, β the asymp-
totic plateau value and γ the year of mid-epidemic. In 2014 and for the particular case of Taiwan,
McEwan et al. (2014) proposed to apply the back-calculation approach used for the HIV past incidence
reconstruction introduced by Becker and Marschner (1993). This approach, based on the expectation-
maximization-smoothing (EMS) algorithm developed by Silverman and Nychka (1990), assumes that all
infections are independent random variables following Poisson distributions. The main goal of our work is
to propose an adaptation of the approach developed by McEwan et al. (2014) to the French national data
of the observed number of deaths due to HCC. Along with this, we introduce some parametric models
based on well-known epidemic models from the literature to give an alternative approach of the work of
McEwan et al. (2014). After a large work of formatting the data, to ensure that we only focus on HCC
deaths related to HCV, comparisons are made with the results generated by the reference approach in
France. The work undertaken in this part has been submitted to Statistics in Medicine.
The fourth part of this thesis is focused on the construction of a deterministic compartmental model
of the spread of HCV in France. The main objective of this work is to estimate the impact of the
new therapeutics anti-HCV on the whole infected population of France. To do this, we distinguish
two parts in this work. In the ﬁrst part, we consider the transmission of HCV and its natural history
in a simple compartmental model. A particular attention is however given on HCV/HIV co-infected
individual. Then, we subdivide the whole country into several sub-populations, corresponding to the ﬁrst
hundred largest French urban areas, and assume that the sub-populations interact with each other via
an original metapopulation model and French migration data. As IDU represent the population where
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the large majority of new HCV infections occur, we focus our model on the IDU population. To take into
account the heterogeneity in contact pattern of the IDU population, each sub-population is assumed to
be organized according to a contact network. First conclusions are drawn from the results obtained with
this simple model, ﬁrst on a toy-country with just three cities and then on the network of France’s 100
largest urban areas.
The second part of this work allows for an enhancement of the previous compartmental model by
adding new features such as the natural history of HCV (ﬁbrosis stages, decompensated cirrhosis, etc),
the main genotypes of the disease (stratiﬁed between genotype 3 or non genotype 3) and the possibility
for an individual to cess the use of injecting drugs. Last, to track the evolution of people leaving the IDU
population after cessation, an alternative compartmental model is computed. Assuming those people does
not participate in the force of infection anymore, no transmission rate is considered in the alternative
model.
Last, we want to emphasize the fact that only the work related to the doctoral thesis is presented
in the following chapters. Indeed, those last three years also provided several opportunities to apply
statistical modeling in various contexts, such as clinical trials (survival analysis) or health economics
(Markov modeling), which are not reported here.
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1 Preliminaries
Français
Ce chapitre a pour but, d’une part, de donner quelques rappels théoriques sur les concepts mathématiques
et les méthodologies employées dans cette thèse de doctorat et, d’autre part, d’introduire quelques modèles
épidémiques. Concernant ces dits modèles, nous nous focalisons en particulier sur la structure épidémique
Susceptible-Infected-Recovered (SIR) aﬁn de présenter quelques modèles bien connus et d’en introduire
des plus complexes. Dans le but de mettre en lumière les similitudes structurelles de ces modèles, nous
en présentons, de manière informelle, les équations de dynamique des populations.
English
This chapter is meant to give some theoretical reminders on the mathematical concepts and methodologies
addressed in this doctoral thesis on the one hand, and to introduce several epidemic models on the other.
Regarding those epidemics models, we focused on the particular Susceptible-Infected-Recovered (SIR)
disease spreading framework to give an overview of some well-known models and to introduce more
complex ones. To highlight the structural similarities of those models, we introduce, in an informal
manner, the equations governing the population dynamics.
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Résumé
Ce premier chapitre oﬀre une présentation des modèles et concepts abordés tout au long de ce travail de
thèse. L’essentiel des travaux de recherche qui ont été entrepris dans cette thèse se sont orientés dans
trois directions diﬀérentes et ont ainsi fait appel à des méthodologies variées. Aussi nous nous proposons
dans cette partie de donner une description sommaire des méthodes utilisées.
Ce chapitre est divisé en deux parties. La première partie se focalise sur la description de quelques
rappels théoriques employés tout au long de ces travaux. Nous présentons ainsi brièvement les diﬀérentes
méthodes paramétriques ou non-paramétriques statistiques utilisées dans le Chapitre 2. à savoir la
méthode des moindres carrés, la méthode du maximum de vraisemblance et celle de Kaplan-Meier.
Nous décrivons ensuite l’algorithme d’espérance maximisation (EM) et son extension l’algorithme
d’espérance maximisation lissé (EMS pour expectation maximization smoothing) principalement em-
ployés au Chapitre 3 pour l’estimation de l’incidence passée du virus de l’hépatite C.
Enﬁn, nous donnons ensuite une rapide description de la théorie des graphes aléatoires et de son
application en épidémiologie. Après en avoir présenté quelques-unes des principales propriétés, plusieurs
modèles de graphes célèbres sont décrits. On retrouve en particulier les modèles d’Erdős-Rényi, de Watts
et Strogatz et de Barabási-Albert.
La seconde partie de ce chapitre oﬀre une description sommaire des modèles compartimentaux utilisés
en épidémiologie. En se basant sur le schéma infectieux du modèle à trois compartiments SIR (susceptible,
infected, recovered), nous donnons quelques éléments de théorie de ces modèles et présentons les équations
qui régissent les dynamiques de population. Nous introduisons ainsi le modèle classique déterministe et
sa contrepartie stochastique. Nous introduisons également les modèles épidémiques Markoviens en temps
discret et en temps continu.
Enﬁn, nous traitons de l’extension du modèle déterministe classique sur un graphe aléatoire. Concrète-
ment, il s’agit d’un graphe aléatoire généré via une distribution de probabilité sur lequel sont appliquées
les équations diﬀérentielles du modèle déterministe classique. La principale diﬀérence avec le modèle
classique est que les individus ne peuvent plus entrer en contact, et donc infecter, n’importe quel autre
individu. Chaque individu est limité à son nombre de voisins (ou degré). Dans cette partie nous faisons la
distinction entre l’approche homogène où il est supposé que tous les individus possèdent le même nombre
de voisins et l’approche hétérogène où cette dernière hypothèse est relaxée. Cette dernière approche est
utilisée au Chapitre 4.
Cette seconde partie se conclue sur un tableau comparatif reprenant les caractéristiques principales
des diﬀérents modèles épidémiques.
1.1 Theoretical reminders
In this section we introduce some fundamental information that will be used as reference for the diﬀerent
works undertaken in this doctoral thesis. We successively give an overview of several estimation methods,
of the random graph theory and present some well-known contact networks.
1.1.1 Least squares estimation
The method of least squares, ﬁrst published by Adrien-Marie Legendre in 1805 (see Legendre (1805)) but
credited to Carl Friedrich Gauss in 1795, is a well-known estimation method. This method consists in
estimating the parameters of a mathematical model by minimizing the sum of the squares of the errors
between the observed data and the data predicted by the model. In other terms, we look for the value of
the parameter which describes at best the data.
For illustrative purposes, we propose to introduce the least squares method in the context of simple
linear regression where a response variable Y is explained by a covariable X independent of Y via a
linear relationship. Let us denote by (x1, y1), . . . , (xn, yn) an observed sampling of n covariables and
their responses and by f(x, β) a parametric model, also called regression function, such as:
yi = f(xi, β) + εi = β0 + β1xi + εi, for i = 1, . . . , n (1.1)
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where β0 and β1 are the parameters of the model and εi a disturbance term. The least squares estimator
of β is the values of β0 and β1 which minimize the quantity:
S =
n∑
i=1
(
yi − f(xi, β)
)2 = n∑
i=1
ε2i . (1.2)
To do this, one must respectively look for the values of β0 and β1 which nullify the partial derivatives of
(1.2) with respect to β0 and to β1.
The least squares method is probably the most popular estimation method in statistics and has been
used in various ﬁelds for diﬀerent kinds of problems in terms of complexity. For example, when dealing
with linear regression, one might consider the fact that the response Y is explained by more than one
covariable. In such a case, the least squares method can be extended to the general linear model and, for
p covariables, one can rewrite (1.1) such as:
yi = β0 + β1xi,1 + · · · + βpxi,p + εi, for i = 1, . . . , n.
That estimation method can also be extended when dealing with a non-linear relationship between
the response and the covariables. In that case, the estimation process is far more complex and is usually
solved via iterative reﬁnement.
1.1.2 Maximum likelihood estimation
Another widely used estimation method addressed in this section is the maximum likelihood estimation.
First introduced by Ronald Fisher between 1912 and 1922 (see Fisher (1912, 1922)), even if it has been
used earlier, amongst others, by Carl Friedrich Gauss and Pierre-Simon Laplace, the maximum likeli-
hood estimation is a parametric estimation method which basically consists in maximizing the likelihood
function of a model, i.e the agreement between the model with the data.
First, let us introduce the concept of likelihood. The likelihood function L(θ;x) is a function of the
parameter θ of a model given the data x that measures the occurrence plausibility of x for each possible
value of θ. This function can be written such as:
L(θ;x) = P(x|θ).
For a set of n independent and identically distributed continuous (resp. discrete) random variables
X1, . . . , Xn which joint probability density function (resp. probability mass function) is f(X1, . . . , Xn|θ)
with an unknown value of θ, the likelihood function is:
L(θ;x1, . . . , xn) = f(x1, . . . , xn|θ) =
n∏
i=1
f(xi|θ) (1.3)
where xi, i = 1, . . . , n, is an observation of the random variable Xi. Then, based on (1.3), we deﬁne the
maximum likelihood estimator of θ such as:
θˆ = arg max
θ
n∏
i=1
f(xi|θ).
In practice, it is even more convenient to maximize the log-likelihood function since log is a monotonic
increasing function. Thus, the maximum likelihood estimator of θ can be deﬁned such as:
θˆ = arg max
θ
n∑
i=1
ln (f(xi|θ)) .
1.1.3 Kaplan-Meier estimation
The Kaplan-Meier estimation, introduced by Edward L. Kaplan and Paul Meier in 1958 (see Kaplan
and Meier (1958)), is a non-parametric estimation method used in survival analysis. Widely used in
medical research, the Kaplan-Meier estimator, also referred to as product-limit estimator, Sˆ(t) oﬀers an
estimation of the quantity S(t) which is the probability that a given individual has lifetime exceeding time
t. However, the Kaplan-Meier estimator is not limited to medical research and has also great applications
in reliability engineering where this estimator is used to measure the time-to-failure of machine parts.
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For illustrative purposes, let us go back to the medical ﬁeld and assume that we follow the times
until death of a population of size N . We denote by ti the occurrence time of the ith death such as
t1  · · ·  tN . Similarly, we denote by ni the number of individuals still alive prior to time ti and di the
number of individuals dead at ti. Then, the non-parametric estimator of S(t) is deﬁned as:
Sˆ(t) =
∏
tit
ni − di
ni
.
A great advantage of the Kaplan-Meier estimator is the fact that it can take into account censored data
and deal with incomplete observation, as is often the case in a real-life setting. In such a case, the number
ni of individuals at risk at ti equals to ni−1 minus the number of individuals who died and those lost to
follow-up between ti−1 and ti.
Being a non-parametric estimation method, the Kaplan-Meier estimation presents some advantages
as well as disadvantages. Indeed, since there is no need to assume that the life data of interest follows a
speciﬁc probability distribution, we avoid the potential bias brought by this assumption. However, the
conﬁdence interval associated to such an estimation method tends to be wider than those obtained with
the parametric estimation. For the estimation of conﬁdence intervals in the non-parametric analysis,
one can refer to the formula introduced by Greenwood in 1926 (see Greenwood (1926)) which gives an
estimation of the variance of Kaplan-Meier estimator such as:
V̂ar(Sˆ(t)) = Sˆ(t)2
∑
tit
di
ni(ni − di).
1.1.4 Expectation-maximization algorithm
Let us now give an overview of the expectation-maximization (EM) algorithm. Introduced by Dempster
et al. (1977), the EM algorithm is an iterative parametric estimation method, based on the maximum
likelihood estimation technic, which estimates the parameters of a statistical model depending on both
observed and unobserved variables. Each iteration of this algorithm is based on two steps. The ﬁrst
step (E step) consists in estimating the unobserved data given the observed data and the value of the
parameters estimated during the previous iteration of the algorithm. Such a step is achieved by computing
the conditional expectation of the log-likelihood function. The second step (M step) consists in estimating
and updating the value of the parameters by maximizing the expectation obtained during the E step.
The EM algorithm is frequently used for data imputation, data clustering or image reconstruction.
As an example, let us consider a set X of observed variables and a set Z of unobserved variables which
realizations are denoted with lowercase letters. For more convenience, we assume that Z is a discrete
variable (similar argument holds for continuous variables). By denoting θ the vector of the parameters
of the model, we wish to estimate θ such that the marginal likelihood L(θ;x) is maximum. We also
denote by p(x, z|θ) the joint probability distribution of X and Z knowing θ such as p(x|θ) is the marginal
probability distribution of X knowing θ. By considering the log-likelihood, one can write:
l(θ;x) = ln (L(θ;x)) = ln (p(x|θ)) = ln
(∑
z
p(x, z|θ)
)
(1.4)
for which the use of the maximum likelihood estimation method (see Section 1.1.2) to estimate θ can be
quite impractical. Hence, by taking an arbitrary distribution q(z) for the unobserved variables Z, one
can rewrite (1.4) such as:
l(θ;x) = ln
(∑
z
q(z) · p(x, z|θ)
q(z)
)
(1.5a)

∑
z
q(z) · ln
(
p(x, z|θ)
q(z)
)
(1.5b)
=
∑
z
q(z) · ln (p(x, z|θ)) −
∑
z
q(z) · ln (q(z)) (1.5c)
= Eq(z)
(
ln (p(x, z|θ)) )−∑
z
q(z) · ln (q(z)) (1.5d)
7
Chapter 1. Preliminaries
where the passage from (1.5a) to (1.5b) is assured by the Jensen’s inequality (see Jensen (1906)). Equation
(1.5d) is said to be a lower bound of the marginal log-likelihood l(θ;x). Thus, by maximizing (1.5d), one
should maximize l(θ;x) at the same time.
However, to ensure that the l(θ;x) increases when (1.5d) is maximized, we need to ﬁnd the optimal
lower bound of l(θ;x), i.e ﬁnd a value for q(·) such that (1.5d) equals l(θ;x) for a given θ(0). One can
show that this optimal lower bound is reached when q(z) = p(z|x; θ(0)). Thus, one can write:
l(θ;x) = Ep(z|x;θ(0))
(
ln (p(x, z|θ)) )−∑
z
p(z|x; θ(0)) · ln
(
p(z|x; θ(0))
)
. (1.6)
Since the second term of the right-hand member of (1.6) does not depend on θ, the M step of the EM
algorithm simply consists in maximizing Ep(z|x;θ(0))
(
ln (p(x, z|θ)) ), i.e we have:
θˆ(1) = arg max
θ
Ep(z|x;θ(0))
(
ln (p(x, z|θ)) ).
Each estimation θˆ(t) is then reused in a new iteration to compute θˆt+1 until convergence of the algorithm.
In the context of image reconstruction, Silverman and Nychka (1990) proposed a variant of the EM
algorithm called expectation-maximization-smoothing (EMS) algorithm. This algorithm is based on the
standard EM algorithm but add a smoothing step after each M step of the EM algorithm. Indeed, this
extra step, meant to limit noisy estimations, consists in recalculating the estimator by considering its
neighbors aﬀected by diﬀerent weighs. In their work, Silverman and Nychka (1990) used a weighted
moving average such as:
θˆ(t)s =
L∑
l=0
ωl × θ˜(t)s+l−L/2, s = 1, . . . , S
where θ˜(t) is the estimation of θ obtained from the M step at the tth iteration, L is the order of the
moving average and the ωl are symmetric weights such as
∑
l ωl = 1. The following convergence criteria
is deﬁned: ∥∥∥θˆ(t+1) − θˆ(t)∥∥∥
2∥∥∥θˆ(t)∥∥∥
2
< ε
where ε can be chosen suﬃciently small and ‖ · ‖2 is the L2 norm in RS .
1.1.5 Random graph theory
This section is meant to give some basic knowledge on the random graph theory. First let us introduce the
principle of graph. A graph is a mathematical structure describing relations between objects. Denoted
by G(V,E), a graph is constituted of a set V of points, also called nodes or vertices, connected with each
other by E edges (or arcs). One can refer to Figure 1.1 for an example of graph where V and E are:
V = {V1, V2, V3, V4, V5, V6},
E = {{V1, V3}, {V3, V5}, {V2, V3}, {V2, V4}, {V2, V6}, {V4, V6}}.
In particular, the graph of Figure 1.1 is said to be undirected since no distinction is made between two
nodes connected with a given edge, i.e no orientation is given for the diﬀerent edges.
V1 V2
V3 V4
V5
V6
Figure 1.1: Example of graph.
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Let us now consider random graphs. A random graph, denoted G(n, p), is deﬁned as a set of n nodes
connected which other by edges generated via a probability distribution p. Random graphs have been
increasingly used to model complex networks structures describing natural and/or societal relationships
between individuals (human beings, animals, computers, etc) and to understand the mechanisms of
various phenomena in the populations considered (the spread of a disease through a population, the
spread of rumors through a social network, etc).
As the mechanics of those phenomena can highly diﬀer, diﬀerent network structures arose in the lit-
erature. Indeed, depending on the probability distribution considered, several authors proposed diﬀerent
ways to generate contact networks. Among the most famous contact networks, one can refer to the
Erdős-Rényi model, the Watts and Strogatz model and the Barabási-Albert model.
1.1.5.1 Some basic concepts
Let us introduce some basic concepts related to the graph theory. The following concepts do not represent
an exhaustive list of the main characteristics of the graph theory but are needed for a better understanding
of the models introduced thereafter. For more in-depth details on the graphe theory, one can refer to
Bondy and Murty (1976).
One of the main fundamental characteristics of graphs is the degree assigned to the nodes. This
notion deﬁnes the number of edges incident to a given node. Basically, it corresponds to the number of
neighbors (or partners) of a given node. By referring to Figure 1.1, one can see that the node V1 has a
degree of 1 while V2 has a degree of 3. In the particular case of random graphs, the network is generated
via a probability distribution since each node is assigned a degree according to a probability.
The next concept introduced in this section is the concept of path. A path, sometimes referred to as
walk, is a ﬁnite or inﬁnite alternative sequence of nodes and edges between two given nodes. Inﬁnite path
is an extension of ﬁnite path where there is neither a starting nor an ending node. In all the following,
we only consider ﬁnite paths. Denoted by W , the walk between two given nodes V0 and Vk is expressed
such as:
W = V1E1,2V2 · · ·Vk−1Ek−1,kVk
where E1,2 is the edge between nodes V1 and V2. Particularly, W is said to be of length k. One can
refer to Figure 1.1 for an illustration of a path of length 2 between V2 and V5. One can also observe two
diﬀerent paths (length 1 and 2) between V2 and V6.
This simple example leads to a recurrent problematic in graph theory which is the search for the
shortest path. Assuming that the graph of Figure 1.1 is unweighted, i.e no weight is associated to the
diﬀerent edges, the shortest path between V2 and V6 is W = V2E2,6V6 which is the path with the fewest
edges. For weighted graphs, the search for the shortest path between two nodes uses far more complex
algorithms to minimize the sum of weights for all the paths between these two nodes.
The last notion addressed in this section is the notion of clustering coeﬃcient. Being a measure of how
much the nodes are gathered, it is an important parameter to study neighborhood in social networks and
is widely used when dealing with small world networks (see Section 1.1.5.3). However, one can discern
two notions of clustering coeﬃcient, the global cluster coeﬃcient associated to the graph and the local
cluster coeﬃcient associated to a node. The global cluster coeﬃcient only considers the number of triplets
in the graph which is the number of three connected nodes (a node with two partners). This deﬁnition
diﬀers from the deﬁnition of a triangle which is a closed triplets. As an example, and by referring to
Figure 1.1, one can see that the nodes V2, V4 and V6 form a triangle. This coeﬃcient is calculated with
the following formula:
C =
3 × number of triangles
number of connected triplets of vertices.
With 1 triangle and 8 triplets, the global cluster coeﬃcient of the graph displayed on Figure 1.1 is 0.375.
As for the local cluster coeﬃcient, this quantity gives an indication on the closeness of a node’s
neighbors. Basically, this coeﬃcient measures how close the neighbors of a given node are to being a
clique, i.e how close the neighbors of a given node are to forming a complete subgraph. By referring to
Figure 1.2, one can notice that the subgraph formed by the neighbors of V2 is complete (each node is
connected with each other). For a given node u, the local cluster coeﬃcient is:
Cu =
2Eu
ku(ku − 1)
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where ku is the degree of u and Eu is the number of edges between the ku partners connected to u. From
Figure 1.2, one can see that V2 as 3 partners and that the number of edges between those is also 3 (the
blue highlighted edges). Thus, the local cluster coeﬃcient of V2 is 1. By now referring to Figure 1.1, we
ﬁnd a local cluster coeﬃcient for V2 of 1/3.
V1 V2
V3 V4
V5
V6
Figure 1.2: Graph with a complete subgraph. The clique formed by the neighbors of V2 is
highlighted by a set of blue thick edges.
1.1.5.2 Erdős-Rényi model
The ﬁrst model addressed in this section is the Erdős-Rényi model introduced by Paul Erdős and Alfréd
Rényi in 1959 (see Erdős and Rényi (1959)). The main assumption of this model is the fact that each
node can independently be connected to each other with a probability p, or in other words each edge has
an independent probability p of existing.
From this assumption, the probability p(k) that a given node, in a graph generated by the Erdős-Rényi
model G(n, p), has exactly k partners is given by:
p(k) =
(
n − 1
k
)
pk(1 − p)n−1−k
which is the binomial distribution function. Indeed, each node in the graph has exactly Ckn−1 ways to
choose k edges from among the n − 1 other nodes, the k edges have a probability pk of existing and no
connection is allowed with n − 1 − k other nodes.
By now referring to the properties of a binomial distribution, when n goes to inﬁnity, and for a very
small p, the binomial distribution converges towards the Poisson distribution:
〈K〉ke−〈K〉
k!
where 〈K〉 is the mean degree of the graph such as 〈K〉 = (n − 1)p.
The Erdős-Rényi model is usually used for its relatively understanding simplicity but lacks of accuracy
when trying to model real phenomena, especially when connections between nodes aren’t independent
which leads to a low clustering coeﬃcient.
1.1.5.3 Watts and Strogatz model
Let us now focus on the model introduced by Duncan J. Watts and Steven Strogatz in 1998 (see Watts
and Strogatz (1998)). Mainly developed to face the limitation of the Erdős-Rényi model regarding local
clustering, the Watts and Strogatz model was built to generate graphs with the small-world properties
such as a high clustering coeﬃcient and short average path lengths.
However, the construction of such graphs is slightly more complex than graph generated by the Erdős-
Rényi model. Indeed, the algorithm for small-world networks generation can be described in two steps.
First, assuming that each node has an even and determinist mean degree 〈K〉, let us consider a regular
ring lattice constituted of N nodes connected with their 〈K〉/2 nearest neighbors on both sides. For illus-
trative purposes, one can refer to Figure 1.3(a) for a regular ring lattice with 10 nodes connected with their
2 nearest neighbors on both sides. Next, each existing edge Ei,j (between node ni and nj) is rewired with
a probability β to be replaced by the edge Ei,k (the node nk is chosen with uniform probability among
all other nodes) such as k = i and k = k′ where Ei,k′ is an already existing edge. Each edge is rewired
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just once in the process. Figures 1.3(a) to 1.3(c) give an illustration of this process for diﬀerent values of β.
(a) β = 0 (b) 0 < β < 1 (c) β = 1
Figure 1.3: Graphs generated with the Watts and Strogatz model for diﬀerent values of β.
Regular ring lattice generated via a Watts and Strogatz model with β = 0 (Figure (a)), small-world graph
generated via a Watts and Strogatz model with 0 < β < 1 (Figure (b)) and random graph generated via
a Watts and Strogatz model with β = 1 (Figure (c)).
Considering the degree distribution of a graph generated by a Watts and Strogatz model, it cor-
responds to a Dirac delta function centered at 〈K〉 when β = 0 (regular ring lattice) and it follows
a Poisson distribution when β = 1 (random graph). For the particular case where 0 < β < 1, the
probability distribution can be expressed as:
p(k) =
f(k,〈K〉)∑
n=0
(〈K〉/2
n
)
· (1 − β)nβ〈K〉/2−n · (β〈K〉/2)
k−〈K〉/2−n
(k − 〈K〉/2 − n)! · e
−β〈K〉/2
for k  〈K〉/2 where f(k, 〈K〉) = min(k − 〈K〉/2, 〈K〉/2). One can refer to the work of Albert and
Barabási (2002) for the full explanations of this result.
Contrary to the Erdős-Rényi model, the Watts and Strogatz model allows for a better description of
real phenomena since the work of Milgram (1967) has highlighted the fact that the human society was
organized according to a small-world type framework. However, this model still lacks of accuracy since
the degree distribution is relatively homogeneous, i.e all nodes have approximatively the same degree.
Moreover, this model does not allow the addition of new nodes over time, i.e the number of nodes in the
graph is constant along the modeling process.
1.1.5.4 Barabási-Albert model
The last model addressed in this section is the model introduced by Albert-László Barabási and Réka
Albert in 2002 (see Albert and Barabási (2002)). Developed to generate scale-free networks, the Barabási-
Albert model allows for the inclusion of two valuable features which are the possibility for the network to
grow over time and the consideration of preferential attachment, an important mechanism of scale-free
networks. Preferential attachment, in the ﬁeld of contact networks, is a process consisting in distributing
new partnerships to nodes according to how many partnerships they already have, i.e an overly connected
node (high degree) has better chance to gain new partners than nodes with a limited number of partners
(low degree). Those graphs are the most widely used to model various kinds of interactions between
individuals (disease spread, social networks, Internet, etc).
The construction of scale-free networks starts with a small set m0 of connected nodes. At each time
step, a node with m edges (m  m0) is added to the graph and connects to m diﬀerent nodes among the
m0 original nodes. Then, for each edge of the new node among the m possibilities, a partner is selected
according to the probability:
pi =
ki∑
j kj
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where ki is the degree of the node i and i ∈ {1, . . . ,m0}. In other words, new nodes tend to connect with
the nodes with the higher degree. As for the degree distribution, scale-free networks are characterized by
a power law distribution such as:
p(k) ∼ k−γ
where 2 < γ < 3 in most applications.
Compared to the previous models, the Barabási-Albert model has the advantage to deal with hetero-
geneous populations, constituted of a few nodes with a lot of connections (referred to as hubs) and of a
majority of nodes which have far less connections. Moreover, this model can describe the evolution of a
dynamic graph over time since the number of nodes in the network is not constant anymore. However,
due to the inﬂuence of high-degree nodes in the creation of new connections, scale-free networks tend to
admit lower a clustering coeﬃcient than small-world networks.
1.2 Review of some epidemic models
In this section, we introduce some well-known epidemic models. By focusing on the Susceptible-Infected-
Recovered (SIR) disease spreading framework, we give an analytical description of some frequently used
transmission models from the classic deterministic approach to recent works on networks. For the sake
of simplicity, we assume that the size of the population N stays constant over time and that there is no
birth or death rate.
1.2.1 Deterministic epidemic model
Deterministic compartmental models, also referred to as mass action models, are the simplest epidemic
models for the study of infectious diseases dynamics. Based on a set of ordinary diﬀerential equations
(ODE), they capture the interactions between the susceptible and the infected populations with respect to
the homogeneous mixing assumption. This assumption considers that individual heterogeneities related
to social structures or geographic locations are negligible. Moreover, as individuals are randomly mixed,
the probability of contact between two individuals directly depends on the proportion in the whole pop-
ulation of their own group (susceptible, infected or recovered). Mainly used when a large population is
involved, deterministic compartmental models have been extensively used in the past century to describe
the dynamics of various infectious diseases such as rubella, measles, the foot-and-mouth disease or the
respiratory syncytial virus (see Anderson (1983), Babad et al. (1995), Ferguson et al. (2001) and Moore
et al. (2014) respectively).
Hence, based on the work of Kermack and McKendrick (1927) (see also Anderson and May (1992)),
one can write the dynamics of the deterministic compartmental model for an SIR-framework epidemic
as:
S(t) + I(t) + R(t) = N
where S(t), I(t) and R(t) represent the number of individuals in each compartment at time t. Figure 1.4
shows the dynamics of the SIR model for a closed population.
Susceptible Infected Recovered
Figure 1.4: Diagram of the SIR model dynamics
By assuming that all the susceptible individuals are in contact with all the infected individuals and
that a susceptible individual becomes infected after a "successful" contact with an infected individual,
the number of new infections per unit time is:
βI(t) × S(t)
where β is the transmission rate of the disease per unit time. We deduce that:
S(t + Δt) = S(t) − βS(t)I(t) × Δt.
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By now assuming that an infected individual recovers from the infection at a rate γ per unit time,
one can write:
R(t + Δt) = R(t) + γI(t) × Δt.
Hence, when Δt → 0, we obtain:
dS(t)
dt = limΔt→0
S(t + Δt) − S(t)
Δt = −βS(t)I(t)
and
dR(t)
dt = limΔt→0
R(t + Δt) − R(t)
Δt = γI(t).
Since N is known and assumed constant, we deduce that:
dI(t)
dt = −
dS(t)
dt −
dR(t)
dt .
It follows that:
dI(t)
dt = βS(t)I(t) − γI(t).
Thus, we obtain:
dS(t)
dt = −βS(t)I(t),
dI(t)
dt = βS(t)I(t) − γI(t), (1.7)
dR(t)
dt = γI(t).
The population dynamics of the deterministic compartmental model are entirely deﬁned by (1.7). In
the next section, we propose to study more complex methods by focusing on stochastic epidemic models
to allow some variability in the population dynamics.
1.2.2 Stochastic epidemic models
First introduced by McKendrick (1926) (see also Bartlett (1949)), stochastic epidemic models are based
on random processes. Rather used when dealing with small communities, stochastic models are mostly
employed when variations have a strong impact on the population dynamics. In this section, we ﬁrst con-
sider epidemic Markov models based on either a discrete-time Markov chain (DTMC) or a continuous-time
Markov chain (CTMC). Then, we study the stochastic counterpart of the model described in Section 1.2.1.
Most of this section is based on the work of Allen (2008).
1.2.2.1 Discrete-time Markov chain approach
Models based on a discrete-time Markov chain can be described as a state-transition process with a time
variable t assumed to be discrete. Those models have been used to model the transmission of various
infectious diseases such as hepatitis A virus, measles or AIDS (see Geng et al. (1998), Bishai et al. (2012)
and Ogunmola (2014) respectively).
In the particular case of an epidemic based on the SIR framework, the Markov chain is subject to the
following constraint:
S(t) + I(t) + R(t) = N
where S(t) (resp. I(t), R(t)) is a discrete random variable which represents the number of susceptible
(resp. infected, recovered) individuals at time t. Since each random variable depends on the two others,
the model’s state is fully deﬁned by S(t) and I(t). Therefore, we only need to deﬁne the joint probability
of (S(t), I(t)):
p(s,i)(t) = P
(
S(t) = s, I(t) = i
)
.
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By dealing with a Markov chain and assuming that time is uniform with a ﬁxed time step of Δt, our
model is deﬁned according to the Markov property:
P
((
S(t + Δt), I(t + Δt)
)
= (st+Δt, it+Δt)|
(
S(0), I(0)
)
= (s0, i0), . . . ,
(
S(t), I(t)
)
= (st, it)
)
= P
((
S(t + Δt), I(t + Δt)
)
= (st+Δt, it+Δt)|
(
S(t), I(t)
)
= (st, it)
)
.
Hence the number of susceptible (resp. infected) individuals at t + Δt only depends on the number
of susceptible (resp. infected) individuals at t.
We now assume that Δt can be chosen suﬃciently small to only allow one transition from a state to
another. In particular, we write:
p(s,i),(s+k,i+j)(t + Δt, t) = P
((
S(t + Δt), I(t + Δt)
)
= (s + k, i + j)|(S(t), I(t)) = (s, i)),
the transition probability from (S(t), I(t)) = (s, i) to
(
S(t + Δt), I(t + Δt)
)
= (s + k, i + j) where
(k, j) =
⎧⎨⎩ (−1, 1) if a susceptible individual gets infected,(0,−1) if an infected individual recovers,(0, 0) otherwise.
By assuming that the Markov chain is time-homogeneous, i.e the transition probabilities are time
independent, one can write:
p(s,i),(s+k,i+j)(t + Δt, t) = p(s,i),(s+k,i+j)(Δt).
From now on, we want to determine the equation governing the Markov chain. Referring to the
representation of the Markov chain time evolution given in Figure 1.5, we have to determine the expression
of p(s,i),(s−1,i+1)(Δt) and p(s,i),(s,i−1)(Δt).
(S(t), I(t))
(S(t) − 1, I(t) + 1)(S(t), I(t) − 1)
(S(t) − 1, I(t)) (S(t) − 2, I(t) + 2)(S(t), I(t) − 2)
p(s,i),(s−1,i+1)(Δt)p(s,i),(s,i−1)(Δt)
p(s,i),(s−1,i+1)(Δt)
p(s,i),(s,i−1)(Δt) p(s,i),(s−1,i+1)(Δt)
p(s,i),(s,i−1)(Δt)
t
t + Δt
t + 2Δt
Figure 1.5: SIR Markov chain evaluation at times t, t + Δt and t + 2Δt.
Red arrows represent the infection process while green arrows represent the recovery process.
Regarding the probability that an infection occurs in [t, t + Δt], one can write:
p(s,i),(s−1,i+1)(Δt) = i × P(an infected individual infects a susceptible individual in [t, t + Δt]). (1.8)
Since an infected individual has to contact a susceptible individual for the infection to transmit, one
can rewrite (1.8) as:
p(s,i),(s−1,i+1)(Δt) = i × P
(
{an infected individual contacts a susceptible individual in [t, t + Δt]}
∩ {the infection occurs}
)
.
Hence, we have p(s,i),(s−1,i+1)(Δt) = i ×
s
N
× βΔt where β is the transmission rate of the infection.
Similarly, by assuming that p(s,i),(s,i−1)(Δt) is the probability that a recovery occurs in [t, t + Δt], one
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can write:
p(s,i),(s,i−1)(Δt) = P(a recovery occurs in [t, t + Δt])
= i × P(an infected individual recovers in [t, t + Δt])
= i × γΔt
where γ is the recovery rate of the infection. Hence, we have:
p(s,i),(s+k,i+j)(Δt) =
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
βisΔt
N
, (k, j) = (−1, 1)
γiΔt, (k, j) = (0,−1)
1 −
(
βis
N
+ γi
)
Δt, (k, j) = (0, 0)
0, otherwise.
Thus, we obtain the following equation:
p(s,i)(t + Δt) =
(
1 −
(
βis
N
+ γi
)
Δt
)
× p(s,i)(t)
+
β(i − 1)(s + 1)Δt
N
× p(s+1,i−1)(t) (1.9)
+ γ(i + 1)Δt × p(s,i+1)(t).
Equation (1.9) describes the evolution of the Markov chain between t and t + Δt. This equation is
also referred as Chapman-Kolmogorov equation. In the next section, we allow the Markov chain to evolve
in continuous time.
1.2.2.2 Continuous-time Markov chain approach
Continuous-time Markov chains share the same characteristics as discrete-time Markov chains except for
the deﬁnition of time. Since epidemic models are mostly deﬁned in continuous time, CTMC models are
rather used than their discrete counterpart. Many authors chose to deal with continuous-time Markov
chain to model the transmission of infectious diseases like the Eyam plague, AIDS, inﬂuenza or measles
(see Ragget (1982), Ball and O’Neill (1993), Dushoﬀ et al. (2004) and Cauchemez and Ferguson (2008)
respectively).
The model is still subject to the following constraint:
S(t) + I(t) + R(t) = N
where S(t) (resp. I(t), R(t)) is a discrete random variable which represents the number of susceptible
(resp. infected, recovered) individuals at time t.
The state of the system can be described by (S(t), I(t)) with joint probability:
p(s,i)(t) = P
(
S(t) = s, I(t) = i
)
.
For 0  t0 < t1 < · · · < tn < tn+1, the Markov property assumes that:
P
((
S(tn+1), I(tn+1) = (stn+1 , itn+1)
)|(S(t0), I(t0)) = (st0 , it0), . . . , (S(tn), I(tn)) = (stn , itn))
= P
((
S(tn+1), I(tn+1) = (stn+1 , itn+1)
)|(S(tn), I(tn)) = (stn , itn)).
Let us now describe in an informal manner the diﬀerent transitions of the model. Assuming that
tn+1 − tn is suﬃciently small to allow only one transition from a state to another, we write:
p(s,i),(s+k,i+j)(tn+1, tn) = P
(
(S(tn+1), I(tn+1)) = (s + k, i + j)|(S(tn), I(tn)) = (s, i)
)
the transition probability from (S(tn), I(tn)) = (s, i) to
(
S(tn+1), I(tn+1)
)
= (s + k, i + j) where
(k, j) =
⎧⎨⎩ (−1, 1) if a susceptible individual gets infected,(0,−1) if an infected individual recovers,(0, 0) otherwise.
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As stated in Section 1.2.2.1, we assume that the Markov chain is time-homogeneous. Thus, one can
write:
p(s,i),(s+k,i+j)(tn+1, tn) = p(s,i),(s+k,i+j)(tn+1 − tn).
More rigorously, by assuming that only one transition can occur instantaneously, inﬁnitesimal transi-
tion probabilities are assumed to be:
p(s,i),(s−1,i+1)(Δt) =
βis
N
× Δt + o(Δt) and p(s,i),(s,i−1)(Δt) = iγ × Δt + o(Δt),
where lim
Δt→0
o(Δt)
Δt = 0.
Thus the process evolution can be deﬁned by the following inﬁnitesimal transition probability:
p(s,i),(s+k,i+j)(Δt) =
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
βisΔt
N
+ o(Δt), (k, j) = (−1, 1)
γiΔt + o(Δt), (k, j) = (0,−1)
1 −
(
βis
N
+ γi
)
Δt + o(Δt), (k, j) = (0, 0)
o(Δt), otherwise.
Hence by writing P(S(t + Δt), I(t + Δt)) according to P(S(t), I(t)) we get the following equation:
p(s,i)(t + Δt) =
β(i − 1)(s + 1)Δt
N
× p(s+1,i−1)(t) + γ(i + 1)Δt × p(s,i+1)(t)
+
(
1 −
(
βis
N
+ γi
)
Δt
)
× p(s,i)(t) + o(Δt).
Then by subtracting p(s,i)(t) and dividing by Δt, we get:
p(s,i)(t + Δt) − p(s,i)(t)
Δt =
β(i − 1)(s + 1)
N
× p(s+1,i−1)(t) + γ(i + 1) × p(s,i+1)(t)
−
(
βis
N
+ γi
)
× p(s,i)(t) +
o(Δt)
Δt .
At the limit, when Δt tends to 0, we have:
dp(s,i)(t)
dt =
β(i − 1)(s + 1)
N
× p(s+1,i−1)(t) + γ(i + 1) × p(s,i+1)(t) −
(
βis
N
+ γi
)
× p(s,i)(t). (1.10)
The diﬀerential equation (1.10), referred to as Forward Kolmogorov Equation, describes the evolution
of the Markov chain between tn and tn+1. In the following section, we propose to study an extension of
the continuous time Markov chains to continuous values.
1.2.2.3 Stochastic diﬀerential equations approach
We propose in this section to describe the stochastic counterpart of the deterministic compartmental
model introduced in Section 1.2.1. We will not deal in-depth with the details but will just give a quick
overview of the compartmental model based on stochastic diﬀerential equations (SDE). This approach,
based on a diﬀusion process, is a direct extension of the continuous-time Markov chain studied in Sec-
tion 1.2.2.2 with continuous values instead of discrete states. As stochastic models are generally used to
describe the dynamics of small size populations, the approach with SDE oﬀers a good approximation for
large size populations as long as the population is ﬁnite (see Traulsen et al. (2012)). Stochastic diﬀerential
equations models have been used to model infectious diseases such as AIDS (see Dalal et al. (2007) or Xu
et al. (2007)), measles or malaria (see Kassem and Ndam (2008) or Bhadra et al. (2011) respectively).
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From Equation 1.10 obtained in the previous section, Allen (2008) (see also Dargatz (2007)) de-
termined an expression of the probability density function p(s,i)(t) in the form of a partial diﬀerential
equation being:
∂p(s,i)(t)
∂t
=
∂
∂s
(
βis
N
× p(s,i)(t)
)
− ∂
∂i
((
βis
N
− γi
)
× p(s,i)(t)
)
+
1
2
∂2
∂s2
(
βis
N
× p(s,i)(t)
)
(1.11)
− ∂
2
∂s∂i
(
βis
N
× p(s,i)(t)
)
+
1
2
∂2
∂i2
((
βis
N
+ γi
)
× p(s,i)(t)
)
.
By denoting x =
(
s
i
)
, μ(x) =
⎛⎜⎝ −βisN
βis
N
− γi
⎞⎟⎠ and Σ(x) =
⎛⎜⎝ βisN −βisN
−βis
N
βis
N
+ γi
⎞⎟⎠, one can rewrite Equa-
tion (1.11) such as:
∂px(t)
∂t
= − ∂
∂x
(
μ(x)px(t)
)
+
1
2
∂2
∂x2
(
Σ(x)px(t)
)
. (1.12)
Equation (1.12) is referred to as Fokker-Planck equation for the probability density px(t) of the random
variable X(t) =
(
S(t)
I(t)
)
. According to Dargatz (2007) and Allen (2007), Equation (1.12) is the Markov
process solution of the following stochastic diﬀerential equation:
dX(t) = μ(X(t))dt + B(X(t))dW (t)
where W (t) is a Wiener process1 and Σ = BtB. Thus, by denoting W1(t) and W2(t) two independent
Wiener processes, one can write:
dS(t) = −βS(t)I(t)
N
dt + B11(X(t))dW1(t) + B12(X(t))dW2(t)
dI(t) =
(
βS(t)I(t)
N
− γI(t)
)
dt + B21(X(t))dW1(t) + B22(X(t))dW2(t)
which describes the time evolution of the stochastic compartmental model.
Next, we propose to study an extension of deterministic compartmental models which can handle
more sophisticated features such as population heterogeneities and relieve the assumption of homogeneous
mixing. Indeed, by assuming that individuals are organized into a speciﬁc framework, one can investigate
the spread of a given epidemic on a diﬀerent population-scale.
1.2.3 Network-based epidemic models
Over the last few decades, important modiﬁcations were provided to the basic epidemiological models built
on the SIR framework. Indeed, many papers exhibited the need to consider population heterogeneities,
interactions between individuals and partnership duration which can play a major role in the propagation
of an epidemic Anderson (1988); Ghani et al. (1997); Rolls et al. (2012a)
To deal with more complex epidemiological mechanisms and to extend the proprieties of the classic de-
terministic SIR model, one can refer to network-based epidemic models which assume that the population
of interest is organized according to a speciﬁc graph. In this section, we ﬁrst consider the homogeneous
mean ﬁeld approach which assumes that every individual in the population admits the same mean number
of partners. By mean number we directly refer to the parameters of the probability distribution which
generates the graph. As the graph is generated just once, all the individuals are assumed to possess the
same ﬁxed number of partners (the mean of the probability distribution). This contrasts with the classic
deterministic compartmental model for which it is assumed that each individual in the population can
enters in contact with anybody else having thus the possibility to infect anyone (full mixing assumption).
Then we focus on the heterogeneous mean ﬁeld approach for which each individual has its own number
of partners. Each degree is assumed to be assigned independently.
In the following, we assume that both approaches considered are applied on a random graph of size
N generated according to a degree distribution denoted p(k) where k is the degree (number of partners)
of a given node. We denote by 〈K〉 the mean degree of the graph.
1The Wiener process is a continuous-time stochastic process such that ΔW = W (t + Δt) − W (t) ∼ N (0, Δt).
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1.2.3.1 Homogeneous mean ﬁeld approach
The homogeneous mean ﬁeld approach is based on the assumption that everyone in the network is
connected to a number 〈K〉 of partners (see Youssef and Scoglio (2011)). This approach simply restrains
the homogeneous mixing assumption of the classical deterministic model to the partners of a given
individual. First, by considering the SIR framework introduced earlier, we denote by S(t) (resp. I(t) and
R(t)) the number of susceptible (resp. infected and recovered) individuals in the network at time t. In
particular, we still have S(t) + I(t) + R(t) = N .
For more convenience, let us work in terms of proportions rather than absolute numbers. Hence, by
denoting proportions of the diﬀerent quantities with lowercase letters, we have:
s(t) =
S(t)
N
, i(t) =
I(t)
N
, and r(t) =
R(t)
N
.
As everyone in the population is connected to a number 〈K〉 of partners, each infected individual can
infect β〈K〉 individuals per unit time. Thus, the proportion of new infections in unit time per infective
is β〈K〉 × s(t). Hence, we have:
ds(t)
dt = −β〈K〉s(t)i(t).
Similarly, by referring to the deterministic compartmental approach, one can write:
dr(t)
dt = γi(t).
From what precedes, we deduce that the governing equations are:
ds(t)
dt = −β〈K〉s(t)i(t),
di(t)
dt = β〈K〉s(t)i(t) − γi(t),
dr(t)
dt = γi(t).
This ﬁrst approach based on contact networks oﬀered an interesting way to deal with social structures.
However, such a model assumes that everyone in the population has the same number of partners (〈K〉)
which might be highly improbable in real-life setting. To account for diﬀerent number of partners, let
us introduce the heterogeneous mean ﬁeld approach which assigns a degree to each individual in the
population according to a probability distribution.
1.2.3.2 Heterogeneous mean ﬁeld approach
To overcome the limitation of the previous approach and give a better approximation of the spread
of an epidemic on a network, one can focus on the heterogeneous mean ﬁeld approach (also called
heterogeneous mixing) (see Pastor-Satorras and Vespignani (2002); Sun et al. (2014)). This approach
assumes that individuals with the same degree have the same behavior. Hence, for each degree k,
individuals are divided into three compartments Sk(t), Ik(t) and Rk(t) representing the susceptible,
infected and recovered individuals with degree k respectively. In particular, one can write:
S(t) + I(t) + R(t) =
∑
k
(
Sk(t) + Ik(t) + Rk(t)
)
= N.
Let us respectively denote by sk(t), ik(t) and rk(t) the proportions of susceptible, infected and recov-
ered individuals with degree k. As the probability for a given susceptible individual to become infected
depends on the number of its infected partners, the proportion of newly infected individuals with degree
k in unit time is proportional to βk × sk(t).
We denote by θk(t) the probability for a node with degree k to have infected partners at time t.
Pastor-Satorras and Vespignani (2002) established the following result:
θk(t) =
∑
k′
p(k′|k)ik′(t)
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where p(k′|k) = k
′p(k′)
〈K〉 is the probability that a node with degree k has a partner with degree k
′. From
what precedes, one can write:
dsk(t)
dt = −βksk(t)θk(t).
Similarly, based on the previous approach, one can write the diﬀerential equation governing the
proportion of recovered individuals with respect to their degree:
drk(t)
dt = γik(t).
We easily deduce the following set of diﬀerential equations:
dsk(t)
dt = −kβsk(t)θk(t),
dik(t)
dt = kβsk(t)θk(t) − γik(t),
drk(t)
dt = γik(t).
This approach relieved the hypothesis of homogeneous mixing assumed in the previous section by
grouping individuals with the same degree in consideration with the heterogeneous connectivity of the
network. However, no speciﬁc information is revealed on the individuals.
1.2.4 Conclusion
We conclude this section by a summary table of the diﬀerent models introduced above. As exhibited in
Table 1.1, we focused on ﬁve characteristics, population scale, time and variable deﬁnitions, the possibility
to handle randomness, the number of contacts and complexity.
Regarding the population scale, deterministic models tend to suit better to large populations since the
homogeneous mixing assumption greatly reduces the impact of individual variability on the population
dynamics. On the contrary, individual variability is better captured by stochastic models such as epidemic
models based on Markov chains. Stochastic models can also be valuable to model the very beginning
of the epidemic where there is a limited number of infected individuals. In the particular case of the
heterogeneous mean ﬁeld approach, the deterministic nature of the model should be preferred for large
populations. However, generating a graph describing the structure of a large population can be quite
unmanageable. In Chapter 4, we adopt this approach but consider several smaller graphs connected with
each other to overcome this limitation.
Other characteristics are quite straightforward. The time deﬁnition is continuous for all the models
but the discrete-time Markov chain. Same goes for the variable deﬁnition which is considered discrete
for both Markov chain based models. Considering randomness, the network based models described
in Section 1.2.3 are deterministic but the graphs are generated randomly. One can note that, for the
heterogeneous mean ﬁeld approach, each generation of the graph gives diﬀerent degree distributions while
the mean degree used for the homogeneous mean ﬁeld approach stays the same. As for the number of
contacts, non-network based models assume that each individual can enter in contact with everyone in
the population (hence N − 1 individuals) while homogeneous and heterogeneous mean ﬁeld approaches
respectively assume a constant number 〈K〉 of partners and a number of contacts based on the degree
of each individual. The complexity of the models directly refers to the theory addressed in the previous
sections.
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2 Some estimation problems in epidemic modeling
Français
Dans le domaine des virus informatiques, un nombre grandissant de modèles mathématiques ont été
publiés durant la dernière décennie. Cette partie propose d’étudier plusieurs méthodes d’estimation ap-
pliquées à deux modèles paramétriques, les modèles "random constant scanning" et "nonhomogeneous ran-
dom scanning", dans le but de comparer les performances des diﬀérents estimateurs à partir de simulations
de populations aléatoires. Nous concluons ce travail en appliquant ces diﬀérentes méthodes d’estimation
à deux jeux de données réelles liés à la propagation de vers sur Internet d’une part et la propagation du
VIH en France d’autre part.
English
In the ﬁeld of computer virus, a growing number of mathematical models have been published during
the last decade. In this part, we consider several estimation methods under two parametric models, the
random constant scanning model and the nonhomogeneous random scanning model, to propose a com-
parison of the estimators’ performances based on the simulation of random populations. We conclude
our work with an application of the diﬀerent estimation methods to two real datasets dealing with worm
propagation on the Internet on the one hand, and dealing with the HIV propagation in France on the other.
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Résumé
Dans ce second chapitre, nous nous proposons de comparer les performances de plusieurs méthodes
d’estimation statistique appliquées à deux modèles épidémiques paramétriques. Les deux modèles con-
sidérés, le modèle "random constant scanning" (RCS) développé par Staniford et al. (2002) et le modèle
"nonhomogeneous random scanning" (NHRS) développé par Kirmani and Hood (2010), ont été dévelop-
pés pour modéliser la propagation d’un pathogène dans une population susceptible. Construits sur le
modèle logistique développé par Verhulst (1838), ces deux modèles diﬀèrent essentiellement au niveau de
la déﬁnition du paramètre β, le taux de contact, qui est supposé dépendant du temps pour le modèle
NRHS et constant pour le modèle RCS.
En notant X(t) le nombre d’individus infectés dans l’intervalle de temps [0, t], Kirmani and Hood
(2010) ont démontré dans leurs travaux que le nombre moyen d’individus infectés sur [0, t] pouvait
s’exprimer de la façon suivante :
I(t) =
N
1 + ψ exp
(
− ∫ t0 β(u) du),
et que la fonction de répartition de T , le temps avant infection d’un individus non-infecté donné,
s’exprimait de telle sorte que l’on ait :
P(T  t) =
1 − exp(−B(t))
1 + ψ exp(−B(t)), t  0.
De ces deux résultats, nous procédons, dans un premier temps, à l’estimation directe des paramètres
euclidiens des modèles RCS et NHRS. En se basant sur une estimation initiale de la fonction I(t), estimée
par Iˆ(t) = X(t) ou Iˆ(t) = X¯(t) selon le nombre de populations simulées considéré, puis de la fonction
de répartition F (t), les paramètres des modèles sont estimés via les méthodes des moindres carrés et du
maximum de vraisemblance. Les performances de chacune de ces méthodes d’estimation sont comparées
entre elles via le calcul des biais relatifs et des écarts-types relatifs de chacun des paramètres. On notera
en particulier que l’approche basée sur l’estimation initiale de F (t) permet la prise en compte de temps
de censure. Diﬀérents pourcentages de censure sont considérés dans ces travaux.
De ces premières estimations, il résulte que la méthode du maximum de vraisemblance permet
d’obtenir de meilleures performances en terme de biais relatif et d’écart-type relatif vis-à-vis de la mé-
thode des moindres carrés et ce pour les deux modèles. Sans surprise, on remarque une nette amélioration
de ces performances lorsque augmente la taille de la population et/ou le nombre de populations simulées.
Les diﬀérences de performance entre les deux méthodes sont nettement moins marquées lorsque l’on con-
sidère la censure.
Dans un second temps, nous étudions l’estimation de la fonction I(t) pour chacun des modèles via les
méthodes des moindres carrés, du maximum de vraisemblance et de Kaplan-Meier. Les performances de
ces estimations sont cette fois-ci comparées via le mean integrated squared error (MISE).
De façon similaire, les résultats obtenus dans cette seconde phase d’estimation pour les modèles RCS
et NHRS ont globalement permis de mettre en évidence la supériorité de la méthode par maximum de
vraisemblance vis-à-vis des autres méthodes. Une fois encore, dans le cas de temps censurés, ces dif-
férences de performance sont sensiblement moins marquées et la méthode des moindres carrés démontre
même de meilleurs résultats lorsque le pourcentage de temps censurés considéré est grand.
Nous concluons ces travaux par une application des modèles RCS et NHRS sur deux jeux de données
réelles. La première base de données considérée est la base caractérisant la propagation du virus Code Red
v2 sur Internet en Juillet 2001 utilisée par Staniford et al. (2002) pour la caractérisation du modèle RCS.
Cette application a permis de mettre en évidence une relative similitude entre les diﬀérentes méthodes
d’estimations. Des diﬀérences sont en revanche apparues dans le cas du modèle NHRS. En eﬀet, de moins
bonnes performances ont été obtenues pour la méthode des moindres carrés.
La seconde base de données considérée caractérise la propagation du VIH en France. Contrairement à
la première base de données, aucune des méthodes n’a réellement pu démontrer de bonnes performances.
Nous en concluons une faible adéquation des modèles RCS et NHRS à ce second jeu de données.
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2.1 Introduction
The simplest but still useful model of the growth of an epidemic is the logistic model ﬁrst introduced
by Verhulst (1838) and later studied by Pearl and Reed (1920). It is based on the assumption that in
a closed homogeneous population consisting of N individuals who are either susceptible to infection or
already infected, X ′(t)/X(t), the per capita growth rate of the number infected by time t, is directly
proportional to (1−X(t))/N , where X(t) is the number of individuals infected during the time period [0,t].
Such a way to allocate the population into diﬀerent compartments directly refers to the Mathematical
theory introduced by Kermack and McKendrick (1927). To allow for the fact that evolution of an
epidemic is a stochastic, rather than a deterministic process, X(t) must be replaced by its expected value
I(t) = E(X(t)). Despite its simplicity, the logistic model has continued to be useful in some practical
situations including internet worm propagation (see Liljenstam et al. (2003); Vojnović and Ganesh (2008);
Zou et al. (2002)). The random constant scanning (RCS) model of worm propagation, applicable to
internet worms which propagate themselves through random scanning of IP addresses to be infected, is,
in essence, a logistic model. Staniford et al. (2002) ﬁtted this model to the total number of inbound
scans seen during [0, t], for 0 < t  16, on port 80 at the Chemical Abstracts Service during the initial
outbreak of version 2 of the Code Red’ worm (CRv2) on July 19, 2001. As the name suggests, the RCS
model of worm propagation, assumes that the worm’s scanning rate is constant in time. To remove this
limitation and develop a more realistic model, Kirmani and Hood (2010) developed a nonhomogeneous
random scanning (NHRS) model which allows the worm’s contact rate to vary during worm propagation.
Kirmani and Hood (2010) proved that, for the NHRS generalization, the expected number of hosts
infected during [0,t] is given by:
I(t) =
N
1 + ψ exp
(
− ∫ t0 β(u) du)
of Kirmani and Hood (2010). Interestingly, Kirmani and Hood (2010) also showed that, for their NHRS
model, the cumulative distribution function (cdf) of T , the time until infection of an initially uninfected
host, is as follows:
P(T  t) =
1 − exp(−B(t))
1 + ψ exp(−B(t)), t  0
of Kirmani et al. (2010). This important result paves the way for statistical inferences regarding the
contact function β(t). The objective of the present chapter is to tackle some problems of estimation of
β(t) and the cdf of T . We propose and study various estimation methods, including the least squares,
maximum likelihood, and Kaplan-Meier methods, for the contact rate β(t) (including the RCS special
case of β(t) = β) and the cdf F (t) = P(T  t). This chapter is organized as follows. First, Section 2
introduces the theoretical background of the models and reviews the diﬀerent estimation methods. Section
3 presents the estimation of the contact rate β(t) based on diﬀerent population sizes and parameter values.
Similarly, Section 4 presents the estimation of the cumulative distribution function F . Section 5 provides
an application of estimation methods to the real dataset initially used by Staniford et al. (2002). Finally,
Section 6 presents our conclusions.
2.2 General theory
2.2.1 Epidemic model background
Our work falls in line with the work of Kirmani and Hood (2010). In the following we will be using
notations and results established by Kirmani and Hood (2010) in their Section 2.1. Consider the spread
of a computer virus in a closed population of N hosts. We denote by X(t) the number of individuals
infected during the time period [0, t]. We write I(t) = E(X(t)).
Let us denote by p(t, t + Δt) the probability that a given individual is contacted by an infected
individual during the inﬁnitesimal time period ]t, t+Δt]. We assume that the probability is the same for
each individual and
p(t, t + Δt) =
β(t)
N
Δt + o(Δt)
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where β(t) denotes the contact rate at time t. By assuming this, we do not allow the local preference
scanning (see Zou et al. (2006)). Note that such a process is an increasing pure jump Markov process.
As previously done by Kirmani and Hood (2010), we consider two parametric models for the contact
rate function β(t):
• the RCS model with β(t) = β for all t  0
• the NHRS model with β(t) = KβKtK−1 for all t  0,
where β and K are positive constants. In the following, we will assume that all contacts between
individuals are independent.
Hence, referring to the paper of Kirmani and Hood (2010), the dynamic of the infection is governed
by the following diﬀerential equation:
I ′(t) = β(t)I(t)
(
1 − I(t)
N
)
for all t > 0. The solution of this equation is:
I(t) =
N
1 + ψ exp
(
− ∫ t0 β(u) du) (2.1)
for all t > 0 and where ψ =
N − I0
I0
with I0 = I(0).
From now on we will deal with two diﬀerent kinds of observation of such a process t → X(t): either
only one path is observed or n independent paths are observable (for example diﬀerent regions with no
or very limited connections). In the ﬁrst case, we will estimate I(t) by Iˆ(t) = X(t) whereas in the second
case we will use Iˆ(t) = X¯(t) where X¯(t) is the mean number of infected individuals at time t among the
n populations.
In the following subsections, we introduce the least squares, the maximum likelihood and the Kaplan-
Meier estimators of some quantities of interest for the RCS and NHRS models.
2.2.2 Inference based on an initial estimation of I(·)
First let us write
B(t) =
∫ t
0
β(u) du, for all t > 0.
From equation (2.1), we can rewrite I(t) as
I(t) =
N
1 + ψ exp (−B(t)). (2.2)
It follows that
B(t) = ln
[
N − I0
I0
I(t)
N − I(t)
]
. (2.3)
Suppose that we are under a NHRS model where B(t) = βKtK . From (2.3), one can give an estimation
of B(t) such as:
Bˆ(t) = ln
[
N − I0
I0
Iˆ(t)
N − Iˆ(t)
]
(2.4)
which, if the NHRS assumption is fulﬁlled, should be close to the theoretical expression B(t) = βKtK .
By taking the logarithm of both expressions B(t) = βKtK and (2.4), and by denoting a0 = K ln(β) and
a1 = K, one can give an estimator of (a0, a1) by using the least squares criterion:
(aˆ0, aˆ1) = argmin
(a0,a1)
m∑
i=1
{
ln
(
ln
(
N − I0
I0
Iˆ(ti)
N − Iˆ(ti)
))
− (a0 + a1 ln(ti))
}2
(2.5)
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where t1, . . . , tm are the diﬀerent observed times of infection. If no times are tied then m = N − I0.
Thus we can write an explicit expression of aˆ0 and aˆ1 and obtain the least squares estimators of β and
K denoted by βˆls1 = exp
(
aˆ0
aˆ1
)
and Kˆls1 = aˆ1 respectively. Finally
Iˆls1(t) =
N
1 + ψ exp
(
−Bˆls1(t)
)
where
Bˆls1(t) = βˆ
Kˆls1
ls1 t
Kˆls1 (2.6)
is an estimation of I(t) based on a least squares criterion under the NHRS model.
2.2.3 Inference based on an initial estimation of the cumulative distribution
function of the time until infection
Let us denote by T the time until infection of a susceptible individual. Kirmani and Hood (2010) have
shown that under the NHRS model we have
F (t) = P(T  t) =
1 − exp(−B(t))
1 + ψ exp(−B(t)), for all t  0. (2.7)
Since I0 hosts are infected at t = 0, a total number of N −I0 infection times can be observed within an
interval [0, t]. Thus, based on the observation of the infection times denoted (T1, . . . , TN−I0), one can give
an estimation of F (t). Unlike the method of Section 2.2.2, such an approach can handle censorship since
we can estimate a cumulative distribution function with censored data using the estimator introduced by
Kaplan and Meier (1958).
Indeed, let us assume that some infection time Ti may not be observed. Thus, the observation for an
individual i is given by {
ui = min(Ti, Ci),
δi = • {TiCi}
where Ci is a random variable which modelizes the censoring time. One can ﬁnd in Klein and Moeschberger
(2003) a pedagogical presentation of statistical inference with censored lifetime data.
Since X(t) is the number of infected hosts at time t, one can write
X(t) = I0 +
N−I0∑
i=1
δi · • {uit}.
The Kaplan-Meier estimation of F (·) based on the observation of these censored data (see Kaplan
and Meier (1958) or Klein and Moeschberger (2003)) will allow us to give parametric and nonparametric
estimations of some quantities of interest.
2.2.3.1 Nonparametric inference
The Kaplan-Meier estimator of F (·) can be written as
Fˆ (u) = 1 −
∏
Tiu
(
1 − ΔX(Ti)
N − I0 − O(Ti)
)
, for u  0 (2.8)
where O(t) =
N−I0∑
i=0
• {ui<t}. Note that N − I0 − O(Ti) is the number at risk at time Ti. From equation
(2.7), we can write B(·) as a function of F (·). Then one can compute a nonparametric estimator of the
cumulative contact rate:
Bˆkm(u) = ln
(
1 + ψFˆ (u)
1 − Fˆ (u)
)
for u  0 (2.9)
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and, from (2.2), we can get a nonparametric estimator of I(·):
Iˆkm(t) =
N
1 + ψ exp(−Bˆkm(t))
= N
(
1 + ψFˆ (t)
1 + ψ
)
. (2.10)
Note that, when dealing with no censorship, the estimator (2.10) is equivalent to the initial estimator
X(t), thus Iˆkm(t) = X(t).
2.2.3.2 Parametric inference
Let us come back to the parametric NHRS model of Section 2.2.1. Using the nonparametric estimators
introduced in Section 2.2.3.1, we are able to introduce new estimators of the parameters β and K and
of the functions I(·) and B(·). It is important to note that these new estimators can take into account
censored data.
A ﬁrst approach consists in following the lines of Section 2.2.2 and using the nonparametric estimator
of the cumulative contact rate Bˆkm(·) given in (2.9) rather than Iˆls1(t).
Thus, one can estimate a0 = K ln(β) and a1 = K by:
(aˆ0, aˆ1) = argmin
(a0,a1)
m∑
i=1
{
ln
(
ln
(
1 + ψFˆ (ti)
1 − Fˆ (ti)
))
− (a0 + a1 ln(ti))
}2
where t1, . . . , tm are still the diﬀerent observed times of infection and Fˆ (·) is deﬁned in expression (2.8).
Hence we obtain new estimators of β and K denoted βˆls2 and Kˆls2 respectively. From these estimators
we can deduce a parametric estimator of I(t) given by:
Iˆls2(t) =
N
1 + ψ exp
(
−Bˆls2(t)
)
where:
Bˆls2(t) = βˆ
Kˆls2
ls2 t
Kˆls2 . (2.11)
Recall that when there is no censoring, all these estimators meet the estimators of Section 2.2.2.
Another way to estimate the parameters of the NHRS model is to consider the maximum likelihood
technic. Indeed, by introducing f(·), the probability density function of the infection time T , one can
compute the likelihood of the censored data (ui, δi)i=1,...,n:
L(t1, . . . , tN−I0 ;β,K) =
N−I0∏
j=1
(f(uj))δj (1 − F (uj))1−δj
where, thanks to (2.7), the probability distribution function f(·) is given by:
f(u) =
ψβ(u)e−B(u)
(1 + ψe−B(u))2, for all u > 0.
Let us denote βˆml and Kˆml the estimators of β and K obtained by maximization of the above likelihood.
Then we can deduce a new parametric estimator of I(t) given by:
Iˆml(t) =
N
1 + ψ exp
(
−Bˆml(t)
)
where
Bˆml(t) = βˆKˆmlml t
Kˆml .
Note that all the above estimators based on the maximum likelihood technique are diﬀerent from the
previous one, even when there is no censoring.
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2.3 Simulation study of the Euclidian parameters
We follow the simulation procedure introduced by Kirmani and Hood (2010). First N − I0 independent
random number in [0, 1] are simulated and denoted {U1, . . . , UN−I0}. Then, {T1, . . . , TN−I0} deﬁned by:
Ti =
1
β
ln
(
1 + ψUi
1 − Ui
) 1
K
, for i = 1, . . . , N − I0
are the times of infection of the N − I0 individuals.
Diﬀerent values for the parameters are considered, β ∈ {0.2, 0.8, 2} for the RCS model and (β,K) ∈
{(0.2, 1.5), (0.2, 2), (0.2, 5), (0.8, 1.5), (0.8, 2), (0.8, 5), (2, 1.5), (2, 2), (2, 5)} for the NHRS model.
Figure 2.1 exhibits a sketch of I(t) under both RCS and NHRS models for the diﬀerent values of β
and K.
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Figure 2.1: Expected number of hosts infected against time under RCS and NHRS models for diﬀerent
values of β and K. (a) RCS model with β = 0.2 (green), β = 0.8 (blue) and β = 2.0 (red). (b) NHRS
model with β = 0.2 (green), β = 0.8 (blue), β = 2.0 (red), K = 1.0 (dotted curves), K = 1.5 (dashed
curves) and K = 5.0 (solid curves).
The number X(t) of infected individuals at t is given by:
X(t) = I0 +
N−I0∑
i=1
• {Tit}.
When dealing with estimators which can handle right censored data, the censoring times are simulated
according to an exponential distribution with parameter λ chosen in order to obtain a given percentage of
censoring. Table 2.1 exhibits the values of λ we found after 1000 simulations which give approximatively
the expected percentage of censoring.
Table 2.1: Values of the exponential distribution parameter. The parameter λ approximatively
gives 10%, 20% and 50% of censoring.
Parameter λ
Percentage of censoring RCS model NHRS model
10% 56.0 32.0
20% 26.0 15.0
50% 8.0 4.7
We consider two population sizes N = 100 and N = 1000 with an initial number of infected individual
I0 = 1 and I0 = 10 respectively for both RCS and NHRS models.
Finally, we consider two numbers of observed population: n = 1 and n = 100. Each of the above
simulation scenarios has been replicated 1000 times, allowing us to evaluate empirically the quality criteria
of our estimators.
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2.3.1 Observation of a single population
In this section, we consider that only one population is observed. Thus, we estimate I(t) by Iˆ(t) = X(t).
2.3.1.1 Study of the estimators based on an initial estimation of I(t)
We consider the least squares estimators βˆls1 and Kˆls1 of β and K. Tables 2.2 and 2.3 exhibit their
empirical relative bias and relative standard deviation under the RCS and the NHRS models. Consid-
ering e.g. βˆls1 , the relative bias and relative standard deviation of βˆls1 are deﬁned as E(βˆls1 − βls1)/βls1
and
√
E(βˆ2ls1) − E(βˆls1)2/βls1 respectively. A more visual information is given by Figures 2.2 and 2.3.
First, one can notice that, as expected, the relative bias and relative standard deviation of βˆls1 and Kˆls1
decrease in absolute value when the value of N , the population size, increases.
Table 2.2: Simulation results for the RCS model. Empirical estimation of the relative bias and
the relative standard deviation (between parentheses) of βˆls1 for diﬀerent values of N and β.
Contact rate β N = 100, I0 = 1 N = 1000, I0 = 10
0.2 2.1 × 10−2 (5.4 × 10−2) 3.5 × 10−3 (1.6 × 10−2)
0.8 2.1 × 10−2 (5.1 × 10−2) 2.7 × 10−3 (1.5 × 10−2)
2.0 2.2 × 10−2 (5.3 × 10−2) 3.9 × 10−3 (1.6 × 10−2)
Table 2.3: Simulation results for the NHRS model. Empirical estimation of the relative bias and
the relative standard deviation (between parentheses) of βˆls1 and Kˆls1 for diﬀerent values of N , β and K.
N = 100, I0 = 1 N = 1000, I0 = 10
Contact rate β = 0.2
K = 1.5 βˆls1 2.4 × 10−1 (6.2 × 10−1) 4.5 × 10−2 (8.5 × 10−2)
Kˆls1 −9.3 × 10−2 (1.8 × 10−1) −3.3 × 10−2 (6.7 × 10−2)
K = 2.0 βˆls1 1.8 × 10−1 (4.5 × 10−1) 3.0 × 10−2 (6.5 × 10−2)
Kˆls1 −9.9 × 10−2 (1.8 × 10−1) −3.0 × 10−2 (7.0 × 10−2)
K = 5.0 βˆls1 1.1 × 10−1 (1.1 × 10−1) 1.1 × 10−2 (2.4 × 10−2)
Kˆls1 −1.5 × 10−1 (1.6 × 10−1) −3.0 × 10−2 (6.6 × 10−2)
Contact rate β = 0.8
K = 1.5 βˆls1 2.8 × 10−1 (6.6 × 10−1) 4.0 × 10−2 (8.6 × 10−2)
Kˆls1 −1.1 × 10−1 (1.8 × 10−1) −2.9 × 10−2 (6.7 × 10−2)
K = 2.0 βˆls1 1.6 × 10−1 (4.8 × 10−1) 3.6 × 10−2 (6.6 × 10−2)
Kˆls1 −9.0 × 10−2 (1.7 × 10−1) −3.6 × 10−2 (7.0 × 10−2)
K = 5.0 βˆls1 5.4 × 10−2 (9.5 × 10−2) 1.2 × 10−2 (2.4 × 10−2)
Kˆls1 −9.4 × 10−2 (1.7 × 10−1) −3.2 × 10−2 (6.8 × 10−2)
Contact rate β = 2.0
K = 1.5 βˆls1 2.3 × 10−1 (4.3 × 10−1) 4.3 × 10−2 (8.5 × 10−2)
Kˆls1 −9.3 × 10−2 (1.8 × 10−1) −3.1 × 10−2 (6.7 × 10−2)
K = 2.0 βˆls1 1.8 × 10−1 (3.2 × 10−1) 2.9 × 10−2 (6.0 × 10−3)
Kˆls1 −1.0 × 10−1 (1.9 × 10−1) −2.9 × 10−2 (7.0 × 10−2)
K = 5.0 βˆls1 5.0 × 10−2 (9.0 × 10−2) 1.1 × 10−2 (2.4 × 10−2)
Kˆls1 −9.0 × 10−2 (1.7 × 10−1) −2.8 × 10−2 (6.6 × 10−2)
One can notice that Table 2.3 exhibits a positive bias for βˆls1 and a negative bias for Kˆls1 whatever
are the population size N and the original parameters (β,K). One can observe that the relative bias and
standard deviation of a parameter aren’t impacted by the value of this parameter as displayed in Figures
2.2, 2.3(c) and 2.3(d). Last, Table 2.3 shows that the relative bias and the relative standard deviation of
βˆls1 decrease when the value of K increases.
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Figure 2.2: Simulation results under the RCS model.
Histograms of the relative bias (Figure (a)) and the relative standard deviation (Figure (b)) of βˆls1 based
on 1000 replications of the population with (N, I0) = (100, 1) and (N, I0) = (1000, 10) for diﬀerent
values of β.
1.5 2.0 5.0
0
0.1
0.2
0.3
0.4
Value of K
R
el
at
iv
e 
B
ia
s
N=100
N=1000
(a) Relative bias of βˆls1
1.5 2.0 5.0
0
0.2
0.4
0.6
Value of K
R
el
at
iv
e 
S
td
N=100
N=1000
(b) Relative standard deviation of βˆls1
1.5 2.0 5.0
−0.2
−0.15
−0.1
−0.05
0
Value of K
R
el
at
iv
e 
B
ia
s
N=100
N=1000
(c) Relative bias of Kˆls1
1.5 2.0 5.0
0
0.1
0.2
Value of K
R
el
at
iv
e 
S
td
N=100
N=1000
(d) Relative standard deviation of Kˆls1
Figure 2.3: Simulation results under the NHRS model.
Histograms of the relative bias (Figure (a)), the relative standard deviation (Figure (b)) of βˆls1 , the relative
bias (Figure (c)) and the relative standard deviation (Figure (d)) of Kˆls1 based on 1000 replications of
the population with (N, I0) = (100, 1) and (N, I0) = (1000, 10) with β = 0.8 and diﬀerent values of K.
2.3.1.2 Study of the estimators based on an initial estimation of F (t)
We consider the least squares estimators βˆls2 and Kˆls2 of β and K. Recall that, unlike the estimators
βˆls1 and Kˆls1 deﬁned in (2.6), the least squares estimators βˆls2 and Kˆls2 deﬁned in (2.11) may handle
censored observations. However, when there is no censoring, the estimators are the same.
Tables 2.4 and 2.5 give the results of the simulation study of the relative bias and the relative standard
deviation of βˆls2 and Kˆls2 under both RCS (with β = 0.8) and NHRS (with β = 0.8 and K = 1.5) models
for diﬀerent sample sizes and percentages of censoring. A more visual information is given by Figures
2.4, 2.5 and 2.6.
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One can notice that, as expected, the absolute value of the relative bias and the relative standard
deviation of βˆls2 and Kˆls2 decrease when N increases. It is also not surprising to see that these criterions
increase with the percentage of censoring. Finally, we denote that Kˆls2 has a negative bias disregarding
the population size N .
We now consider the maximum likelihood estimators βˆml and Kˆml of β and K. Tables 2.4 and 2.5
give the results of the simulation study of the relative bias and the relative standard deviation of βˆml and
Kˆml under both RCS and NHRS models (with β = 0.8 and K = 1.5). See Figures 2.4, 2.5 and 2.6 for a
more visual information.
One can notice again that, as expected, the absolute value of the relative bias and the relative stan-
dard deviation of βˆml and Kˆml increase with the percentage of censoring and decrease with N .
Comparing the least squares estimators (βˆls2 , Kˆls2) with the maximum likelihood estimators (βˆml,
Kˆml), one can notice that the values of the relative bias and the relative standard deviation of (βˆml, Kˆml)
are almost always smaller than the values of the relative bias and the relative standard deviation of (βˆls2 ,
Kˆls2).
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Figure 2.4: Simulation results under the RCS model. Histograms of the relative bias (Figure (a)),
the relative standard deviation (Figure (c)) of βˆls2 , the relative bias (Figure (b)) and the relative standard
deviation (Figure (d)) of βˆml based on 1000 replications of the population with (N, I0) = (100, 1) and
(N, I0) = (1000, 10) with β = 0.8 for diﬀerent percentages of censoring.
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Figure 2.5: Simulation results under the NHRS model.
Histograms of the relative bias (Figure (a)), the relative standard deviation (Figure (c)) of βˆls2 , the relative
bias (Figure (b)) and the relative standard deviation (Figure (d)) of βˆml based on 1000 replications of
the population with (N, I0) = (100, 1) and (N, I0) = (1000, 10) with β = 0.8 and K = 1.5 for diﬀerent
percentages of censoring.
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Figure 2.6: Simulation results under the NHRS model.
Histograms of the relative bias (Figure (a)), the relative standard deviation (Figure (c)) of Kˆls2 , the rela-
tive bias (Figure (b)) and the relative standard deviation (Figure (d)) of Kˆml based on 1000 replications
of the population with (N, I0) = (100, 1) and (N, I0) = (1000, 10) with β = 0.8 and K = 1.5 for diﬀerent
percentages of censoring.
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2.3.2 Observation of several independent populations
In this section, we compare the estimation results for n = 1 and n = 100 independent populations. Recall
that, we estimate I(t) by Iˆ(t) = X¯(t) in the particular case n = 100.
Let us ﬁrst consider the least squares estimators βˆls1 and Kˆls1 of β and K. Tables 2.6 and 2.7 displays
the relative bias and the relative standard deviation of the estimators βˆls1 and Kˆls1 under the RCS and
NHRS models with β = 0.8, K = 1.5 for (N, I0) = (100, 1) and (N, I0) = (1000, 10) in the particular case
n = 100. One can notice that, as expected, the relative bias and relative standard deviation of βˆls1 and
Kˆls1 decrease when the value of N increases. One can compare those results with the ones displayed in
Tables 2.2 and 2.3 for n = 1.
In Figure 2.7, we compare the relative bias and standard deviation when n = 1 and n = 100. We only
displayed the case (N, I0) = (100, 1) since similar trends were observed with (N, I0) = (1000, 10). One
can notice that, as expected, the absolute value of the relative bias and the relative standard deviation
greatly decrease as the value of n increases. Figures 2.7(c) and 2.7(d) show again that the relative bias
and the relative standard deviation of βˆls1 decrease when the value of K increases.
As stated before, we observe a positive bias for βˆls1 and a negative bias for Kˆls1 independently of the
parameters (β,K). We conclude that the behavior of βˆls1 (resp. Kˆls1) when n = 100 is similar to the
behavior of βˆls1 (resp. Kˆls1) when n = 1 and that there is a global improvement of the estimations in the
case n = 100.
Table 2.6: Simulation results for the RCS model. Empirical estimation of the relative bias and the
relative standard deviation (between parentheses) of βˆls1 for diﬀerent values of N and β with n = 100.
Contact rate β N = 100, I0 = 1 N = 1000, I0 = 10
0.2 4.1 × 10−4 (4.9 × 10−3) 1.2 × 10−4 (1.5 × 10−3)
0.8 6.5 × 10−4 (5.0 × 10−3) 1.8 × 10−4 (1.6 × 10−3)
2.0 6.0 × 10−4 (4.8 × 10−3) 1.1 × 10−4 (1.6 × 10−3)
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Table 2.7: Simulation results for the NHRS model. Empirical estimation of the relative bias and
the relative standard deviation (between parentheses) of βˆls1 and Kˆls1 for diﬀerent values of N , β and K
with n = 100.
N = 100, I0 = 1 N = 1000, I0 = 10
Contact rate β = 0.2
K = 1.5 βˆls1 8.0 × 10−3 (2.5 × 10−2) 1.5 × 10−3 (7.0 × 10−3)
Kˆls1 −6.7 × 10−3 (2.3 × 10−2) −1.2 × 10−3 (6.7 × 10−3)
K = 2.0 βˆls1 5.5 × 10−3 (1.9 × 10−2) 1.0 × 10−3 (5.5 × 10−3)
Kˆls1 −6.5 × 10−3 (2.3 × 10−2) −1.4 × 10−3 (7.0 × 10−3)
K = 5.0 βˆls1 2.0 × 10−3 (7.0 × 10−3) 5.0 × 10−4 (2.0 × 10−3)
Kˆls1 −5.8 × 10−3 (2.2 × 10−2) −1.1 × 10−3 (7.0 × 10−3)
Contact rate β = 0.8
K = 1.5 βˆls1 8.1 × 10−3 (2.4 × 10−2) 1.6 × 10−3 (7.2 × 10−3)
Kˆls1 −7.3 × 10−3 (2.3 × 10−2) −1.5 × 10−3 (6.7 × 10−3)
K = 2.0 βˆls1 6.2 × 10−3 (1.9 × 10−2) 6.3 × 10−4 (5.7 × 10−3)
Kˆls1 −7.5 × 10−3 (2.3 × 10−2) −7.5 × 10−4 (7.5 × 10−3)
K = 5.0 βˆls1 2.1 × 10−3 (7.1 × 10−3) 3.8 × 10−4 (2.2 × 10−3)
Kˆls1 −6.4 × 10−3 (2.2 × 10−2) −1.3 × 10−3 (7.0 × 10−3)
Contact rate β = 2.0
K = 1.5 βˆls1 8.0 × 10−3 (2.4 × 10−2) 1.0 × 10−3 (7.0 × 10−3)
Kˆls1 −7.3 × 10−3 (2.1 × 10−2) −1.1 × 10−3 (6.4 × 10−3)
K = 2.0 βˆls1 6.5 × 10−3 (1.9 × 10−2) 9.5 × 10−4 (5.5 × 10−3)
Kˆls1 −7.5 × 10−3 (2.3 × 10−2) −1.3 × 10−3 (6.5 × 10−3)
K = 5.0 βˆls1 2.2 × 10−3 (7.5 × 10−3) 3.5 × 10−4 (2.2 × 10−3)
Kˆls1 −6.6 × 10−3 (2.2 × 10−2) −1.1 × 10−3 (7.0 × 10−3)
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Figure 2.7: Simulation results for diﬀerent values of β, K and n.
Histograms of the relative bias (Figure (a)) and the relative standard deviation (Figure (b)) of βˆls1 based
on 1000 replications of population with (N, I0) = (100, 1) under the RCS model. Histograms of the
relative bias (Figure (c)), the relative standard deviation (Figure (d)) of βˆls1 , the relative bias (Figure
(e)) and the relative standard deviation (Figure (f)) of Kˆls1 based on 1000 replications of the population
with (N, I0) = (100, 1) under the NHRS model with β = 0.8.
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We now consider the maximum likelihood estimators βˆml and Kˆml of β and K. Tables 2.8 and 2.9
give the results of the simulation study of the relative bias and the relative standard deviation of βˆml and
Kˆml under, respectively, the RCS and NHRS models with β = 0.8 and K = 1.5 for (N, I0) = (100, 1)
and (N, I0) = (1000, 10) in the particular case n = 100. As expected, we ﬁnd again that the absolute
value of the relative bias and the relative standard deviation of βˆml and Kˆml increase with the percentage
of censoring. One can compare those results with the ones displayed in Tables 2.4 and 2.5 for n = 1.
Referring to censored observations in Table 2.9, one can notice that the relative bias of Kˆml is negative as
observed for the previous estimators (see Tables 2.3, 2.5 and 2.7) while the relative bias of βˆml is positive.
As previously, we only displayed the results of the particular case N = 100 in Figure 2.8 where a
comparison between n = 1 and n = 100 is done. One can notice that the value of the standard deviation
greatly decreases as the value of n increases. However, only a limited improvement is exhibited for the rel-
ative bias of βˆml and Kˆml. Considering Figure 2.8(e), one can notice that the relative bias of Kˆml doesn’t
decrease when n increases. This phenomenon is a consequence of the strange variations observed in Fig-
ure 2.6(b). As observed before, the relative bias of Kˆml is negative while the relative bias of βˆml is positive.
Table 2.8: Simulation results for the RCS model (β = 0.8). Empirical estimation of the relative
bias and the relative standard deviation (between parentheses) of βˆml for diﬀerent percentages of censoring
and diﬀerent values of N with n = 100.
Maximum likelihood estimator
Percentage of censoring N = 100, I0 = 1 N = 1000, I0 = 10
0% 9.1 × 10−5 (3.4 × 10−3) 7.9 × 10−6 (1.1 × 10−3)
10% 1.2 × 10−2 (3.6 × 10−3) 1.2 × 10−2 (3.4 × 10−3)
20% 2.6 × 10−2 (3.9 × 10−3) 2.1 × 10−2 (3.9 × 10−3)
50% 9.0 × 10−2 (5.1 × 10−3) 8.9 × 10−2 (5.0 × 10−3)
Table 2.9: Simulation results for the NHRS model (β = 0.8 and K = 1.5). Empirical estimation
of the relative bias and the relative standard deviation (between parentheses) of βˆml and Kˆml for diﬀerent
percentages of censored times and diﬀerent values of N with n = 100.
Maximum likelihood estimator
Percentage of censoring N = 100, I0 = 1 N = 1000, I0 = 10
0% βˆ −8.0 × 10−4 (1.0 × 10−2) −6.5 × 10−5 (3.0 × 10−3)
Kˆ 6.7 × 10−4 (8.7 × 10−3) 7.3 × 10−5 (2.8 × 10−3)
10% βˆ 1.8 × 10−2 (1.3 × 10−2) 1.3 × 10−2 (7.3 × 10−3)
Kˆ −1.0 × 10−2 (1.1 × 10−2) −8.0 × 10−3 (2.9 × 10−3)
20% βˆ 3.3 × 10−2 (1.4 × 10−2) 3.0 × 10−2 (1.2 × 10−2)
Kˆ −1.7 × 10−2 (1.1 × 10−2) −1.5 × 10−2 (3.0 × 10−3)
50% βˆ 1.2 × 10−1 (2.0 × 10−2) −1.2 × 10−1 (1.9 × 10−2)
Kˆ −6.3 × 10−2 (1.3 × 10−2) −3.7 × 10−2 (6.7 × 10−3)
Since least squares estimators (βˆls1 , Kˆls1) can’t handle censored observations, the comparison between
the relative bias and the relative standard deviation of (βˆls1 , Kˆls1) and (βˆml, Kˆml) is only driven when
there is no censoring. Referring to the estimators’ comparison done in Tables 2.4 and 2.5 when n = 1,
we now compare (βˆls1 , Kˆls1) and (βˆml, Kˆml) when n = 100.
Tables 2.10 and 2.11 show that the values of the relative bias and the relative standard deviation of
(βˆml, Kˆml) are smaller than the values of the relative bias and the relative standard deviation of (βˆls1 ,
Kˆls1) under both RCS and NHRS models.
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Figure 2.8: Simulation results for diﬀerent percentages of censoring and diﬀerent values
of n. Histograms of the relative bias (Figure (a)) and the relative standard deviation (Figure (b)) of
βˆml based on 1000 replications of the population with (N, I0) = (100, 1) under the RCS model with
β = 0.8. Histograms of the relative bias (Figure (c)) and the relative standard deviation (Figure (d))
of βˆml, and the relative bias (Figure (e)) and the relative standard deviation (Figure (f)) of Kˆml based
on 1000 replications of the population with (N, I0) = (100, 1) under the NHRS model with β = 0.8 and
K = 1.5.
Table 2.10: Simulation results for the RCS model (β = 0.8). Empirical estimation of the relative
bias and the relative standard deviation (between parentheses) of βˆls1 and βˆml for diﬀerent values of N
with n = 100.
N = 100, I0 = 1 N = 1000, I0 = 10
Least squares estimator 6.5 × 10−4 (5.0 × 10−3) 1.8 × 10−4 (1.6 × 10−3)
Maximum likelihood estimator 9.1 × 10−5 (3.4 × 10−3) 7.9 × 10−6 (1.1 × 10−3)
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Table 2.11: Simulation results for the NHRS model (β = 0.8 and K = 1.5). Empirical estimation
of the relative bias and the relative standard deviation (between parentheses) of βˆls1 , Kˆls1 , βˆml and Kˆml
for diﬀerent values of N with n = 100.
N = 100, I0 = 1 N = 1000, I0 = 10
βˆ
Least squares estimator 8.1 × 10−3 (2.4 × 10−2) 1.6 × 10−3 (7.3 × 10−3)
Maximum likelihood estimator −4.3 × 10−4 (5.3 × 10−3) −3.5 × 10−5 (1.6 × 10−3)
Kˆ
Least squares estimator −1.4 × 10−2 (4.3 × 10−2) −2.9 × 10−3 (1.3 × 10−2)
Maximum likelihood estimator 6.7 × 10−4 (8.7 × 10−3) 7.3 × 10−5 (2.8 × 10−3)
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2.4 Simulation study of the estimators of the function I(·)
Contrary to what has been done previously, in this section we will not focus on the estimators of the
euclidean parameters β and K anymore but will consider and compare diﬀerent estimators of the function
I(·). Those comparisons will be illustrated via simulated examples for diﬀerent population sizes, number
of populations and percentages of censoring.
First, Figure 2.9 gives a representation of the epidemic model I(t) and the corresponding simulated
observations of X(t) under RCS and NHRS models, for N = 100 and N = 1000 individuals.
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Figure 2.9: Simulation of RCS and NHRS models for (N = 100, I0 = 1) and (N = 1000, I0 = 10).
Blue curves correspond to the RCS model (β = 0.8) and red curves to the NHRS model (β = 0.8 and
K = 1.5).
Considering now n independent populations, we estimate I(t) by Iˆ(t) = X¯(t) where X¯(t) is the mean
number of infected individuals at time t among the n independent populations.
Figure 2.10 gives a representation of the epidemic model I(t) and the corresponding observations X¯(t)
under RCS and NHRS models for 100 populations of size N = 100 and N = 1000.
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Figure 2.10: Simulation of RCS and NHRS models for N = 100, I0 = 1 and N = 1000, I0 = 10.
Blue curves correspond to the RCS model (β = 0.8) and red curves to the NHRS model (β = 0.8 and
K = 1.5).
Let us consider Iˆkm(t). Figure 2.11 gives a representation of the estimator Iˆkm(t) of I(t) with diﬀerent
level of censoring compared with the theoretical epidemic model I(t). Recall that this estimation is based
on a Kaplan-Meier estimation of the cumulative distribution function F (t).
Figure 2.11 shows the bounds of a 95% conﬁdence interval which are obtained thanks to the Greenwood
estimator of the variance. Only the case N = 100 was displayed. The particular case N = 1000 didn’t
give relevant information since both the estimation and theoretical curves were mixed up.
39
Chapter 2. Some estimation problems in epidemic modeling
0 2 4 6 8 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(a) Censoring = 0% - RCS
0 2 4 6 8 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(b) Censoring = 10% - RCS
0 2 4 6 8 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(c) Censoring = 20% - RCS
0 2 4 6 8 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(d) Censoring = 50% - RCS
0 2 4 6 8 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(e) Censoring = 0% - NHRS
0 5 10 15
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(f) Censoring = 10% - NHRS
0 2 4 6 8 10 12
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(g) Censoring = 20% - NHRS
0 5 10
0
20
40
60
80
100
Time
C
um
ul
at
iv
e 
in
fe
ct
io
ns
Estimation
95% CI
Theoretical
(h) Censoring = 50% - NHRS
Figure 2.11: Simulated examples. Plot of I(t), Iˆkm(t) and the pointwise 95% conﬁdence bounds
under the RCS model (with β = 0.8) and the NHRS model (with β = 0.8 and K = 1.5) with 0%, 10%,
20% and 50% of censoring and (N, I0) = (100, 1).
As an indicator of the quality of estimation, we consider the mean integrated squared error (MISE)
for the diﬀerent estimation methods of the function I(·). The MISE of an estimator Iˆ(·) of I(·) is deﬁned
by:
E
[
‖Iˆ − I‖22
]
= E
[∫ +∞
0
(
Iˆ(t) − I(t)
)2
dt
]
(2.12)
where ‖·‖2 is the L2 norm. One can give an empirical estimation of (2.12) by computing the arithmetic
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mean over m simulations of ‖Iˆ(·) − I(·)‖22, i.e:
1
m
m∑
i=1
[∫ +∞
0
(
Iˆi(t) − I(t)
)2
dt
]
where Iˆi(t) is the estimator of I(t) obtained on the ith simulation.
First, let us recall the expression of the four estimators of I(t) deﬁned Section 2.2:
Iˆls1(t) =
N
1 + ψ exp
(
−Bˆls1(t)
)
Iˆkm(t) = N
(
1 + ψFˆ (t)
1 + ψ
)
Iˆls2(t) =
N
1 + ψ exp
(
−Bˆls2(t)
)
Iˆml(t) =
N
1 + ψ exp
(
−Bˆml(t)
).
By following the simulation procedure deﬁned in Section 2.3 for diﬀerent values of N and n, we can
compute the MISE of the diﬀerent estimators over m = 1000 simulations. Hence, Tables 2.12 and 2.13
exhibit the values of the MISE under the RCS (β = 0.8) and the NHRS (β = 0.8 and K = 1.5) models
respectively.
Recall that only the estimators Iˆls1(t) and Iˆml(t) of I(t) have been introduced when dealing with 100
independent populations, thus values of the MISE are missing for Iˆkm(t) and Iˆls2(t) in Tables 2.12 and
2.13 when n = 100.
Since I(t) ∈ [0, N ], one can notice that the value of the MISE increases with the value of N . As
expected, the MISE of each estimator increases with the percentage of censoring and decreases when the
value n increases.
Considering Table 2.12, one can notice that the MISE of the maximum likelihood estimator Iˆml(·) is
the best under the RCS model when dealing with no censored observations and whatever the values of
N and n are. However, when censored data are involved, the MISE of the least squares estimator Iˆls2(·)
is the lowest.
Similar comments can be made when considering Table 2.13 which deals with the NHRS model. As
long as no censored data are considered, the MISE of Iˆml(·) is the best but Iˆls2(·) is doing better when
censored data are involved.
41
Chapter 2. Some estimation problems in epidemic modeling
Table 2.12: Simulation results for the RCS model (β = 0.8). Empirical estimation of the MISE
of the diﬀerent estimations of I(t) for diﬀerent values of N , n and diﬀerent percentages of censoring.
N = 100, I0 = 1 N = 1000, I0 = 10
n = 1 n = 100 n = 1 n = 100 Censoring (%)
Iˆls1(·)
127.4 1.2 1 116 11.8 0%
Iˆkm(·)
127.9 – 1 205 – 0%
240.4 – 6 022 – 10%
519.1 – 25 374 – 20%
4 208 – 380 480 – 50%
Iˆls2(·)
135.7 – 1 243 – 0%
151.0 – 1 393 – 10%
170.5 – 1 611 – 20%
305.4 – 2 647 – 50%
Iˆml(·)
51.9 0.6 559.7 5.5 0%
62.3 1.1 1 294 9.7 10%
100.1 27.1 3 839 306.9 20%
460.9 68.2 33 694 1 256 50%
Table 2.13: Simulation results for the NHRS model (β = 0.8 and K = 1.5). Empirical estimation
of the MISE of the diﬀerent estimations of I(t) for diﬀerent values of N , n and diﬀerent percentages of
censoring.
N = 100, I0 = 1 N = 1000, I0 = 10
n = 1 n = 100 n = 1 n = 100 Censoring (%)
Iˆls1(·)
104.5 0.8 934.4 7.5 0%
Iˆkm(·)
54.8 – 651.8 – 0%
95.8 – 1 602 – 10%
168.0 – 7 714 – 20%
1 383 – 117 750 – 50%
Iˆls2(·)
96.0 – 941.6 – 0%
99.2 – 1 075 – 10%
123.1 – 1 117 – 20%
265.5 – 3 124 – 50%
Iˆml(·)
31.4 0.3 305.5 3.0 0%
37.8 0.42 510 6.1 10%
46.1 1.2 1 140 18.4 20%
149 2.4 8 658 102.6 50%
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2.5 Applications on real data sets
We study two datasets to give a concrete illustration of the diﬀerent estimators. First, we use the dataset
of the Code Red v2 (CRv2) epidemic used by Kirmani et al. (2010). Then we use a dataset of the
reported AIDS (acquired immune deﬁciency syndrome) cases in France.
2.5.1 Application to the Code Red v2 worm propagation
Let us consider in this section the Code Red v2 (CRv2) dataset used by Moore et al. (2002). This dataset,
published on the website of Caida1, presents the propagation of the CRv2 worm during approximately 30
hours. Code Red v2 is a computer worm attacking computers running Microsoft’s ISS web server which
infected more than 359000 computers mainly in the United States, Korea, China and Taiwan during the
19th and the 20th of July, 2001.
The dataset provided on the website of Caida is merged from three diﬀerent sources which recorded
the spread of CRv2 starting from the 19th of July at midnight UTC to the 20th July at 7 UTC in the
morning. That dataset consists of a count of each single one infection with the corresponding relative
time (in seconds) at infection. Figure 2.12 displays a sketch of the number of distinct IP addresses from
t = 0 to t = 30 where t is in hours.
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Figure 2.12: Cumulative number of unique IP addresses infected by the Code Red v2
worm.
We now estimate the parameters of the RCS and the NHRS models by using the estimation methods
introduced earlier. From Table 2.14, one can notice that the least squares estimators and the maximum
likelihood estimators give similar values of βˆ for the RCS model . However, we denote some diﬀerences,
especially for βˆ, between the two methods when dealing with the NHRS model. Those diﬀerences are
illustrated in Figure 2.13.
Table 2.14: Estimation results for the RCS model and the NHRS model. Empirical estimation
of the parameters β for the RCS model and (β,K) for the NHRS model.
NHRS model
RCS model β K
Least squares estimator 2.1 × 10−4 1.4 × 10−2 3.8 × 10−1
Maximum likelihood estimator 2.2 × 10−4 5.0 × 10−4 7.4 × 10−1
Figure 2.13 gives an illustration of the estimation of the RCS and NHRS models for the diﬀerent
estimators. One can notice that the three estimation methods give a quite similar estimation of the RCS
model. In contrast, we denote that the least squares technic diﬀers from the two others methods when
considering the NHRS model.
1http://www.caida.org/home/
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Figure 2.13: Code Red v2 worm propagation dataset. Plot of X(t), Iˆls1(t), Iˆml(t) and Iˆkm(t)
under the RCS model (a) and the NHRS model (b).
2.5.2 Application to the human immunodeﬁciency virus (HIV) transmission
We now focus on the spread of HIV in France. In order to do this, we refer to the dataset of yearly re-
ported AIDS cases from 1982 to 2011 published on the website of Eco-Santé2. Since AIDS is an advanced
stage of HIV infection and by assuming a constant AIDS incubation period, we may consider that the
evolution of AIDS incidence reﬂects quite well the number of new HIV infections per year.
Since the dataset only gives the incidence of AIDS cases, we reconstruct the prevalence curve by
summing the values from previous years. Thus, Figure 2.14 displays the prevalence curve of AIDS cases
from an initial number of I0 = 31 cases in 1982 to a ﬁnal number of N = 67508 cases in 2011.
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Figure 2.14: Cumulative number of AIDS cases in France.
Next, we estimate the parameters of the RCS model and the NHRS model by computing the same
estimation methods as used in Section 2.5.1. From Table 2.15, one can denote that the least squares
estimator and the maximum likelihood estimator give diﬀerent estimations for both RCS and NHRS
models. As shown in Table 2.14, the higher diﬀerence still comes from βˆ in the particular case of the
NHRS model.
Figure 2.15 gives an illustration of the estimation of the RCS and NHRS models for the diﬀerent
estimators. One can notice that for both RCS and NHRS model, estimations are quite diﬃcult whatever
the estimation method. It is especially true for the Kaplan-Meier estimator. We may conclude that both
RCS and NHRS models aren’t suitable to ﬁt that dataset.
2http://www.ecosante.fr
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Table 2.15: Estimation results for the RCS model and the NHRS model. Empirical estimation
of the parameters β for the RCS model and (β,K) for the NHRS model.
NHRS model
RCS model β K
Least squares estimator 5.7 × 10−1 1.2 7.3 × 10−1
Maximum likelihood estimator 4.0 × 10−1 3.0 × 10 3.4 × 10−1
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Figure 2.15: Reported AIDS cases dataset. Plot of X(t), Iˆls1(t), Iˆml(t) and Iˆkm(t) under the RCS
model (a) and the NHRS model (b).
2.6 Conclusions
We investigated several estimation methods for the well known logistic model of worm propagation. First,
we studied the relative bias and the relative standard deviation of the euclidean parameters in Section
2.3. Under the RCS and the NHRS models, the maximum likelihood estimator provided almost always
better estimations than the least squares estimator for both the relative bias and the relative standard
deviation. The least squares estimators were doing better only in the particular case of a high amount of
censoring. Then, by referring to the study of the mean integrated squared error (MISE) in Section 2.4,
our study demonstrated again that the maximum likelihood estimator was the best estimator as long as
a relatively low amount of censoring is involved. However, when the amount of censoring increases, the
least squares estimator tends to be more reliable. Finally, we applied those estimation methods to a real
dataset of the Code Red v2 worm propagation. In the particular case of the RCS model, the diﬀerent
estimation methods gave similar results. Considering the NHRS model, results were more contrasted with
a fairly poor ﬁt for the least squares estimator. However, considering the HIV dataset, all the methods
demonstrated a poor ﬁt to the epidemic curve exhibiting the fact that both models were not suitable for
this dataset.
The studied estimators have proved to be quite eﬃcient tools to deal with the estimation of epidemic
models’ parameters and could be applied to much wider problems such as models of the propagation of
communicable diseases in populations to support health care decision makers. However, some issues are
still to be addressed. Indeed, the development of statistical methods to assess whether the model is in
line with the nature of the studied data should be considered. Moreover, one could ﬁnd of interest to
theoretically study the asymptotic properties of the diﬀerent estimators.
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3 Some models of back-calculation for the hepatitisC virus infection incidence in France
Français
L’hépatite C étant une maladie asymptomatique, l’estimation de sa prévalence reste aujourd’hui un déﬁ
pour les responsables des politiques de santé. En faisant l’hypothèse que le taux d’incidence annuel
du virus de l’hépatite C (VHC) suit une distribution de Poisson, nous traitons dans cette partie deux
méthodes de rétro-calcul basées sur l’estimation par maximum de vraisemblance et sur l’algorithme EM.
En ce basant sur un jeu de données du nombre de décès dus au carcinome hépatocellulaire (CHC) suivi
d’un travail de nettoyage de données pour s’assurer de la pertinence de celles-ci, les deux méthodes de
rétro-calcul sont comparées avec l’approche proposée par Deuﬃc et al. Nos résultats montrent que la
méthode basée sur l’algorithme EM démontre de meilleures performances par rapport aux autres et oﬀre
des résultats en accord avec la prévalence estimée du VHC en France.
English
Since hepatitis C is an asymptomatic disease, its prevalence estimation remains a challenge for health
care policy makers. Assuming that hepatitis C virus (HCV) annual incidence rates follow a Poisson
distribution, we consider in this part two back-calculation methods based on the maximum likelihood
approach and on the EM-algorithm. Using a CépiDc’s database on the number of deaths related to hep-
atocellular carcinoma (HCC) and after a large data cleansing activity to ensure for the data’s relevance,
both back-calculation methods are compared with the approach proposed by Deuﬃc et al. It is found
that the method based on the EM-algorithm demonstrates better performances than other approaches
and oﬀers consistent results with the estimated HCV prevalence in France.
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Résumé
Ce troisième chapitre se propose d’étudier plusieurs modèles de rétro-calcul pour l’estimation de l’incidence
du virus de l’hépatite C (VHC) en France. Les résultats de ces modèles sont notamment comparés avec
l’approche de référence en France développée par Deuﬃc-Burban et al. (1999) et basée sur un modèle
logistique.
L’hépatite C est une maladie asymptomatique dont l’une des conséquences est la survenue, au bout de
quelques décennies, d’un carcinome hépatocellulaire (CHC) dont le pronostic médical est souvent fatal.
En se basant d’une part sur les données des décès liés au CHC et d’autre part sur le temps entre l’infection
par le VHC et le décès lié au CHC, nous nous proposons de développer des modèles de rétro-calcul aﬁn
de remonter à l’incidence passée du VHC.
L’hypothèse générale autour de laquelle s’articule ce chapitre suppose que le nombre d’infections du
au VHC peut être modélisé via des distributions de Poisson. Ainsi, en notant Yj le nombre de décès dus
au CHC l’année j et Xij le nombre de contamination par le VHC l’année i dont le décès par CHC s’est
produit l’année j, on écrit :
E(Yj) =
∑
i
θifj−i
où θi est le nombre moyen de nouvelles infections l’année i et fj−i la probabilité qu’un individu infecté
par le VHC l’année i décède d’un CHC l’année j.
Dans le but d’estimer θi, nous nous intéressons dans un premier temps à deux modèles paramétriques
(modèle logistique et modèle exponentiel gaussien) et à la méthode du maximum de vraisemblance.
Puis, aﬁn de s’aﬀranchir du biais généré par ces modèles paramétriques, nous nous orientons vers une
approche basée sur l’algorithme d’espérance maximisation lissé (EMS pour expectation maximization
smoothing, Silverman and Nychka (1990)) extension directe de l’algorithme d’espérance maximisation
(EM) développé par Dempster et al. (1977).
Dans ce chapitre, le traitement des données prend une place prépondérante. En eﬀet, suite à un
changement de CIM (classiﬁcation internationale des maladies) en 1999, les données de décès liés au
CHC ont été reportées diﬀéremment avant et après 1999 entraînant un décalage conséquent entre les
données de décès pré-1999 et post-1999. Nous parvenons ainsi à obtenir une série chronologique des décès
par CHC lié au VHC cohérente et supposons que ce nombre de décès est nul en France avant 1920.
Nous nous proposons ensuite de donner une estimation de fj−i à partir d’un modèle d’histoire naturelle
de la maladie. Ce modèle de type chaîne de Markov à temps discrets est construit à partir de données de
la littérature, Deuﬃc-Burban et al. (1999) principalement, et permet de donner une estimation de fj−i
en calculant le temps moyen passé par un individu dans la chaîne de Markov.
Nous nous focalisons ensuite sur le développement d’une version simpliﬁée du modèle de Deuﬃc-
Burban et al. (1999). Les performances de ces modèles sont directement mesurées par l’intermédiaire du
critère des moindres carrés.
Les résultats obtenus à partir de nos trois modèles sont satisfaisants avec un avantage net pour
le modèle basé sur l’algorithme d’espérance maximisation lissé. En eﬀet, ces résultats sont à la fois en
accord avec les résultats obtenus par le modèle simpliﬁé de Deuﬃc-Burban et al. (1999) en ce qui concerne
l’estimation de l’incidence passée du VHC en France ainsi qu’avec l’estimation de la prévalence réalisée
par l’INVS pour l’année 2004.
3.1 Introduction
In the last decades, hepatitis C virus (HCV) has become a major threat to public health with an esti-
mated 80 million chronic carriers worldwide (see Gower et al. (2014)). Leading to severe end-stage liver
complications such as liver cirrhosis, hepatic failure and hepatocellular carcinoma (HCC), HCV is respon-
sible for hundreds of thousands of deaths each year. In France, the prevalence of anti-HCV antibodies
has been estimated at 0.84% (95%CI:0.65-1.10) in 2004 with a proportion of individuals aware of their
sero-status estimated at 57% (95%CI:43-71) (see Institut de veille sanitaire (2007)). As new therapeutics
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emerge, establishing successful strategies to eliminate the virus requires to estimate the total number of
infected individuals and to identify the stage of ﬁbrosis.
To address this issue, one might use mathematical technics, such as back-calculation, to reconstruct the
past incidence and model the future burden of the disease (see Deuﬃc-Burban et al. (1999); Griﬃths and
Nix (2002); McEwan et al. (2014); Sweeting et al. (2007)). Basically, back-calculation is based on the use
of actual observed data (i.e death certiﬁcates, diagnoses, etc) and on the assessment of the time between
infection and those data to estimate the number of infections that took place in the past. Considering
the particular case of France and assuming that the past incidence of HCV is a logistic function, Deuﬃc-
Burban et al. (1999) proposed an eﬃcient back-calculation approach based on the weighted least squares
criterion and reported HCC deaths to estimate that past incidence.
In 2014, to estimate the past incidence of HCV in Taiwan, McEwan et al. (2014) used an approach
based on the human immunodeﬁciency virus (HIV) past incidence reconstruction (see Bacchetti et al.
(1993); Becker and Marschner (1993); Brookmeyer and Gail (1994)) assuming all HCV infections were in-
dependent random variables following Poisson distributions. This approach makes use of the expectation-
maximization-smoothing (EMS) algorithm by Silverman and Nychka (1990), based on the original ex-
pectation maximization (EM) algorithm by Dempster et al. (1977), and does not make assumptions on
the shape of the past incidence curve.
The objective of this chapter is to propose an adaptation of the approach developed by McEwan
et al. (2014) to the French national data of the observed number of deaths due to HCC, to estimate
the past incidence of the chronic hepatitis C virus infection in France. Along with this, we introduce
some parametric models based on well-known epidemic models from the literature to give an alternative
approach of the work of McEwan et al. (2014). After a large work of formatting the data, to ensure that
we only focus on HCC deaths, comparisons will be made with the model developed by Deuﬃc-Burban
et al. (1999).
This chapter is organized as follows: Section 2 provides an overview of the model studied and the
diﬀerent estimation methods considered. The presentation of the dataset and of the lifetime distribution
are given in Section 3. Then, Section 4 exhibits our results and compares the diﬀerent models. Finally,
Section 5 presents our conclusions.
3.2 Models and estimation methods
In this part, we propose to model the past incidence of HCV via Poisson distributions. Several estimation
methods will be introduced to make some comparisons with the model developed by Deuﬃc-Burban et al.
(1999) on the estimation of the past infections of HCV.
3.2.1 Model
Let us denote {Xij} the unobserved number of people infected in year i who died of HCC related to HCV
in year j, for i  j. For the sake of practicality, we assume that j − i  100. We denote {Xi} the number
of people infected in year i which leads to Xi =
∑i+100
j=i Xij .
We assume that the random variables {Xij} are realizations of independent Poisson variables with
parameters θifij where θi is the mean number of new infections in year i and fij the probability that an
individual infected by HCV in year i dies of HCC related to HCV in year j.
We assume that fij remains the same for each individual and does not vary over time. For more
convenience, we change the notation fij to fj−i where fj−i is the probability that the duration between
the infection of a given individual and his death by HCC is j − i. In the following pages, we refer to f
as lifetime distribution.
However, as {Xi} and {Xij} are unobserved data, we introduce the observed data {Yj} which is the
number of people who died from HCC related to HCV in year j, −∞ < j  T where T corresponds to
the last year of observation. In practice, we have t0  j  T where t0 is the time of the beginning of the
epidemic. Thus, one can write:
Yj =
j∑
i=t0j
Xij .
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where t0j = max(t0, j − 100). Since we assumed that each infected individual is assigned a lifetime
independently and that the number of new infections is independent from one year to another, the
random variable {Yj} are independent Poisson random variables with mean:
E(Yj) =
j∑
i=t0j
θifj−i. (3.1)
In the next section, we propose to set several parametric models over the θi to give an estimation of
the past incidence of HCV based on well-known epidemic models of the literature.
3.2.2 Maximum likelihood estimation
To give an estimation of θi using the maximum likelihood estimation method, we compute the likelihood
of {Yj} with parameter θ = (θt0 , . . . , θT ):
L(Y ; θ) =
T∏
j=t0
⎡⎣ 1
yj !
⎛⎝ j∑
i=t0j
θifj−i
⎞⎠yj exp
⎛⎝− j∑
i=t0j
θifj−i
⎞⎠⎤⎦ .
It follows that the log-likelihood of {Yj} with parameter θ is:
l(Y ; θ) =
T∑
j=t0
⎡⎣yj × ln
⎛⎝ j∑
i=t0j
θifj−i
⎞⎠− j∑
i=t0j
θifj−i − ln(yj !)
⎤⎦ . (3.2)
We will now introduce two diﬀerent parametric models for θ. Let us ﬁrst consider the logistic model
for population dynamics introduced by Verhulst (1838) with equation:
fL(t;K,α, β) =
K
1 + e−α(t−β), (3.3)
where K is the plateau value as t → ∞, the parameter α is the growth rate and β a translation parameter.
To allow for a general decrease of new infected cases corresponding to the elimination of transfusion-
associated HCV infections after 1989, we modify (3.3) by assuming a reduction of 40% of new cases,
exactly as Deuﬃc-Burban et al. (1999) did. Thus, we have:
fL(t;K,α, β) =
⎧⎪⎪⎨⎪⎪⎩
K
1 + e−α(t−β), for t < 1990
0.6 × K1 + e−α(t−β), otherwise.
Next, by assuming a declining number of infected cases after a peak of infection, we introduce a model
based on an exponentially modiﬁed Gaussian (EMG) function (see Grushka (1972)):
fE(t;H,λ, μ, σ) =
Hλ
2 e
λ
2 (2μ+λσ
2−2t) ercf
(
μ + λσ2 − t√
2σ
)
,
where H is a scale parameter and ercf the complementary error function deﬁned as:
ercf(t) =
2√
π
∫ ∞
t
e−x
2
dx.
By replacing the expression of θi in equation (3.2) by fL(i; ·) or fE(i; ·), one can estimate the model
parameters by maximizing the following likelihoods:
lL(Y ;K,α, β) =
T∑
j=t0
⎡⎣yj × ln
⎛⎝ j∑
i=t0j
(
Kfj−i
1 + e−α(i−β) · • {i<1990} +
0.6 × Kfj−i
1 + e−α(i−β) · • {i1990}
)⎞⎠
−
j∑
i=t0j
(
Kfj−i
1 + e−α(i−β) · • {i<1990} +
0.6 × Kfj−i
1 + e−α(i−β) · • {i1990}
)
− ln(yj !)
⎤⎦ ,
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lE(Y ;H,λ, μ, σ) =
T∑
j=t0
⎡⎣yj × ln
⎛⎝ j∑
i=t0j
Hλ
2 e
λ
2 (2μ+λσ
2−2i) ercf
(
μ + λσ2 − i√
2σ
)
fj−i
⎞⎠
−
j∑
i=t0j
Hλ
2 e
λ
2 (2μ+λσ
2−2i) ercf
(
μ + λσ2 − i√
2σ
)
fj−i − ln(yj !)
⎤⎦ .
Let us denote Kˆ, αˆ, βˆ, Hˆ, λˆ, μˆ and σˆ the maximum likelihood estimators of K, α, β, H, λ, μ and σ
obtained by maximization of the above likelihoods. Then we can deduce maximum likelihood estimators
of θ given by:
θˆiL =
Kˆ
1 + e−αˆ(i−βˆ)
· • {i<1990} +
0.6 × Kˆ
1 + e−αˆ(i−βˆ)
· • {i1990}
and
θˆiE =
Hˆλˆ
2 e
λˆ
2 (2μˆ+λˆσˆ
2−2i) ercf
(
μˆ + λˆσˆ2 − i√
2σˆ
)
.
We will compare the models introduced previously with a simpliﬁed version of the model developed
by Deuﬃc-Burban et al. (1999) (see Section 3.3.5).
However, setting parametric models on θi, induce some bias inherent to the models. Indeed, by choos-
ing a logistic or an exponentially modiﬁed Gaussian model, we constraint θi to a particular shape. Thus,
to address this issue, we propose to use an estimation procedure based on the expectation maximization
smoothing (EMS) algorithm developed by Silverman and Nychka (1990).
3.2.3 Expectation maximization smoothing algorithm
To give an estimation of θ, one can apply the EMS algorithm on the unobserved complete data {Xij},
for t0  i  j  T . As {Xij} follows a Poisson distribution with mean θifj−i, one can compute the
log-likelihood of {Xij} given θ:
l(X; θ) ∝
T∑
i=t0
Tmax,i∑
j=i
[xij × ln (θifj−i) − θifj−i] , (3.4)
where Tmax,i = min(i + 100, T ). Then, we compute the conditional expectation of (3.4) given {Yj}, for
t0  j  T , and θ˜(p):
E
(
l(X; θ)|{Yj = yj ; j = t0, . . . , T}, θ˜(p)
)
∝
T∑
i=t0
Tmax,i∑
j=i
(
E
(
Xij |{Yj = yj ; j = t0, . . . , T}, θ˜(p)
)
× ln (θifj−i) − θifj−i
)
,
(3.5)
where θ˜(p) is the estimate of θ at the p-th iteration. From (3.5) we deduce that the E-step of the EM
algorithm is reduced to computing E
(
Xij |{Yj = yj ; j = t0, . . . , T}, θ˜(p)
)
.
Since for independent Poisson variables X and Y with parameters θX and θY , we have:
E(X|X + Y ) = (X + Y ) θX
θX + θY
,
we easily deduce that:
E
(
Xij |{Yj = yj ; j = t0, . . . , T}, θ˜(p)
)
= yj ×
θ˜
(p)
i fj−i∑j
k=t0j θ˜
(p)
k fj−k
.
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Next, we compute the M-step by deriving (3.5) with respect to θi and setting the derivative equal
to 0.
Tmax,i∑
j=i
⎡⎣yj × θ˜(p)i fj−i∑j
k=t0j θ˜
(p)
k fj−k
× fj−i
θ˜ifj−i
− fj−i
⎤⎦ = 0, for i = t0, . . . , T.
Thus, the estimate of θi at the (p + 1)th iteration is given by:
θ˜
(p+1)
i =
1∑Tmax,i
j=i fj−i
Tmax,i∑
j=i
⎡⎣yj × θ˜(p)i fj−i∑j
k=t0j θ˜
(p)
k fj−k
⎤⎦ , for i = t0, . . . , T. (3.6)
However, such an estimation technic leads to a very unstable estimation of θi contrasting with the rel-
ative smoothness of the curve of incident cases per year. Indeed, as highlighted by Becker and Marschner
(1993), the unsmoothed estimate tends to have some erratic pattern. Hence, we add an extra step to the
EM algorithm by applying a moving average on the θ˜i provided by equation (3.6). We write:
θˆ
(p+1)
i =
L∑
l=0
ωl × θ˜(p+1)i+l−L/2 (3.7)
where L is the order of the moving average and the ωl are symmetric weights such as
∑
l ωl = 1.
Referring to Bacchetti et al. (1993); Becker and Marschner (1993); Brookmeyer and Gail (1994); Silverman
and Nychka (1990), we rely on a weighted moving average by setting ωl proportional to the binomial
coeﬃcients. Hence, we have:
ωl =
1
2L ×
(
L
l
)
, l = {0, 1, . . . , L},
which is known as binomial ﬁlter with bandwidth L. The value obtained in equation (3.7) is then reused
in a new iteration of the EMS algorithm.
Finally, we deﬁne a criterion for convergence for the EMS algorithm. We choose ε as small as possible
such that: ∥∥∥θˆ(p+1) − θˆ(p)∥∥∥
2∥∥∥θˆ(p)∥∥∥
2
< ε
where ‖ · ‖2 is the L2 norm in RT . In the following pages, we choose ε = 10−4 and denote θˆ the resulting
estimator.
3.2.4 Precision
Dealing with a large number of parameters and a smoothing step which leads to additional uncertainties,
one can compute a conﬁdence interval to get additional information on the precision of the estimation.
Following the procedure proposed by Becker and Marschner (1993), we generate a point-wise bootstrap
conﬁdence interval for θˆ.
Firstly, for t0  j  T , we compute N realizations Y (1)j , . . . , Y
(N)
j from a Poisson distribution with
mean
j∑
i=t0j
θ˜ifj−i
where θ˜i is the unsmoothed estimator of θi obtained in equation (3.6). We use the unsmoothed es-
timator of θi to compensate for the uncertainty brought by the density estimation obtained via the
kernel-smoothing method (see Becker and Marschner (1993)).
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Secondly, we apply the EMS algorithm to the N realizations Y (1)j , . . . , Y
(N)
j , for t0  j  T . We
obtain N new smoothed estimators of θi denoted θˆ(1)i , . . . , θˆ
(N)
i , for t0  i  T .
Finally, we sort θˆi − θˆ(1)i , . . . , θˆi − θˆ(N)i in ascending order and compute μi,1−α/2 (resp. μi,α/2) the
1 − α/2 (resp. α/2) percentile of the bootstrap distribution of θˆi. Thus,
[
θˆi − μi,1−α/2; θˆi − μi,α/2
]
are
pointwise bootstrapped 1 − α conﬁdence intervals of θˆi, for i = t0, . . . , T . The same procedure is applied
to the models described in Section 3.2.2 to get pointwise bootstrapped 1 − α conﬁdence intervals of θˆiL
and θˆiE .
3.3 The CépiDc dataset of death by HCC in France between
1979 and 2012
3.3.1 Data
We refer to the database of the number of reported deaths by HCC in France from 1979 to 2012 published
on the website of CépiDc1. As diseases classiﬁcation changed in 2000, we reported in Table 3.1 the codes
used for the data extraction where ICD-9 and ICD-10 stand for International Classiﬁcation of Diseases,
Ninth and Tenth Revisions (see World Health Organization (1977, 1992)). Since we consider HCC, we
only focus on the codes 155.0 and C22.0. However, due to some misclassiﬁed codes, the codes 155.2 and
C22.9 were also used to estimate the data.
Table 3.1: Causes of death extracted from CépiDc.
ICD Code Description
version
ICD-9 155.0 Malignant neoplasm of liver, primary
155.2 Malignant neoplasm of liver, not speciﬁed as primary or secondary
ICD-10 C22.0 Liver cell carcinoma
C22.9 Malignant neoplasm of liver, not speciﬁed as primary or secondary
Only HCC deaths related to compensated cirrhosis were considered since HCC deaths related to de-
compensated cirrhosis were reported as death related to cirrhosis and not HCC (see Mourad (2014)).
By computing the mean proportion of people of each gender in the database of HCC deaths, one can
ﬁnd that the proportion of men is 81.4%. Since this proportion does not reﬂect the proportion of men
in the overall population infected by HCV, we decide to study each gender apart and adjust the results
to estimate the overall infected population. Based on the cohort studied by Deuﬃc-Burban et al. (2008),
we assume that the proportion of men is 57%. Then by multiplying the number of men who died of HCC
related to HCV by 0.57/0.814 = 0.7002 and the number of women who died of HCC related to HCV
by 0.43/0.186 = 2.3118, one can compute the number of HCC related to HCV deaths for the overall
population.
As a consequence of the changement of classiﬁcation, one can notice large gaps between values in
year 1999 and values in year 2000 for both men and women in Figures 3.1(a) and 3.1(b). This lack of
correspondence between data before and after 2000 has already been raised by Duberg and Hultcrantz
(2008) in a correspondance with Bosetti et al. (2008).
However, considering the two gaps, one can notice a relative symmetry which allows us to think that
some death certiﬁcates might have been misclassiﬁed. Qualiﬁed experts of CépiDC conﬁrmed that hy-
pothesis by aﬃrming that some death certiﬁcates could have been coded 155.0 instead of 155.2.
Hence, for the sake of simplicity, we propose to multiply the number of deaths coded 155.0 for men
(resp. women) by some constant cm (resp. cw) assuming a general increase of the trend in mortality
1Centre d’épidémiologie sur les causes médicales de décès - http://www.cepidc.inserm.fr/site4/
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of HCC. As the number of deaths coded C22.0 after 2000 is nearly constant until 2012, we assume that
the number of deaths coded 155.0 in 1999 for men (resp. for women) equals the number of deaths coded
C22.0 in 2000 divided by cm (resp. cw). Thus, by denoting Y m1999 (resp. Y w1999 ) the number of death
certiﬁcates coded 155.0 in 1999 for men (resp. women) and Y m2000 (resp. Y w2000) the number of death
certiﬁcates coded C22.0 in 2000 for men (resp. women), we write:
cm =
Y m2000
Y m1999
= 0.8354 and cw =
Y w2000
Y w1999
= 0.6897. (3.8)
Since we are studying HCV, we need to estimate the proportion of HCC deaths related to HCV as
various causes lead to HCC. Many studies have reported so far some contrasted values for the proportion
of HCC attributable to HCV in diﬀerent countries (see Deuﬃc-Burban et al. (1999); El-Serag (2002);
El-Zayadi et al. (2005); Yoshizawa (2002)). Globally, Perez et al. (2006) reported a worldwide proportion
p of HCV-related HCC of 25% for the year 2002 while Marcellin et al. (2008) reported a proportion of
22.5% for the year 2001 in France. Let us take p = 0.225 as it corresponds to the most recent estimation
based on French data.
On the basis of what precedes, Figure 3.2 displays the adjusted dataset for the overall population and
for both men and women between 1979 and 2012.
Finally, to face some computational issues due to the lack of data before 1979, we extrapolate the
number of HCC deaths related to HCV in the past. To give a realistic shape to the curve of the past
deaths and assuming that there is no death from HCC related to HCV before 1920, we ﬁt a gaussian
function
f(x) = α exp
⎛⎝−( (x − β)
γ
)2⎞⎠
with a non-linear least squares procedure which gives us the following values α = 912.8, β = 2008 and
γ = 23.51. Values of f(x) were rounded up. Extrapolated data before 1979 are displayed in Figure 3.2
for t0 = 1920 and T = 2012.
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(a) Annual number of reported death for men
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(b) Annual number of reported death for women
Figure 3.1: Number of reported deaths due to a liver tumor in France extracted from
CépiDC.
The mid grey dots represent the number of annual reported deaths coded 155.0 then C22.0 and the light
grey dots represent the number of annual reported deaths coded 155.2 then C22.9. (a) Annual number
of deaths for men. (b) Annual number of deaths for women.
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Figure 3.2: Adjusted number of HCC deaths related to HCV in France.
The mid grey dots represent the adjusted data for men, the light grey dots represent the adjusted data
for women and the black dots represent the adjusted data for the overall population.
3.3.2 Natural history model
Since HCV has a long asymptomatic period, it is quite diﬃcult to know the period duration between the
infection and the deaths by HCC. To estimate this lifetime distribution, we model the natural history of
the disease. Once the infection occurs, the subject enters in the so-called acute phase of infection denoted
state A. This phase is followed by the chronic phase if no spontaneous clearance happens within the six
months after infection. The chronic phase corresponds to the slow decay of the liver in a 5-step process
(from F0 to F4) named ﬁbrosis which leads to the development of cirrhosis. As the cirrhosis progresses,
the subject may develop a hepatocellular carcinoma (state HCC) or a decompensated cirrhosis (state
DC) which could lead to death.
Let us consider a discrete time Markov chain as a model of the natural history of HCV, with graph
displayed in Figure 3.3. We denote by pSi→Sj the annual transition probabilities between two given stages
Si and Sj of the Markov chain. For simpliﬁcation purposes, death unrelated to HCV was not displayed
on the graph.
Susceptible
population
A F0 F1 F2 F3 F4
DCHCCD
Chronic HCV progressionpS→A
pA→C
1 − pA→C
p0→1 p1→2 p2→3 p3→4
p3→H
p4→H
p4→DC
pH→D
pDC→D
pDC→H
Figure 3.3: Markov model of the natural history of HCV.
A, acute infection; F0-F4, stages of the ﬁbrosis progression based on the Metavir scoring system indicating
the degree of inﬂammation; HCC, hepatocellular carcinoma; DC, decompensated cirrhosis; D, death due
to HCV.
As the total prevalence was estimated for chronic carriers in 2004 in France (see Institut de veille
sanitaire (2007)), we choose to focus on chronic carriers of HCV. Moreover, since no data is available for
the number of death from HCC related to a decompensated cirrhosis nor from decompensated cirrhosis
related to HCV, the state DC is discarded of the model. Thus, as a ﬁrst step, we will only study the
population who died from HCC related to HCV and simplify the previous Markov chain to focus on the
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chain with graph displayed in Figure 3.4.
F0 F1 F2 F3 F4
HCCD
Chronic HCV progression
p0→1 p1→2 p2→3 p3→4
p′3→H
p′4→H
pH→D
Figure 3.4: Simpliﬁed Markov model of the natural history of HCV.
F0-F4, stages of the ﬁbrosis progression based on the Metavir scoring system indicating the degree of
inﬂammation; HCC, hepatocellular carcinoma; D, death due to HCV.
Especially, one can notice that transition probabilities from F3 and F4 to HCC are not the same
between the two chains. The reason of that modiﬁcation is that p3→H and p4→H apply to the whole
infected population while p′3→H and p′4→H apply to the infected population who will develop HCC.
As all infected patients do not necessarily develop HCC, we have:
p′3→H = p3→H/h × ρ and p′4→H = p4→H/h × φ (3.9)
where h is the proportion of patients who will develop HCC and ρ and φ the proportions of patients
coming from F3 and F4 respectively.
To determine p′3→H and p′4→H , we need to determine the proportion h of patients who actually develop
HCC. Since Lok et al. (2009) reported a proportion of 4.9% among a population of 1,005 patients in 2009,
we choose h = 0.049. In the same time, they estimated a cumulative 5-year HCC incidence of 4.1% and
7.0% for patients with bridging ﬁbrosis (F3) and for patients with cirrhosis (F4) respectively. From this,
we may compute:
ρ =
0.041
(0.07 + 0.041) = 0.37 and φ =
0.07
(0.07 + 0.041) = 0.63.
We can also compute the transition probabilities p3→H and p4→H by applying the following transforma-
tion:
− ln(1 − CIr)
d
where CIr is the cumulative incidence rate and d the period of time during which CIr is measured. With
d = 5 and CIr = 0.041 for patients with bridging ﬁbrosis and CIr = 0.07 for patients with cirrhosis
given by Lok et al. (2009), we obtain p3→H = 0.0084 and p4→H = 0.0145 respectively. From (3.9), we
obtain p′3→H = 0.0634 and p′4→H = 0.1864.
The remaining transition probabilities reported in Table 3.2 were found in the literature. Those
were mainly found in the work of Deuﬃc-Burban et al. (2008) who considered gender, age and alcohol
consumption (slight vs heavy drinkers) as covariates in HIV-negative patients. Hence, to compute our
transition probabilities, we assume that gender, age and alcohol consumption distributions have the same
distributions as the cohort studied by Deuﬃc-Burban et al. (2008) since no data on those covariates were
available in the database of CépiDc.
We assume a spontaneous clearance of 25% over 6 months, as reported by Micallef et al. (2006). Thus,
we obtain pA→C = 0.5625 as an annual rate .
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Table 3.2: Annual transition probabilities of the natural history model.
†Transition during the ﬁrst year. ‡Transition during the second year and after.
Parameters Values used in the model Sources
pA→C 0.5625 Micallef et al. (2006)
p0→1 0.1401 Deuﬃc-Burban et al. (2008)
p1→2 0.1401 Deuﬃc-Burban et al. (2008)
p2→3 0.1401 Deuﬃc-Burban et al. (2008)
p3→4 0.1581 Deuﬃc-Burban et al. (2008)
p3→H / p′3→H 0.0084 / 0.0634 Lok et al. (2009)
p4→H / p′4→H 0.0145 / 0.1864 Lok et al. (2009)
p4→DC 0.0711 Deuﬃc-Burban et al. (2008)
pDC→H 0.0534 Planas et al. (2004)
pDC→D 0.3900† / 0.1100‡ D’Amico et al. (2006)
pH→D 0.7456† / 0.2726‡ El-Serag et al. (2001)
3.3.3 Lifetime distribution of an individual who develop and die of HCC
From the Markov chain established in the previous section, we want to determine the lifetime distribution
f deﬁned in Section 3.2.1. The survival can be characterized as the time spent by a given individual in
the Markov chain. We denote by S the random variable describing the time spent by an individual in
the Markov chain:
{F0, F1, F2, F3, F4, HCC, D}.
Let us denote P the transition matrix of the Markov chain described in Figure 3.4. Hence, we have:
P =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝
1 − p0→1 p0→1 0 0 0 0 0
0 1 − p1→2 p1→2 0 0 0 0
0 0 1 − p2→3 p2→3 0 0 0
0 0 0 1 − p3→4 − p′3→H p3→4 p′3→H 0
0 0 0 0 1 − p′4→H p′4→H 0
0 0 0 0 0 1 − pH→D pH→D
0 0 0 0 0 0 1
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠
.
We may simplify P as the following block matrix:
P =
(
Q Q0
0 1
)
where Q0 = (0, 0, 0, 0, 0, pH→D)ᵀ, 0 = (0, 0, 0, 0, 0, 0) and
Q =
⎛⎜⎜⎜⎜⎜⎜⎝
1 − p0→1 p0→1 0 0 0 0
0 1 − p1→2 p1→2 0 0 0
0 0 1 − p2→3 p2→3 0 0
0 0 0 1 − p3→4 − p′3→H p3→4 p′3→H
0 0 0 0 1 − p′4→H p′4→H
0 0 0 0 0 1 − pH→D
⎞⎟⎟⎟⎟⎟⎟⎠ .
Thus, by denoting τ = (1, 0, 0, 0, 0, 0) the initial distribution, we obtain:
P(S = k) = τQk−1Q0,
where k is the number of cycles spent in the Markov chain. By writing f(k) = P(S = k), the random
variable S is said to be phase-type distributed with probability distribution function f . One can consult
Asmussen (2003) for a full account of the theory of phase-type distributions. With our previous notation,
fj−i = τQ(j−i)−1Q0.
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The main disadvantage of this method is the fact that by referring to a discrete time Markov chain,
we are limited to fj−i = 0, for j − i = 1, . . . , 6, since 6 years is considered as the minimum absorbing
time of the Markov chain. To solve this issue, we decide to ﬁt the phase-type distribution f with a given
distribution by estimating its parameters with respect to the least squares criterion.
Since the phase-type distribution considered is discrete, the following distributions were tested:
{Binomial, Poisson, Negative Binomial, Geometric}.
It turned out that the negative binomial distribution was the best ﬁt with estimators (rˆ, pˆ) = (7.2634, 0.8122)
with graph displayed in Figure 3.5. We conclude that:
fj−i =
(
j − i + rˆ − 1
j − i
)
· pˆj−i(1 − pˆ)rˆ.
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Figure 3.5: Lifetime distribution. Lifetime distribution adjusted by a negative binomial distribution
with parameters (rˆ, pˆ) = (7.2634, 0.8122).
By computing the mean of the negative binomial distribution with parameters estimated above, we
obtain 31.4 years. As occurrence of HCC after HCV infection and the mean lifetime of untreated patients
with HCC have been estimated to 25-30 years (see Castells et al. (1995); Tong et al. (1995)) and to 0-3
years (see Cabibbo et al. (2010); Giannini et al. (2015)) respectively, our estimation is comparable to
these.
3.3.4 Distribution of the time to death from HCC in the overall population
Until now, we focused on estimating the population who will actually develop and die of HCC. To es-
timate the overall population, we denote by Θi the mean number of people infected by HCV in year i.
We assume that Θi follows the same trend as θi, more precisely that Θi = λ · θi, where λ > 0. Thus, we
will estimate Θi by λˆ · θˆi where the estimator λˆ is given below. Similar argument holds for θˆiL and θˆiE
introduced in Section 3.2.2.
To give an estimation of λ, let us modify the Markov chain described in Figure 3.4 by including a new
state OCD (Other Cause of Death) corresponding to the patient ﬂows leaving the Markov chain, i.e the
patients leaving due to natural mortality or development of a decompensated cirrhosis. The states of this
new Markov chain are {F0, F1, F2, F3, F4, HCC, D, OCD} with graph described in Figure 3.6 where pm
is the French natural mortality rate extracted from the database of Insee2.
2Institut national de la statistique et des études économiques - http://www.insee.fr/
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F0 F1 F2 F3 F4
HCCD
OCD
Chronic HCV progression
p0→1 p1→2 p2→3 p3→4
p3→H
p4→H
pH→D
pm
pm
pm
pm
p4→DC + pm
pm
Figure 3.6: Simpliﬁed Markov model of the natural history of HCV with extra state OCD.
F0-F4, stages of the ﬁbrosis progression based on the Metavir scoring system indicating the degree of
inﬂammation; HCC, hepatocellular carcinoma; D, death due to HCV; OCD, patients who left due to
natural mortality or decompensated cirrhosis.
By denoting P ′ the transition matrix of the Markov chain with graph displayed in Figure 3.6, we
have:
P ′ =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
p0 p0→1 0 0 0 0 0 pm
0 p1 p1→2 0 0 0 0 pm
0 0 p2 p2→3 0 0 0 pm
0 0 0 p3 p3→4 p3→H 0 pm
0 0 0 0 p4 p4→H 0 pm + p4→DC
0 0 0 0 0 1 − pH→D − pm pH→D pm
0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 1
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
. (3.10)
To simplify the expression of (3.10), we used the following notations:⎧⎪⎪⎪⎪⎨⎪⎪⎪⎪⎩
p0 = 1 − p0→1 − pm
p1 = 1 − p1→2 − pm
p2 = 1 − p2→3 − pm
p3 = 1 − p3→4 − p3→H − pm
p4 = 1 − p4→H − p4→DC − pm.
Let xk be a row vector of length 8 describing the estimated mean number of individuals in each state of
the Markov chain at the end of year k. In particular, assuming that the value of λ is known, we have
xt0(1) = λ · θˆt0 and xt0(6) = 0 which are the estimated mean number of people in the states "F0" and
"HCC" the ﬁrst year respectively. One can calculate the mean number of people in each state at year
k + 1 by computing:
xk+1 = xk × P ′ +
[
λ · θˆk+1 0 · · · 0
]
.
Thus, we estimate λ with respect to the least squares criterion:
λˆ = argmin
λ
T∑
k=t0
(Yk − xk−1(6) × pH→D)2
where T is the year of last observation. Similarly, based on θˆiL and θˆiE , we obtain λˆL and λˆE .
3.3.5 Simpliﬁed Deuﬃc et al. model
In this section, we describe a simpliﬁed version of the model initially developed by Deuﬃc-Burban et al.
(1999). As age of the patients was not taken into consideration in the previous models, we had to sim-
plify their model to make the comparisons. Furthermore, as the prevalence of HCV in France has been
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estimated at 221,386 (95%CI:158,909-283,862) cases for the year 2004, Deuﬃc-Burban et al. (1999) devel-
oped their model in the presence of an equality constraint taking into account the estimated prevalence
of HCV in 2004. However, as this estimation admits a relatively wide conﬁdence interval, we decided to
dispense with that constraint in our simpliﬁed Deuﬃc model (SDM).
Finally, in their original model, they estimated the transition probabilities of their Markov chain while
we just took their own estimations to build ours as a complement to published probabilities from the
literature. Hence, some computation diﬀerences may arise but the general theory stays the same. We
consider the same Markov chain as the one with graph displayed in Figure 3.6.
The models described in Sections 3.2.2 and 3.2.3 estimate the past number of HCV-infected indi-
viduals who died from HCC. With the estimation of λ in Section 3.3.4, one can reconstruct the past
number of all HCV infections. On the contrary, the model developed by Deuﬃc-Burban et al. (1999)
directly estimates the past number of all HCV infections and does not need any additional estimation
step. Hence, in this section we focus on Θi the mean number of people infected by HCV in year i.
The simpliﬁed model of Deuﬃc-Burban et al. (1999) supposes a parametric model for Θ in the form
of the following equation:
fD(t;α, β, γ) =
⎧⎪⎪⎨⎪⎪⎩
exp(a(t − t0))
b + β−1 exp(a(t − t0)), for t < 1990
0.6 × exp(a(t − t0))
b + β−1 exp(a(t − t0)), otherwise
with a = 4 × α × β−1 and b = β−1 × exp(a(γ − t0)) where α is the slope of the curve, β the asymptotic
plateau value and γ the year of mid-epidemic.
From the notations introduced in the previous section, let us write:
xk+1 = xk × P ′ +
[
fD(t;α, β, γ) 0 · · · 0
]
.
Deuﬃc-Burban et al. (1999) proposed to estimate the parameters (α, β, γ) with respect to the weighted
least squares criterion:
(αˆ, βˆ, γˆ) = argmin
(α,β,γ)
T∑
k=t0
(Yk − xk−1(6) × pH→D)2
σ2Yk
where σ2Yk is the estimated variance of Yk. Assuming that Yk follows a binomial distribution, we have:
Yk ∼ B
(
xk−1(6), pH→D
)
,
where nk is the number of individuals in the Markov chain in year k and pk the probability that an
individual die from HCC related to HCV in year k. Thus, one can write:
σ2Yk = xk−1(6) × pH→D × (1 − pH→D) .
We obtain an estimator of Θ given by:
ΘˆiD =
exp(aˆ(t − t0))
bˆ + βˆ−1 exp(aˆ(t − t0))
· • {i<1990} +
0.6 × exp(aˆ(t − t0))
bˆ + βˆ−1 exp(aˆ(t − t0))
· • {i1990}
where aˆ and bˆ are the estimators of a, b. Assuming the parameters (αˆ, βˆ, γˆ) admit a normal asymptotic dis-
tribution, the corresponding 95% conﬁdence intervals are computed by estimating the variance-covariance
matrix of the parameters.
3.3.6 Quality of the models
To determine which model ﬁts best the data, we will use the mean squared error (MSE) criterion:
MSE =
1
T
T∑
k=1
(Yk − xk−1(6) × pH→D)2
where xk+1 = xk × P ′ +
[
Θˆk+1 0 · · · 0
]
and P ′ is the transition matrix deﬁned in Section 3.3.4.
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3.4 Results
First, let us recall the walkthrough of this study. Our estimations are based on observed data Yj , for
j = t0, . . . , T , from death certiﬁcates of French patients who died of hepatocellular carcinoma (HCC)
related to hepatitis C virus (HCV). Several epidemic models and statistical procedures, introduced in
Sections 3.2.2 and 3.2.3, are computed to determine θˆi, θˆiL and θˆiE the estimators of the mean past
incidence of patients who got infected in year i and who died of HCC.
From this, models are scaled to the overall population thanks to a parameter λ which is estimated
with respect to the least squares criterion and given in Table 3.3. One can notice that those coeﬃcients
admit similar values for the three models.
Table 3.3: Scale coeﬃcients estimation.
Models Coeﬃcients
EMS 7.3187
Logistic 7.2465
EMG 7.3100
Considering the smoothing step of the EMS algorithm, several values for the order L of the binomial
ﬁlter were tested and it turned out that L = 4 was approximatively reﬂecting the expected trend of HCV
incidence in France. In fact, since the precision of θˆi declines as i increases, a solution would be to increase
the bandwidth of the binomial ﬁlter with i. However, we noticed that by increasing the bandwidth L,
the distant values of θˆi did not admit strong ﬂuctuations while recent values did. This motivated our
choice for L = 4.
Graphics on Figure 3.7 exhibit the past incidence of HCV in France (Θˆi, ΘˆiL and ΘˆiE) estimated by
the three methods introduced earlier and the simpliﬁed Deuﬃc model (ΘˆiD). One can notice that the
four models follow a similar trend and admit a maximum expected number of infections around 7,000 –
9,000 cases. The model estimated by the EMS algorithm and the parametric model based on the EMG
function admit a peak of infection during the late 70s’. One can observe that the SDM and logistic model
admit the same trend since the plateau value is reached in the early 80s’. While no assumption are made
on the general shape of the model estimated by the EMS algorithm, one can see that the model still
reﬂects the general decrease of infections past the infection peak.
One can also notice on Figure 3.7 that the diﬀerent conﬁdence intervals are not symmetric. This
phenomenon is due to the fact that the conﬁdence intervals are generated via a Poisson distribution
which is not a symmetric distribution. Particularly, a peak in the conﬁdence interval of the EMS model
can be observed on Figure 3.7(a). This anomaly is a consequence of the lack of data available for the
estimation of Θi when i gets closer to T . The same anomaly is exhibited on Figure 3.10(a). Estimators
and 95% conﬁdence intervals of the diﬀerent parameters are given in Table 3.4.
Graphics on Figure 3.8 plot for each models the estimated number of death from HCC due to HCV as
well as the number of observed HCC deaths. Conﬁdence intervals for our three models were constructed
by bootstrap as described in Section 3.2.4. One can notice that all the models seem to ﬁt correctly the
adjusted data from CépiDC.
Table 3.5 exhibits the mean squared error computed for the diﬀerent models. One can see that the
EMS-based model seems to have the lower MSE among the models. It is followed by the EMG and SDM
models which admit similar values.
In Table 3.6, we compare our results with the prevalence of chronic carriers of HCV estimated by
InVS3 (see Institut de veille sanitaire (2007)) in 2004 in France. One can notice that our estimates seem
lower than what was estimated by InVS for the year 2004. However, conﬁdence intervals are overlapping.
Such a diﬀerence could be explained by the fact that in Section 3.3.4, no consideration is made about
patients exiting the model when getting cured (standard treatment or liver transplant) and how much
3"Institut de veille sanitaire", the French institute for public health surveillance.
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the treatment decelerates the disease’s progression. Moreover, no patient was assumed to develop and
eventually die from a fulminant hepatitis neither. However, one can observe that the models based on
a logistic function (logistic model and SDM) admit the highest values and, then, are closer to the value
estimated by InVS. As exhibited in Figure 3.9, one can see that the conﬁdence intervals obtained for our
models are signiﬁcantly smaller than the one obtained by InVS.
Finally, Figure 3.10 shows the estimated prevalence of HCV in France. As said above, one can observe
that the four models follow a similar trend. There is a general increase from the end of 1940 to reach a
relative stagnation during 1990 decade. From there, one can notice a decrease in the prevalence of HCV
in France.
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(a) Expectation maximization smoothing model (EMS)
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(b) Modiﬁed logistic model (Logistic)
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(c) Exponential modiﬁed Gaussian model (EMG)
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(d) Simpliﬁed Deuﬃc et al. model (SDM)
Figure 3.7: Estimation of the expected number of HCV infections.
Solid curves represent the estimation of the expected number of annual infections while dashed curves
are the bootstrapped 95% conﬁdence intervals.
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(a) Expectation maximization smoothing model (EMS)
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(b) Modiﬁed logistic model (Logistic)
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(c) Exponential modiﬁed Gaussian model (EMG)
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(d) Simpliﬁed Deuﬃc et al. model (SDM)
Figure 3.8: Estimation of the expected number of deaths from HCC related to HCV.
Solid curves represent the estimation of the expected number of annual deaths while dashed curves are
the bootstrapped 95% conﬁdence intervals. Dotted curve are the number of observed HCC due to HCV
each year.
Table 3.4: Parameter estimation and conﬁdence interval for the diﬀerent models.
Parameters
Models Estimates CI 95%
Logistic
K 1,200.9 [1,152.7 – 1,237.8]
α 0.2039 [0.1997 – 0.2209]
β 1,961.31 [1,960.41 – 1,961.77]
EMG
K 4.25 × 106 [1.45 × 106 – 8.48 × 106]
λ 1.3942 [1.3276 – 2.303]
μ 0.622 [-119.03 – 1.1858]
σ 11.3638 [11.0478 – 12.9392]
SDM
α 435.65 [416.91 – 454.38]
β 8,443.69 [8,192.02 – 8,695.35]
θ 1,960.32 [1,959.66 – 1,960.98]
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Table 3.5: Mean squared error result for the diﬀerent models.
Models Mean squared error
EMS 467.16
Logistic 723.35
EMG 522.08
SDM 585.27
Table 3.6: Estimation and 95% conﬁdence interval of total HCV chronic carriers in 2004.
Prevalence in 2004
Models Estimates CI 95%
InVS 221,386 [158,909 – 283,862]
EMS 187,038 [166,989 – 213,656]
Logistic 197,604 [194,450 – 205,609]
EMG 179,864 [160,812 – 189,432]
SDM 194,014 –
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Figure 3.9: Estimation and 95% conﬁdence interval of total HCV chronic carriers in 2004.
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(a) Expectation maximization smoothing model (EMS)
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(b) Modiﬁed logistic model (Logistic)
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(c) Exponential modiﬁed Gaussian model (EMG)
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(d) Simpliﬁed Deuﬃc et al. model (SDM)
Figure 3.10: Estimated prevalence of total chronic HCV in France.
Solid curves represent the estimation of the prevalence of the chronic carries of HCV while dashed curves
are the bootstrapped 95% conﬁdence intervals.
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3.5 Discussion
In this chapter, we have presented several models based on the natural history of HCV to estimate the
past incidence of the virus in France from 1930 to 2012. Those estimations were conducted via a back-
calculation approach computed on actual French data of death from HCC. Our results have been and
were compared with the model developed by Deuﬃc-Burban et al. (1999). The diﬀerent models exhibited
similar trends on the evolution of incidence and prevalence of HCV in France with an incidence’s peak
value reached by the models at around 8,000 cases during the late 70’. Similarly, the diﬀerent models
estimated the prevalence of HCV at a little less than 200,000 cases in 2004 which is consistent with the
estimation reported by InVS at 221,386 (95%CI:159,000-284,000) cases (see Institut de veille sanitaire
(2007)). The diﬀerence between the prevalence values could be explained by the fact that no treatment
has been incorporated in the model. As the addition of therapeutics would strongly alter the lifetime
distribution, the total number of infected individuals must have been underestimated.
The main advantage of the model developed with the expectation maximization smoothing algorithm
is the fact that no particular assumption was made on the form of the θi(·) function. This helped us to
limit the bias induced by an arbitrary choice of a given parametric function. Indeed, the poor performance
of the parametric models (particularly the logistic model and, to a lesser extent, the SDM and the EMG
model) on the mean squared error computation, precisely highlights this advantage. Then, an advantage
inherent to the use of the bootstrap method and Poisson distributions, is the possibility to easily compute
conﬁdence intervals of the diﬀerent functions (incidence and prevalence), while this might be harder to
achieve with the model developed by Deuﬃc-Burban et al. (1999) without knowing the distribution of
the estimated parameters.
However, our approach presents some limitations. First, as HCV progression is quite long, such a back-
calculation approach cannot provide accurate estimations of recent HCV incidence. The consideration of
HCV diagnoses in addition to HCC certiﬁcate deaths could lead to a better approximation of the recent
incidence (see Cui and Becker (2000) or Bellocco and Marschner (2000) for the particular case of HIV).
Second, contrary to what has been done by Deuﬃc-Burban et al. (1999), we only focus on the population
who died of HCC related to HCV. To estimate the overall population, we need an extra step which induce
some additional bias. Third, in terms of model construction, some important parameters have been set
aside. Indeed, we would like to emphasize the fact that no consideration was made regarding the use of
covariates such as age or gender of the patients. No consideration was made about treated patients or
HIV-coinfected patients while these could have a signiﬁcant impact on the ﬁbrosis’ progression. However,
as the development of therapeutics against HCV is relatively recent, these should have a limited impact
on our back-calculation approach.
Last, we would like to highlight the fact that this study is inﬂuenced by the quality of the data.
Since no accurate data exists on neither the number of death from HCC related to HCV nor the number
of death from HCV, the results reported in this study could be improved. However, we believe that
we have done a substantial work in the processing of data of CépiDC and one could expect a reliable
approximation of the reality from those data.
In conclusion, the models addressed in this study have shown consistent results with the expected
incidence of HCV in France. However, those should be completed in consideration with the prognostic
factors of HCV for the sake of eﬃciency. The limitations formulated above could be subject to further
research.
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4 Network model for the propagation of hepatitis Cvirus in France
Français
Nous étudions un modèle de propagation épidémique pour un virus de type hépatite C sur un réseau à
deux niveaux, à savoir le réseau des aires urbaines françaises. Le premier niveau de ce réseau modélise
les interactions entre individus au sein de chaque aire urbaine. Le second niveau est celui des aires
urbaines elles-mêmes, reliées entre elles par les individus voyageant entre celles-ci et propageant par
la même occasion l’épidémie de ville en ville. Nous encodons le second niveau du réseau en tant que
noeud supplémentaire à l’intérieur du premier niveau et observons que cette méthode donne des résultats
tangibles en termes d’ampleur et de vitesse de propagation d’une épidémie. Nous appliquons ensuite
cette méthodologie à un modèle de propagation épidémique plus complexe aﬁn de mesurer l’impact des
nouvelles thérapeutiques anti-hépatite C sur la population infectée en France.
English
We examine a model of epidemic propagation for a virus such as hepatitis C on a multiplex network,
namely the network of French urban areas. One network level is that of the individual interactions inside
each urban area. The second level is that of the areas themselves, linked by individuals travelling between
these areas and potentially helping the epidemic spread from one city to another. We choose to encode
the second level of the network as extra, special nodes in the ﬁrst level. We observe that such an encoding
leads to sensible results in terms of the extent and speed of propagation of an epidemic, depending on
its source point. We then applied this methodology to a more complex model of epidemic propagation
in order to measure the impact of new anti-hepatitis C therapeutics on the French infected population.
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Résumé
Ce dernier chapitre de thèse se propose d’étudier un modèle dynamique de propagation du virus de
l’hépatite C (VHC) en France aﬁn de quantiﬁer l’impact des nouvelles thérapeutiques anti-VHC. Ce
travail se décompose en deux parties au cours desquelles sont successivement présentés :
• un modèle de métapopulation dont chaque sous-population est décrite par un réseau de contact sur
lequel est appliqué un modèle simpliste d’histoire naturelle du VHC;
• une extension de ce modèle simpliste incluant des fonctionnalités plus avancées telles que le génotype
de la maladie ou la progression à travers les diﬀérents états de ﬁbrose.
A l’heure actuelle, la grande majorité des nouvelles contaminations par le VHC dans les pays dévelop-
pés a lieu au sein de la population toxicomane. En eﬀet, l’hépatite C se transmettant très principalement
par le sang, les usagers de drogues injectables sont une population d’autant plus vulnérable que la plupart
ignore leur statut sérologique.
Aussi, aﬁn de tenter de prendre en compte l’hétérogénéité de cette population en termes d’usage de
produits illicites, nous nous intéressons à une modélisation par graphe de contact où chaque contact
correspond à un échange de matériel (seringues, aiguilles, etc). Cette modélisation par graphe de contact
souﬀre néanmoins d’une limitation importante. En eﬀet, très peu de données sont disponibles sur la
structure d’un tel graphe et, quand bien même ces données seraient disponibles, on pourrait se poser la
question de la pertinence d’un tel graphe réalisé à l’échelle nationale.
Dans cette optique, la première partie de ce chapitre s’articule donc autour du concept de méta-
population. Ce concept, formulé par le mathématicien Richard Levins en 1969, considère les dynamiques
de plusieurs sous-populations (ou patchs) interagissant les unes avec les autres par un phénomène appelé
dispersion.
Dans le cas qui nous intéresse, nous modélisons donc plusieurs sous-populations toxicomanes, par des
graphes de contact générés avec des distributions données, interagissant entre elles par un phénomène de
migration s’appuyant sur les données de déménagement publiées par l’INSEE.
Concrètement la structure d’un graphe donné reste inchangée (nombre de noeuds, distribution des
degrés) mais chaque graphe voisin inﬂue sur la propagation de l’épidémie au sein dudit graphe à hauteur
de la proportion d’individus infectés au sein de chaque graphe d’une part et des migrations entre ledit
graphe et les autres d’autre part. Nous modélisons ensuite les dynamiques de ces sous-populations à
l’aide d’un modèle type SIS (susceptible-infected-susceptible) adapté au VHC.
Les premiers résultats obtenus sont encourageants et oﬀre une illustration de l’importance de consi-
dérer les interactions entre les diﬀérentes sous-populations dans la modélisation de la propagation du virus.
Dans la seconde partie de ce chapitre, nous nous proposons de garder la structure de métapopulation
introduite en première partie et de se concentrer sur un modèle dynamique de la propagation du VHC
plus poussé.
En se basant cette fois-ci sur la prévalence actuelle du virus en France, nous déterminons l’impact
des nouvelles thérapies en prenant en compte les diﬀérents états de ﬁbrose du patient, le génotype par
lequel il est infecté mais aussi la possibilité pour un individu de rejoindre ou de quitter la population
toxicomane. Aﬁn de mesurer au mieux l’impact des nouvelles thérapeutiques anti-VHC, l’évolution des
individus quittant la population toxicomane est capturée par un second modèle.
Ce modèle alternatif est un simple modèle d’histoire naturelle similaire en tout point au modèle ori-
ginal mais ne prenant pas en compte la possibilité pour les individus de se faire infecter. En eﬀet, tout au
long de ce chapitre, nous nous focalisons sur la population toxicomane comme principal foyer de nouvelles
infections.
Les résultats obtenus dans cette seconde partie permettent de mettre en évidence un impact marqué
des nouvelles thérapeutiques anti-VHC ainsi que l’importance des comportements individuels en termes
de partage de seringues sur la prévalence de la maladie.
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4.1 Introduction
Modeling the propagation of epidemics is a long-standing endeavour in the medical and mathematical
sciences. In the past decade or so, multiple developments in the science of complex systems in general,
and networks in particular, has led to new models, along with the possibility to test their predictions on
datasets, the size of which keeps increasing (see for instance Colizza et al. (2007); Hufnagel et al. (2004),
and references therein).
Particularly challenging are the study and modeling of epidemics involving speciﬁc, sometimes marginal,
segments of the general population. For instance, viruses and diseases that are particularly prevalent
among people who inject drugs (PWID). Things become even more involved if one tries to take into
account correlations between interrelated epidemics, such as hepatitis C virus (HCV) and AIDS (HIV)
among PWID populations.
In this chapter, we introduce a simple model of propagation for HCV on a network of networks, repre-
senting PWID populations in distinct but interconnected urban areas. We then applied this methodology
to a more complex epidemic model in order to measure the impact of new anti-hepatitis C therapeutics
on the French infected population.
In our models, the PWID population of each urban area is a network of individuals, and the fact that
people may travel or even move houses from one city to another makes for a second level of links, between
cities themselves. We choose to represent this second level via the introduction of special nodes at the
ﬁrst level, that will represent at the individual level in each city, contacts with individuals from other
cities. This means that if cities A and B are linked (in the sense that a number of individuals travel from
one of them to the other), then we add a node in the network representing individuals in city A. The
degree and other characteristics of this special node in city A will depend on the number of individuals
from city B travelling to city A and on the size of the infected population in city B. This makes for a
simple treatment of the links between cities. We also adapt the standard susceptible-infected-recovered
(SIR) equations to reﬂect the speciﬁcs of the HCV epidemics, as well as to take into account the special
type of network we are working with. The construction of the simple model is detailed in Section 2 and 3.
In Section 4, we examine, via numerical simulations, how our model works, ﬁrst on a toy-country
with just three cities and then on the network of France’s 100 largest urban areas. We explore part of
the phase space arising when the values chosen for certain crucial parameters (such as the transmission
rate) are allowed to vary across ranges away from their current reported or observed value. We ﬁnd that
simulations run for diﬀerent values of the parameters lead to sensible stylized facts in terms of the extent
and speed of propagation of an HCV epidemics in France.
In Section 5, we develop our second model for HCV propagation by considering some important
features such as the ﬁbrosis stages or the diﬀerent genotypes and apply it on the network of networks
methodology. Corresponding results are presented in Section 6. Section 7 presents our conclusions.
4.2 Epidemic models
4.2.1 Initial model of the spread of hepatitis C virus
Let us consider the compartmental model describing the infection dynamics of hepatitis C virus (HCV)
displayed in Figure 4.1. This model is based on a susceptible-infected-susceptible (SIS) model which is
a derivative of the classic susceptible-infected-recovered (SIR) model introduced by Kermack and McK-
endrick (1927).
We denote by S the number of susceptible individuals, by A the number of individuals in the acute
phase of the infection and by C the number of individuals in the chronic phase of the infection. Assuming
that the number of individuals in the total population is constant over time, which is not a strong
assumption for large populations, we write S(t) + A(t) + C(t) = N . In particular, we assume that the
number of people who died from HCV or from some other cause equals the number of people joining the
population as new susceptibles.
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S A C
Λ
μ μ μ
δβ (1 − p)σ
pσ
γ
Figure 4.1: Compartmental model of HCV’s natural history.
S, susceptible; A, acute HCV infection; C, chronic HCV infection; D, death.
From now on, we choose to work in terms of proportions rather than absolute numbers. The proportion
of susceptible, acute-HCV infected and chronic-HCV infected at time t are denoted s(t), a(t) and c(t)
respectively. By denoting β the transmission rate, γ the recovery rate, δ the death rate, μ the natural
mortality rate, Λ the joining rate, 1/σ the duration of the acute phase and p the spontaneous clearance, i.e.
the probability that a given individual clears the infection, one can write the following set of diﬀerential
equations:
ds(t)
dt = Λ − βs(t)
(
a(t) + c(t)
)
+ pσa(t) + γc(t) − μs(t), (4.1a)
da(t)
dt = βs(t)
(
a(t) + c(t)
)− (σ + μ)a(t), (4.1b)
dc(t)
dt = (1 − p)σa(t) − (γ + δ + μ)c(t). (4.1c)
Since HCV is an asymptomatic disease, very limited individuals are diagnosed during the acute phase of
the infection. Thus we assume that only individuals in the chronic phase have access to a treatment, i.e
only people in the chronic phase can recover.
We want to emphasize the fact that one can rewrite the transmission rate β as:
β = − ln
(
1 − (1 − (1 − π)ω)
)
where ω is the contact rate (the number of contacts per unit time) and π the transmission risk (the risk
of infection for a given contact). Moreover, as not every patient is actually treated, one can rewrite γ as
γ = ν × q where ν is the recovery rate per patient and q the proportion of treated patients.
The model deﬁned in the set of equations (4.1), also called mass action model, oﬀers a simple and
convenient manner of describing the dynamics of an epidemic in a large population. However, it fails at
dealing with population heterogeneities and individual interactions which can greatly aﬀect the rate of
transmission of the virus.
Considering HCV, it has been stated that the primary route of transmission in the developed world
is intravenous drug use (IDU) (see Maheshwari et al. (2010)). As people who inject drugs (PWID)
tend to share drug injecting equipment with a limited number of partners (see for example the social
network described by Rolls et al. (2012b)), the use of the model described by (4.1) might by questionable.
Hence, assuming that individuals with the same number of sharing partners present the same risk in
the infectious process, we choose to focus on the heterogeneous mean ﬁeld approach, ﬁrst introduced by
Pastor-Satorras and Vespignani (2001). In this approach, each individual is assigned a degree (a number
of partners) k, where 1  k  N − 1, and constitutes an element of the network (also referred to as node
in graph theory). As individuals with 0 partner do not contribute to the spread of the epidemic, only
individuals with at least one partner will be considered. Figure 4.2 oﬀers a visual representation of a
static network of sharing partners infected by HCV. For every individual dying, it is assumed that a new
susceptible takes its place.
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Figure 4.2: Network of PWID infected by HCV and their sharing partners.
Blue nodes represent susceptible individuals, yellow nodes represent individuals in the acute phase of
HCV, red nodes represent individuals in the chronic phase of HCV and black nodes are individuals who
died from HCV.
Let us denote by ρ the degree distribution, i.e. ρ(k) is the proportion of individuals with degree k.
Be denoting sk(t) (resp. ak(t) and ck(t)) the proportion of susceptible (resp. acute-HCV infected and
chronic-HCV infected) individuals with degree k, one can write:
s(t) =
N−1∑
k=1
sk(t), a(t) =
N−1∑
k=1
ak(t) and c(t) =
N−1∑
k=1
ck(t).
Referring now to Pastor-Satorras and Vespignani (2001), the proportion of infected partners for an
individual with degree k is given by:
θk(t) =
N−1∑
k′=1
ρN (k′|k)
(
ak′(t) + ck′(t)
)
where ρN (k′|k) is the proportion of partners with degree k′ among all partners of an individual with
degree k. It can be shown that:
ρN (k′|k) =
k′ρ(k′)
〈k〉
where 〈k〉 is the mean degree of the network. As ρN (k′|k) does not depend on k, we rewrite ρN (k′|k) as
ρN (k′). From what precedes, one can rewrite (4.1) as:
dsk(t)
dt = Λ − kβsk(t)θk(t) + pσak(t) + γck(t) − μsk(t), (4.2a)
dak(t)
dt = kβsk(t)θk(t) − (σ + μ)ak(t), (4.2b)
dck(t)
dt = (1 − p)σak(t) − (γ + δ + μ)ck(t). (4.2c)
To determine which degree distribution should be used to model the drug equipment sharing pattern
between PWID, we refer to the work of Dombrowski et al. (2013) who studied the social network of
PWID in the Bushwick neighborhood of Brooklyn, New York, by analyzing its degree distribution (see
also Pelude (2007)).
This analysis showed that the resulting degree distribution could be assimilated to a power law dis-
tribution. Being the main characteristic of scale-free networks (see Barabási and Réka (1999)), power
law distributions reﬂect a preferential attachment dynamics which is consistent with the fact that new
PWID network members tend to join a particular injector network via someone who is already part of it.
Henceforth, we assume that the social network of PWID admits a scale-free topology. In particular,
one can write ρ(k) ∼ k−α where α is called scale parameter. However, according to Clauset et al. (2009),
it appears that power laws with exponential cutoﬀ tend to ﬁt natural networks even better than pure
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power laws. Indeed, the power law is a long tailed distribution, hence, by applying an exponential cutoﬀ,
one can shrink the tail of the distribution faster as individuals with a huge amount of partners is highly
improbable. Thus, based on this result and for an arbitrary cutoﬀ κ, one can write:
ρ(k) =
k−αe−k/κ
Liα
(
e−1/κ
)
where Lin is the polylogarithm of order n.
4.2.2 Incorporating contact with HIV-infected individuals
The model developed in the previous section should lead to a reasonable approximation of the spread of
HCV on a network. However, one may want to add some details by allowing individuals to get infected
by human immunodeﬁciency virus (HIV). Indeed, by dealing with PWID, people infected by HCV are
often co-infected by HIV which greatly increases the risk of death.
We now consider the possibility for each individual to get infected by HIV. Hence, we introduce three
new compartments representing individuals infected only by HIV (S∗), individuals in the acute phase of
the HCV infection and infected by HIV (A∗) and individuals in the chronic phase of the HCV infection
and infected by HIV (C∗). Particularly, we have S(t) + A(t) + C(t) + S∗(t) + A∗(t) + C∗(t) = N .
We also introduce γ∗ and δ∗ the recovery and the death rates of HCV for people already infected by
HIV. As well, we introduce β∗ = 1 − (1 − π∗)ω the transmission rate of HIV, β† = 1 − (1 − π†)ω the
transmission rate of both HCV and HIV and p∗ the spontaneous clearance of HCV for people infected
by HIV. Finally, we denote by μ∗ the mortality rate of PWID infected by HIV. A visual representation
of the model is given in Figure 4.3.
S A C
S∗ A∗ C∗
Λ
μ
μ μ
μ∗ μ∗ μ∗
δ
δ∗
β
β†
(1 − p)σpσ
γ
β (1 − p∗)σ
p∗σ
γ∗
β∗ β∗ β∗
Figure 4.3: Compartmental model of HCV’s natural history with HIV coinfection.
S, susceptible; A, acute HCV infection; C, chronic HCV infection. Starred compartments represent HIV
infected individuals.
As done in Section 4.2.1, proportions of the diﬀerent quantities are denoted with small letters. We
now introduce the probabilities that an individual with degree k has an infected partner whichever the
infection. Hence, we have the probability that an individual with degree k has an HCV infected partner:
θk(t) =
N−1∑
k′=1
ρN (k′)
(
ak′(t) + ck′(t) + a∗k′(t) + c∗k′(t)
)
, (4.3)
the probability that an individual with degree k has an HIV infected partner:
θ∗k(t) =
N−1∑
k′=1
ρN (k′)
(
s∗k′(t) + a∗k′(t) + c∗k′(t)
)
, (4.4)
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and the probability that an individual with degree k has an HCV/HIV co-infected partner:
θ∗∗k (t) =
N−1∑
k′=1
ρN (k′)
(
a∗k′(t) + c∗k′(t)
)
. (4.5)
From those equations and based on the model of Figure 4.3, one can easily rewrite (4.2) as:
dsk(t)
dt = Λ − kβsk(t)θk(t) − kβ
∗sk(t)θ∗k(t) − kβ†sk(t)θ∗∗k (t) + pσak(t) + γck(t) − μsk(t), (4.6a)
ds∗k(t)
dt = −kβs
∗
k(t)θk(t) + kβ∗sk(t)θ∗k(t) + p∗σa∗k(t) + γ∗c∗k(t) − μ∗s∗k(t), (4.6b)
dak(t)
dt = kβsk(t)θk(t) − (σ + μ)ak(t) − kβ
∗ak(t)θ∗k(t), (4.6c)
da∗k(t)
dt = kβs
∗
k(t)θk(t) + kβ†sk(t)θ∗∗k (t) + kβ∗ak(t)θ∗k(t) − (σ + μ∗)a∗k(t), (4.6d)
dck(t)
dt = (1 − p)σak(t) − kβ
∗ck(t)θ∗k(t) − (γ + δ + μ)ck(t), (4.6e)
dc∗k(t)
dt = (1 − p
∗)σa∗k(t) + kβ∗ck(t)θ∗k(t) − (γ∗ + δ∗ + μ∗)c∗k(t). (4.6f)
Such a framework allows for the study of an epidemic on a given network. However, when dealing
with a large population, it might be wiser to deal with several subnetworks connected with each other.
Indeed, when dealing with an epidemic, say at a country scale, computing a subnetwork for each city
and allowing human movements between them might be more accurate than computing a single giant
network. Based on this hypothesis, we propose to study, in the next section, the spread of the epidemic
of HCV deﬁned by (4.6) across several subnetworks.
4.3 Epidemic propagation on a metapopulation model
Metapopulation models, ﬁrst described by Levins (1969), consist in modeling the interactions of several
spatially separated populations. Those models have been extensively used in the ﬁeld of epidemiology to
describe the spread of infectious diseases at a large scale by dividing the population into subpopulations
corresponding to diﬀerent households, cities, etc. Depending on human movements, a subpopulation, or
patch, containing infected individuals is allowed to interact with other patches spreading the infection to
neighboring subpopulations. We refer the reader for instance to Hufnagel et al. (2004) and Colizza et al.
(2007) for an illustration of the role of the global aviation network in the spread of the SARS infection.
Here we adapt this type of model to study the spread of HCV on a network of cities, assuming that
the population of each city can be considered as a patch of a global metapopulation model. Each subpop-
ulation admits a scale-free structure as deﬁned in Section 4.2.1 and the spread of the virus is governed
by the set of diﬀerential equations (4.6). To keep things simple while making them concrete, we work in
this section on networks of two and three cities.
Two-city network. Let us consider two cities A and B with injecting drug populations NA and NB re-
spectively. Assuming that these populations are organized in scale-free networks, we denote respectively
by 〈kA〉 and 〈kB〉 their mean degree and by ρA(k) and ρB(k) their degree distributions. We update the
notations of the quantities of (4.6) by adding a subscript of the corresponding city, e.g. sA(t) and sB(t)
denote the proportions of susceptible individuals in cities A and B respectively.
To model the eﬀect of B on the spread of the disease in A, we propose to add a node in the network
of A which is interacting with every node of A. In the same way, we add an extra node into the network
of B to model the eﬀect of A on B. These extra nodes allow the population of A (resp. B) to connect
with the new individuals moving from B to A (resp. from A to B). A visual representation of the process
is given in Figure 4.4.
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A B
Figure 4.4: Networks of A and B with the additional nodes representing people from A in
B and vice versa.
Network of the city A (resp. B) in blue (resp. red) with the additional node of B (resp. A) in red (resp.
in blue) interacting with every node. The blue light arrow represents the population travelling from A
to B while the red light arrow represents the population from B to A.
The extra node in the network of A contains the main characteristics of B, i.e. the proportion of
infected individuals in B and τB,A the number of people travelling from B to A. Similarly, the extra
node in the network of B contains the main characteristics of A.
Hence, by focusing on the ﬁrst equation of (4.6a), one can write:
dsk,A(t)
dt = −kβsk,A(t)θk,A(t) − kβ
∗sk,A(t)θ∗k,A(t) − kβ†sk,A(t)θ∗∗k,A(t) − μsk,A(t)
−sk,A(t)
(
τB,A
nA + τB,A
)
·
[
β
(
aB(t) + cB(t) + a∗B(t) + c∗B(t)
)
(4.7)
+β∗
(
s∗B(t) + a∗B(t) + c∗B(t)
)
+ β†
(
a∗B(t) + c∗B(t)
)]
+ pσak,A(t) + γck,A(t)
where nA is the population still alive in city A. In particular, nA is deﬁned as:
nA = sA(t) + aA(t) + cA(t) + s∗A(t) + a∗A(t) + c∗A(t).
Three-city network. Let us introduce a third city C with population NC . As above, we assume that
C is organized in a scale-free network with mean degree 〈kC〉 and degree distribution ρC(k). To model
the interactions between A and C (resp. B and C), we add another node in the graph of A (resp. B)
containing the main characteristics of C. See Figure 4.5 for a graphical visualization of the process in
the particular case of A.
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A
Figure 4.5: Network of A with the additional nodes corresponding to cities B and C.
The network of city A is represented in blue. The additional nodes corresponding to cities B and C are
represented in red and green respectively. The red light arrow represents the population travelling from
B to A while the green light arrow represents the population travelling from C to A.
Adding the new node corresponding to city C, equation (4.7) becomes:
dsk,A(t)
dt = −kβsk,A(t)θk,A(t) − kβ
∗sk,A(t)θ∗k,A(t) − kβ†sk,A(t)θ∗∗k,A(t) − μsk,A(t)
−sk,A(t)
∑
Φ∈{B,C}
(
τΦ,A
nA +
∑
Φ∈{B,C} τΦ,A
)
·
[
β
(
aΦ(t) + cΦ(t) + a∗Φ(t) + c∗Φ(t)
)
(4.8)
+β∗
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
+ β†
(
a∗Φ(t) + c∗Φ(t)
)]
+ pσak,A(t) + γck,A(t).
Full details of the complete set of diﬀerential equations are available in Appendix A.
4.4 Simulations
4.4.1 Parameter values
Let us ﬁrst consider three abstract cities A, B and C which PWID communities of 10000, 8000 and 5000
injecting drug users respectively. Cities with larger populations tend to be more attractive, so we use
a simple gravitational model to determine the proportion of a city’s travelling population driven to a
particular city among all other cities:
τA,B =
mpnAnB
nB + nC
where mp is the moving population percentage. Values of the diﬀerent population movements were
rounded up and reported in Table 4.1. Those percentages were kept low to consider that fact the popu-
lation of a given city is far greater than the moving population.
As far as network parameters are concerned, very limited data is available for their estimation. Hence,
we use the values obtained by Dombrowski et al. (2013), which were α = 1.8 for the scale parameter and
〈k〉 = 3.0 for the mean degree. Based on this, we initiate 1000 simulations of the degree distribution with
α = 1.8 and diﬀerent values of the exponential cut-oﬀ until reaching the value of 3.0 for the mean degree.
The resulting cutoﬀ was κ = 40. Figure 4.6 illustrates the degree distribution of a network of N=10,000.
One can see on Figure 4.6 that degrees can reach high values (> 102). Since the model described
in Appendix A is degree based, a high degree can lead to a very large amount of diﬀerential equations.
Hence, for the sake of practicality, we decide to split the population into four arbitrary groups: people
with degree 1, people whose degree lies between 2 and 5, people whose degree lies between 6 and 10 and
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Destination
mp = 0.1% mp = 1%
A B C A B C
A 0 6 4 0 62 39
B 5 0 3 53 0 27
C 3 2 0 28 22 0
Table 4.1: Annual origin-destination matrix.
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Figure 4.6: Degree distribution of a scale-free network constituted of 10,000 nodes.
The degree distribution was computed for a network of 10,000 nodes based on a power law distribution
with exponential cutoﬀ which parameters are α = 1.8 and κ = 40.
people whose degree is greater than 10.
The values of the transmission risks of HCV and HIV are diﬃcult to estimate. Several studies reported
diﬀerent values for the per contact probability of HCV transmission for PWID ranging from 0.5% to 10%
(see Bayoumi and Zaric (2008); Boelen et al. (2014); O’Leary and Green (2003); Rolls et al. (2012b);
Vickerman et al. (2007)). As for the transmission of HCV, we refer to Rolls et al. (2012b) who estimated
a transmission risk of 1% in a network of PWID in Australia. Considering the transmission of HIV, we
refer to Patel et al. (2014) who reported 63 transmissions for 10,000 exposures for the US epidemic. These
transmission risks represent the probabilities of getting infected per act of sharing needles. Assuming
that these probabilities are independent, the transmission risk π† of both HCV and HIV is given by
π† = π × π∗.
As for the frequency of needle/syringe sharing, diﬃculties arise when one tries to obtain accurate
estimations. Referring to Vickerman et al. (2007) we choose the value of 16 sharing acts per month.
However, as this frequency is shared among the diﬀerent partners of a given individual, we assume a
per-partner sharing frequency such as 16/3 = 5.33 where 3 is the mean number of partners.
The values of the transmission risks introduced above reﬂect somehow the true HCV and HIV trans-
mission risks for PWID. However, for illustrative purposes, we propose to temporary choose greater
values for those risks by multiplying the transmission risks π, π∗ and π† by some constant λ to observe
the impact of migrating people on the spread of the epidemic.
Considering the treatment of HCV, we decided to focus on the recent direct-acting antivirals (DAAs)
which leads to high recovery rates. Indeed, based on a recent ANRS press release, the recovery rate of the
new DAAs has been estimated up to 93% for HCV/HIV co-infected patients (see ANRS (2015)). Similar
results were observed for HCV mono-infected patients. Due to the fact that HCV is an asymptomatic
disease, a large part of HCV infected patients are not aware of their serostatus. Globally, this involves a
very low proportion of infected patients accessing to health care. Indeed, although France has one of the
highest treatment rates in Europe, this proportion hardly reaches 5.2% (see Razavi et al. (2014)).
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As for the mortality rates of PWID infected by HCV, HIV or HCV and HIV, we refer to the work
of van Santen et al. (2014) who calculated all-cause and cause-speciﬁc crude mortality rates (per 1000
person-years) and standardized mortality ratios for PWID in the Netherlands. A summary of the pa-
rameters used in the model are given in Table 4.2.
Since we want to quantify the impact of the interactions between cities, we assume that the epidemic
starts in one of the three cities and observe the impact on the two others. For the epidemic to begin,
we set a relatively low amount of individual in city A such as sA(0) = 0.985, cA(0) = 0.01 (HCV mono-
infected individuals in chronic phase) and c∗A(0) = 0.005 (HIV/HCV co-infected individuals in chronic
phase). The values chosen for the initiation of the model are purely arbitrary.
Due to the random nature of the network framework, we will focus on the mean of each quantity over
1000 simulations.
Table 4.2: Parameters used in the model to simulate the spread of HCV.
Parameter Notation Value Source
Risk of transmission per contact
HCV, % π 1 Rolls et al. (2012b)
HIV, % π∗ 0.63 Patel et al. (2014)
HCV and HIV, % π† 6.3 × 10−5 –
Semi-annual HCV spontaneous clearance
HCV mono-infected, % p 26 Micallef et al. (2006)
HCV/HIV co-infected, % p∗ 10 Hernandez and Sherman (2011)
Annual risk of death
HCV/HIV uninfected, %
 μ 10.4 van Santen et al. (2014)
HCV mono-infected, %
 δ 22.7 van Santen et al. (2014)
HIV mono-infected, %
 μ∗ 44.3 van Santen et al. (2014)
HCV/HIV co-infected, %
 δ∗ 54.9 van Santen et al. (2014)
Network characteristics
Mean degree 〈k〉 3.0 Dombrowski et al. (2013)
Scale parameter α 1.8 Dombrowski et al. (2013)
Exponential cutoﬀ κ 40 –
Anti-HCV treatment characteristics
Recovery rate, % ν 93 ANRS (2015)
Proportion of treated patients, % q 5.2 Razavi et al. (2014)
Other parameters
Per-partner sharing frequency, per month ω 5.33 Vickerman et al. (2007)
Duration of the acute phase, years 1/σ 1/2 Micallef et al. (2006)
Unit time, years – 1 –
4.4.2 Results on an abstract three-city network
Figures 4.7, 4.8 and 4.9 display the evolution of the susceptible, the HCV mono-infected and HIV/HCV
co-infected populations in the whole system (cities A, B and C). The diﬀerent curves of the three
ﬁgures represent the population dynamics when no migration is assumed (blue markers), 0.1% of the
population is migrating (red markers) and 1% of the population is migrating (green markers). Each
quantity displayed in Figures 4.7, 4.8 and 4.9 is the sum of the corresponding quantity over the four
degree groups.
Considering Figure 4.7, one can see that the susceptible population gradually depletes with the per-
centage of migrating population. As more and more people move from city A, the epidemic spreads faster
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and has a stronger impact on the cities B and C. As expected, the spread of the epidemic is even stronger
when the coeﬃcient α increases. One can see that the blue curves reach a minimum value between 60%
and 70%. This phenomenon is due to the fact that the susceptible populations of the cities B and C stay
intact (no initial infected individual nor migration from infected cities).
As for Figure 4.8, one can observe the same dynamics as for Figure 4.7. The proportion of HCV mono-
infected individuals in the population is greatly impacted by the percentage of migrating people and by
the coeﬃcient α. Similarly, the blue curves here correspond to the proportion of HCV mono-infected
individuals in the city A. This explains why that proportion is never higher than 33.3%.
Lastly, Figure 4.9 exhibits the same evolutions as the two previous ﬁgures. One can particularly
observe on Figure 4.9 that the evolution of the HIV/HCV co-infected population is greater than the
evolution of the HCV mono-infected population of Figure 4.8. This is due to the fact that, contrary to
HCV, no treatment for HIV is considered in the model. Thus, each HCV mono-infected individual tends
to get also infected by HIV as time goes by.
In the next section we propose to study the spread of the infection assuming the epidemic starts
from a particular patch. To highlight the impact of people migration on the spread of an infection, two
diﬀerent patches are studied.
mp = 0%/λ = 1 mp = 0.1%/λ = 1 mp = 1%/λ = 1
mp = 0%/λ = 5 mp = 0.1%/λ = 5 mp = 1%/λ = 5
mp = 0%/λ = 10 mp = 0.1%/λ = 10 mp = 1%/λ = 10
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Figure 4.7: Mean evolution of the susceptible population in the whole system.
The diﬀerent curves represent the mean quantities over 1000 simulations. Blue curves represent the
evolution of the susceptible population when no interactions between the cities are allowed (mp = 0%),
red curves represent the evolution of the susceptible population assuming interactions up to 0.1% of the
populations (mp = 0.1%) and green curves represent the evolution of the susceptible population assuming
interactions up to 1% of the populations (mp = 1%).
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Figure 4.8: Mean evolution of the HCV mono-infected population in the whole system.
The diﬀerent curves represent the mean quantities over 1000 simulations. Blue curves represent the
evolution of the HCV mono-infected population when no interactions between the cities are allowed (mp =
0%), red curves represent the evolution of the HCV mono-infected population assuming interactions up to
0.1% of the populations (mp = 0.1%) and green curves represent the evolution of the HCV mono-infected
population assuming interactions up to 1% of the populations (mp = 1%).
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Figure 4.9: Mean evolution of the HIV/HCV co-infected population in the whole system.
The diﬀerent curves represent the mean quantities over 1000 simulations. Blue curves represent the
evolution of the HIV/HCV co-infected population when no interactions between the cities are allowed
(mp = 0%), red curves represent the evolution of the HIV/HCV co-infected population assuming in-
teractions up to 0.1% of the populations (mp = 0.1%) and green curves represent the evolution of the
HIV/HCV co-infected population assuming interactions up to 1% of the populations (mp = 1%).
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4.4.3 Results on the network of France’s 100 largest urban areas
We generalize the metapopulation model of Section 4.4.1 by studying the spread of HCV across a whole
country: France. As we want our predictions to be relatively accurate without considering every single
city, we choose to focus on the ﬁrst hundred biggest urban areas in France (metropolitan France only)
for a population of 43,187,838 individuals in 2012. Indeed, by referring to the work of Rachlis et al.
(2007) who identiﬁed legal problems, entering drug treatment program and drug tourism as PWID’s
main drivers of mobility, we assume that the great majority of PWID tend to move towards and between
the main urban areas.
Then, the population of these urban areas is multiplied by the prevalence of PWID in France estimated
at 5.9 %
 by the OFDT1 in 2006 (see Costes et al. (2009)). Since this prevalence has been estimated for
the population aged 15 to 64 (63,8% of the total French population in 2012, i.e 40,433,870 individuals),
we multiply the population of the French urban areas by 40433870/43187838 = 0.94 for both populations
to match. The original populations retained for the simulations are reported in Appendix B.
Considering the origin-destination matrix of such a model, no data is available for the annual mi-
gration of PWID. Hence, we refer to a French database of residential mobility during a ﬁve-year period
published on the website of INSEE2. Values are divided by 5 and rounded to obtain an annual origin-
destination matrix. To only consider PWID, values are multiplied by 5.9 %
.
As we want to study the impact of migrating populations on the spread of the infection, we shall
consider two diﬀerent starting points. We ﬁrst choose Paris as a starting point since this city has the
highest level of interactions with nearly all other French cities. To select the second starting point, we
need a city which possesses a far lower level of interactions with all other cities than Paris. However, to
prevent the snowball eﬀect, it is better to also focus on a city which has very limited interactions with
Paris. Hence, we choose Forbach, a small urban area in the North-Eastern part of France, as the starting
point in a second set of simulations.
Referring to Section 4.4.1, we set the proportion of susceptible individuals to 98.5% in the city where
the epidemic starts. The proportions of HCV mono-infected (chronic phase) and HIV mono-infected
patients are set to 1% and 0.5% respectively in that same city. All other cities are initiated at 100% of
susceptible individuals. Similarly, we assume that each urban area is organized according to a scale-free
network which degree distribution follows a power law with exponential cutoﬀs and assume a multiplica-
tive constant λ of 10. Parameters considered for this model are reported in Table 4.2.
Results. Evolution of the diﬀerent mean quantities are represented in Figure 4.10 where two diﬀerent
scenarios are exhibited in plain and dashed curves. One notices that, as expected, the epidemic spreads
much more easily to the whole country when starting from Paris rather than Forbach. Indeed, as Paris has
a lot more interactions with other urban areas than Forbach, the epidemic spreads faster. Particularly,
one can see that the proportion of susceptible individuals depletes rapidly between the third and the
eighth year when the epidemic starts in Paris while this proportion depletes between the seventh and the
fourteenth year when the epidemic starts in Forbach. Similarly, one can observe that the proportion of
HCV mono-infected patients increases during a few years then decreases due to the superinfection with
HIV.
Figures 4.11 and 4.12 give a comparison of the spread of the infection in the country. Generally, one
can see that the epidemic spreads further and faster when starting in Paris. Indeed, one can observe that,
ten years after the beginning of the epidemic, the high majority of urban areas admits a proportion of
HCV infected individuals (mono-infection or co-infection) superior to 40% when the epidemic outbreak
takes place in Paris. As for Forbach’s epidemic outbreak, not even all urban areas are aﬀected by the
infection after ten years. Last, one can denote that the last epidemic-aﬀected city seems to be Cluses in
both Figures 4.11 and 4.12. This can be explained by the fact that this urban area presents the lowest
level of interaction with other French cities (it only interacts signiﬁcantly with Genève-Annemasse).
1Observatoire français des drogues et des toxicomanies, the French monitoring centre for drugs & drug addiction.
2Institut national de la statistique et des études économiques, the French oﬃce for national statistics.
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Paris as starting point Susceptible HCV mono-infected HIV/HCV co-infected
Forbach as starting point Susceptible HCV mono-infected HIV/HCV co-infected
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Figure 4.10: Mean evolution of the population dynamics in France.
The diﬀerent curves represent the mean quantities over 1000 simulations. Dotted curves represent the
evolution of the French population when Forbach is chosen as the epidemic starting point while (+)
markers represent the evolution of the French population when Paris is chosen as the epidemic starting
point. The blue markers represent the susceptible population while the red and the green markers
represent the HCV mono-infected and the HIV/HCV co-infected populations respectively
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No infected individual Less than 20% of infected individuals
From 20% to 40% of infected individuals From 40% to 60% of infected individuals
From 60% to 80% of infected individuals More than 80% of infected individuals
(a) One year after epidemic start (b) Three years after epidemic start
(c) Five years after epidemic start (d) Ten years after epidemic start
Figure 4.11: Evolution of the spread of HCV in France with an epidemic start in Paris.
Estimations of the proportions of HCV infected individuals in France over 1000 simulations. Each colored
dot represents a French urban area. Starting point was 98.5% of susceptible, 1% of HCV infected
individuals and 0.5% of HIV infected individuals in Paris. Every other city started at 100% of susceptible
individuals.
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No infected individual Less than 20% of infected individuals
From 20% to 40% of infected individuals From 40% to 60% of infected individuals
From 60% to 80% of infected individuals More than 80% of infected individuals
(a) One year after epidemic start (b) Three years after epidemic start
(c) Five years after epidemic start (d) Ten years after epidemic start
Figure 4.12: Evolution of the spread of HCV in France with an epidemic start in Forbach.
Estimations of the proportions of HCV infected individuals in France over 1000 simulations. Each colored
dot represents a French urban area. Starting point was 98.5% of susceptible, 1% of HCV infected indi-
viduals and 0.5% of HIV infected individuals in Forbach. Every other city started at 100% of susceptible
individuals.
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4.5 Enhanced HCV model
In the following sections, we enhance the original model developed in Section 4.2.2 by adding supplemen-
tary details such as the progression of ﬁbrosis, the development of end-stage liver diseases or the diﬀeren-
tiation between the main HCV genotypes. We also examine an alternative model for non-injecting drug
users to track HCV infected patients once they leave the injecting-drug population. In this alternative
model, transmission of HCV or HIV is not considered as non-IDU do not participate to the force of
infection within the injecting-drug population anymore.
4.5.1 Model structure
4.5.1.1 Fibrosis progression and end-stage liver diseases
The natural history of HCV is mainly characterized by the destruction of the liver in a process called
ﬁbrosis. The progression of ﬁbrosis along the years can be divided in ﬁve diﬀerent stages associated with
the gravity of the ﬁbrosis. See the Metavir scores in Table 4.3 for a description of the diﬀerent stages.
Table 4.3: Metavir ﬁbrosis scoring
Score Description
F0 No ﬁbrosis
F1 Portal ﬁbrosis without septa
F2 Portal ﬁbrosis with few septa
F3 Numerous septa without cirrhosis
F4 Cirrhosis
Once an individual reaches the late ﬁbrosis stages (typically F3 or F4), one may develop a decompen-
sated cirrhosis (DC) and/or a hepatocellular carcinoma (HCC) which lead to a short-term death if no
appropriate treatment is undertaken.
Let us denote by F0(t) (resp. F1(t), F2(t), F3(t) and F4(t)) the number of individuals in stage 0
(resp. 1, 2, 3 and 4) of ﬁbrosis at time t, by HCC(t) the number of individuals with a hepatocellular
carcinoma at t and by DC(t) the number of individuals with a decompensated cirrhosis at t. From what
precedes, one can modify state C of the model in Figure 4.3 by including the stages corresponding to
the ﬁbrosis progression and to end-stage liver diseases (ESLD). Such a model is displayed in Figure 4.13
in the speciﬁc case of HCV mono-infection where λ1, λ2, λ3, λ4, λh, λH , λDH , λD, λHD and λDD are
the diﬀerent progression rates to the stages of ﬁbrosis, HCC, decompensated cirrhosis and death due to
HCV. The natural mortality rate μ is not displayed for better clarity.
· · · F0 F1 F2 F3 F4
DCHCC· · ·
(1 − p)σ λ1 λ2 λ3 λ4
λh λD
λH
λDH
λDD
λHD
Figure 4.13: Compartmental model of ﬁbrosis progression and end-stage liver diseases.
F0-F4, stages of the ﬁbrosis progression based on the Metavir scoring system indicating the degree of
inﬂammation; HCC, hepatocellular carcinoma; DC, decompensated cirrhosis.
To compute the diﬀerential equation of the proportion of susceptible individuals in that particular
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framework, we denote by:
φ(t) = a(t) + f0(t) + f1(t) + f2(t) + f3(t) + f4(t) + dc(t) + hcc(t)
the proportion of individuals infected by HCV at time t. Similarly, let us denote by:
φ∗(t) = a∗(t) + f∗0 (t) + f∗1 (t) + f∗2 (t) + f∗3 (t) + f∗4 (t) + dc∗(t) + hcc∗(t)
the proportion of individuals infected by HCV and HIV at time t. Hence, one can respectively rewrite
equations (4.3), (4.4) and (4.5) as:
θk(t) =
N−1∑
k′=1
ρN (k′)
(
φk′(t) + φ∗k′(t)
)
, (4.9a)
θ∗k(t) =
N−1∑
k′=1
ρN (k′)
(
s∗k′(t) + φ∗k′(t)
)
(4.9b)
and θ∗∗k (t) =
N−1∑
k′=1
ρN (k′) × φ∗k′(t). (4.9c)
Based on these notations, one can rewrite (4.8) as:
dsk,A(t)
dt = −kβsk,A(t)θk,A(t) − kβ
∗sk,A(t)θ∗k,A(t) − kβ†sk,A(t)θ∗∗k,A(t) − μsk,A(t)
−sk,A(t)
∑
Φ
(
τΦ,A
nA +
∑
Φ τΦ,A
)
·
[
β
(
φΦ(t) + φ∗Φ(t)
)
(4.10)
+β∗
(
s∗Φ(t) + φ∗Φ(t)
)
+ β†φ∗Φ(t)
]
+ pσak,A(t).
4.5.1.2 Main HCV genotypes
In the previous section, no particular attention was paid to the genotype of HCV. Yet, it has been clearly
established that HCV genotypes entice a signiﬁcant diﬀerence in the progression of ﬁbrosis, the occurence
of ESLD and the response to treatment. Indeed, recent studies have demonstrated an acceleration of
the ﬁbrosis progression and an increase of hepatocellular carcinoma risk incidence in genotype 3 HCV
infected patients compared to genotype 1 HCV infected patients (see Asselah et al. (2006); Bochud et al.
(2009); Kanwal et al. (2014); Nkontchou et al. (2011); Tapper and Afdhal (2013)). Those results are
particularly important since genotypes 1 and 3 are the most common genotypes in France (see Payan
et al. (2005)).
Henceforth, we choose to focus on genotypes 1 and 3. Let us assume that the notations introduced
in Section 4.5.1.1 refer now to individuals infected by genotype 1 HCV and let us introduce equivalent
notations for genotype 3 HCV infected individuals. By denoting Aˇ the number of patients in the acute
phase of genotype 3 HCV infection, each individual can either get infected by genotype 1 HCV or genotype
3 HCV as displayed in Figure 4.14. As above, the natural mortality rate μ is not displayed for better
clarity.
SAˇ· · · A · · ·β
pσ
pσ
β
(1 − p)σ(1 − p)σ
Genotype 3 HCV infection Genotype 1 HCV infection
Figure 4.14: Compartmental model of the infection by the diﬀerent HCV genotypes.
Next, we denote by Fˇ0(t) (resp. Fˇ1(t), Fˇ2(t), Fˇ3(t) and Fˇ4(t)) the number of genotype 3 HCV infected
individuals in the stage 0 (resp. 1, 2, 3 and 4) of ﬁbrosis at t, by ˇHCC(t) the number of genotype 3 HCV
infected individuals with a hepatocellular carcinoma at t and by DˇC(t) the number of genotype 3 HCV
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infected individuals with a decompensated cirrhosis at t. Based on these notations, we consider the
model displayed in Figure 4.15. As done in Figure 4.13, HIV co-infected individuals were not displayed
in Figure 4.15 for the sake of simplicity. The progression rates κ1, κ2, κ3, κ4, κh, κH , κDH , κD, κHD and
κDD are equivalent to the rates introduced in Section 4.5.1.1 for genotype 3 HCV infected individuals.
· · · Fˇ0 Fˇ1 Fˇ2 Fˇ3 Fˇ4
DˇCˇHCC· · ·
(1 − p)σ κ1 κ2 κ3 κ4
κh κD
κH
κDH
κDD
κHD
Figure 4.15: Compartmental model of ﬁbrosis progression and end-stage liver diseases for
patients infected by genotype 3 HCV.
Fˇ0-Fˇ4, stages of the ﬁbrosis progression based on the Metavir scoring system indicating the degree of
inﬂammation; ˇHCC, hepatocellular carcinoma; DˇC, decompensated cirrhosis.
Based on the model displayed in Figure 4.15, we denote by:
ψ(t) = aˇ(t) + fˇ0(t) + fˇ1(t) + fˇ2(t) + fˇ3(t) + fˇ4(t) + dˇc(t) + hˇcc(t)
the proportion of individuals with genotype 3 HCV infection at t. Similarly, we denote by:
ψ∗(t) = aˇ∗(t) + fˇ∗0 (t) + fˇ∗1 (t) + fˇ∗2 (t) + fˇ∗3 (t) + fˇ∗4 (t) + dˇc
∗(t) + hˇcc∗(t)
the proportion of individuals with genotype 3 HCV and HIV co-infection at time t. Hence, one can
modify the expression of (4.9) as follows:
θk(t) =
N−1∑
k′=1
ρN (k′)
(
φk′(t) + φ∗k′(t) + ψk′(t) + ψ∗k′(t)
)
,
θ∗k(t) =
N−1∑
k′=1
ρN (k′)
(
s∗k′(t) + φ∗k′(t) + ψ∗k′(t)
)
and θ∗∗k (t) =
N−1∑
k′=1
ρN (k′)
(
φ∗k′(t) + ψ∗k′(t)
)
.
Based on what precedes, one can write:
dsk,A(t)
dt = −kβsk,A(t)θk,A(t) − kβ
∗sk,A(t)θ∗k,A(t) − kβ†sk,A(t)θ∗∗k,A(t) − μsk,A(t)
−sk,A(t)
∑
Φ
(
τΦ,A
nA +
∑
Φ τΦ,A
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
(4.11)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(ak,A(t) + aˇk,A(t)).
In the next section, we add another feature by integrating the possibility for patients to receive
treatment or transplant during the course of HCV.
4.5.1.3 Anti-HCV treatment and liver transplant
Treatment of HCV has always been a challenge due to the low success rates of the diﬀerent treatments
and to the occurrence of numerous side eﬀects. In the past few years, new treatments have been developed
oﬀering a greater improvement in terms of success rates and a lower adverse events incidence. Deﬁned as
the achievement of sustained virology response (undetectable viral load), the success rates of those new
therapies, referred as second-generation direct-acting antivirals (2nd-gen DAAs), can exceed 95% after
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· · · F2
A2
S2
· · ·λ2(1 − λS1)
(1 − p)σ
λS2
βpσ
λ3(1 − λS2)
(a) Direct-acting antivirals treatment
· · · · · ·
DCHCCLT· · ·
λh λD
λH
λDH
λDL
λLλLD
λHD
λDD
(b) Liver transplant
Figure 4.16: Compartmental models of HCV treatment and liver transplant.
HCC, hepatocellular carcinoma; DC, decompensated cirrhosis; LT, liver transplant. (a) Compartmental
model for HIV uninfected patients in ﬁbrosis stage F2 treated with direct-acting antivirals. (b) Compart-
mental model for HIV uninfected patients transplanted after reaching hepatocellular carcinoma and/or
decompensated cirrhosis.
12 or 24 weeks of therapy (see Hézode (2016); Pol et al. (2016); Wyles et al. (2015)). Moreover, 2nd-gen
DAAs showed high sustained virology response (SVR) rates for every genotype and for patients in any
ﬁbrosis stage.
Considering treatment indication, patients at greater risk initiate 2nd-gen DAAs sooner to limit the
liver destruction caused by the ﬁbrosis progression. Indeed, in France, patients with HCV mono-infection
do not initiate 2nd-gen DAAs before reaching the ﬁbrosis stage F2 while HCV/HIV co-infected patients
can initiate the treatment at any ﬁbrosis stage (see Haute Autorité de Santé (2014)). However, the
French National Authority for Health recently recommended to extend the indication of those 2nd-gen
DAAs to F0-F1 patients without comorbidities. Despite the eﬃcacy of those new treatments, 2nd-gen
DAAs initiation might not be the most viable option for patients who reach ESLD. Indeed, with sur-
vival rates constantly improving, liver transplant might represent a better alternative for eligible patients.
In this section, we add to our model more speciﬁc patient care by assigning a probability to reach
SVR depending on the ﬁbrosis stage. Considering liver transplant, this feature is only available in the
alternative model since PWID are not eligible (see Dhumeaux (2014)).
For the sake of simplicity, we assume that the ﬁbrosis process cannot regress even after SVR achieve-
ment. Hence, we introduce new compartments corresponding to individuals who cured the virus but are
still aﬀected by either ﬁbrosis, decompensated cirrhosis and/or HIV. Similarly, some new compartments
are introduced for patients who enters an acute phase after reinfection. By denoting S2 (resp. A2) the
number of susceptible (resp. acutely infected) individuals in ﬁbrosis stage F2, one can observe on Figure
4.16(a) an illustration of HIV uninfected patients who cured the virus in ﬁbrosis stage F2 and got rein-
fected. Figure 4.16(b) displays the compartmental model of patients accessing liver transplantation where
λL (resp. λDL) is the transition rate from hepatocellular carcinoma (resp. decompensated cirrhosis) to
liver transplant.
Denoting s2,k,A(t) the proportion of susceptible individual with stage F2 ﬁbrosis and degree k in
sub-population A, one can deduce from Figure 4.16(a) and Equation (4.11) the following diﬀerential
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equation:
ds2,k,A(t)
dt = −kβs2,k,A(t)θk,A(t) − kβ
∗s2,k,A(t)θ∗k,A(t) − kβ†s2,k,A(t)θ∗∗k,A(t)
−s2,k,A(t)
∑
Φ
(
τΦ,A
nA +
∑
Φ τΦ,A
)
·
[
β†
(
φ∗Φ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+pσ
(
a2,k,A(t) + aˇ2,k,A(t)
)
+ λS2f2,k,A(t) + κS2 fˇ2,k,A(t) − μs2,k,A(t).
where λS2 = ν2 × q and κS2 = νˇ2 × q correspond to the proportions of patients recovering from stage F2
ﬁbrosis either infected by genotype 1 or genotype 3 respectively. Note that q is the proportion of treated
patients introduced in Section 4.2.1 and ν2 (resp. νˇ2) is the recovery rate of a patient in ﬁbrosis stage
F2 infected by the genotype 1 (resp. genotype 3). In all the following, we denote by νi (resp. νˇi) the
recovery rate of a patient in ﬁbrosis stage Fi, i = 0, . . . , 4, either infected by genotype 1 or genotype 3
respectively. Recovery rate for patients with decompensated cirrhosis and genotype 1 (resp. genotype 3)
infection is denoted by νD (resp. νˇD). Similarly, referring to Figure 4.16(b), one can write:
dltk,A(t)
dt = λDLdck,A(t) + λLhcck,A(t) − kβ
∗ltk,A(t)θ∗k,A(t) − (λLD + μ)ltk,A(t)
−ltk,A(t)
∑
Φ
β∗
(
τΦ,A
nA +
∑
Φ τΦ,A
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
.
4.5.1.4 Initiation and cessation rates
Let us now consider the possibility for an individual to enter or leave the population. Indeed, by focusing
on IDU, one should consider the possibility for an individual to initiate the use of injectable drugs and
join the network of IDU or to discontinue the use of drugs. In that optic, let us denote by τ the cessation
rate for each individual.
Considering the number of individuals entering the population each year, we assume that the total
number of people in each sub-population stays constant over time. Indeed, as diﬃculties emerge when
one try to obtain reliable data not only on the incidence of IDU in France but also on the prevalence
itself, assuming a constant-size population might be the best option. Hence, we denote by ΛA(t) the
proportion of people entering sub-population A at time t which is assumed to be the sum of the following
proportions:
• people of A discontinuing the use of injectable drugs at t,
• people of A dying from HCV at t,
• and people of A dying from a cause unrelated to HCV at t.
For simplicity purposes, we assume that every entering individual is a susceptible individual. Thus, from
what precedes, one can rewrite (4.11) as follows:
dsk,A(t)
dt = Λk,A(t) − kβsk,A(t)θk,A(t) − kβ
∗sk,A(t)θ∗k,A(t) − kβ†sk,A(t)θ∗∗k,A(t)
−sk,A(t)
∑
Φ
(
τΦ,A
nA +
∑
Φ τΦ,A
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
(4.12)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(ak,A(t) + aˇk,A(t))
+λS0f0,k,A(t) + κS0 fˇ0,k,A(t) − (τ + μ)sk,A(t).
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4.5.2 Parameter values
Let us consider the values of the diﬀerent parameters addressed in the previous sections so far. Since
limited data are available for genotype 3 HCV infected patients, we will assume that there is no signiﬁcant
diﬀerence when appropriate. A summary of all the parameters value is available in Tables 4.4 and 4.6.
First, we refer to Bochud et al. (2009) who estimated ﬁbrosis progression rates for both individuals
infected by genotype 1 or genotype 3 HCV from the Swiss Hepatitis C Cohort database. It was reported
a mean ﬁbrosis progression acceleration by 1.39 for genotype 3 HCV infected patients. We also refer
to Thein et al. (2008) who estimated ﬁbrosis progression rates based on a meta-analysis of 111 studies
of chronic HCV infected patients (0.117, 0.085, 0.120 and 0.116 for the progression to F1, F2, F3 and
F4 respectively). As for HIV co-infection, Soto et al. (1997) estimated a mean time interval from HCV
infection to cirrhosis of 23.2 versus 6.9 years for HCV mono-infected patients and HCV/HIV co-infected
patients respectively. Considering the work of Benhamou et al. (1999), an estimation of the median
ﬁbrosis progression rates for HCV/HIV co-infected and HCV mono-infected patients resulted to 0.153
and 0.106 respectively. Last, Mohsen et al. (2003) estimated a ﬁbrosis progression acceleration of 1.4 and
an acceleration of advanced ﬁbrosis (stages 3 and 4) development of 3 for co-infected patients. Based on
those results, we assume that HIV co-infection contributes to the acceleration of ﬁbrosis progression by
a mean factor of 2 for the progression to F1 and F2 and by a mean factor of 2.6 for the progression to F3
and F4.
Considering the progression rates from cirrhosis to decompensated cirrhosis, McGarry et al. (2012)
used the value of 0.03 for their economic model and Re et al. (2014) reported a risk for decompensation
of 9.5 events per 1000 person-years vs 5.7 events per 1000 person-years for HCV/HIV co-infected and
HCV mono-infected patients respectively, i.e a relative risk of 1.67. As the majority of patients were
infected by genotype 1 HCV, we assume no signiﬁcant impact of genotype 3 infection on the incidence
of decompensated cirrhosis.
As for the proportion of HCV-infected patients who develop HCC, Lok et al. (2009) reported a
proportion of 4.9% among a population of 1,005 patients. Moreover, they estimated a cumulative 5-year
HCC incidence of 4.1% and 7.0% for patients with bridging ﬁbrosis (F3) and for patients with cirrhosis
(F4) respectively. These results give an annual progression rate of 0.84% and 1.45% for patients in ﬁbrosis
stage F3 and F4 respectively. As 93% of patients were infected by genotype 1, no impact on HCC incidence
had been measured. However, Nkontchou et al. (2011) and Kanwal et al. (2014) estimated a hazard ratio
of 3.54 and 1.80 for the impact of genotype 3 infection on the development of HCC respectively. Based on
this, we choose a mean rate of HCC progression acceleration of 2.67. Considering progression to HCC in
co-infected patients, only scarce data was available, however Kramer et al. (2015) estimated an incidence
rate 1.48 times higher among HIV-positive patients than among HIV-negative patients.
Let us consider the progression rate from decompensated cirrhosis to HCC. In their economic model,
McGarry et al. (2012) reported an annual rate of 0.079. As data on the impact of HIV is not available,
we assume an incidence rate of HCC 1.48 times higher as above (0.1169).
As for the spontaneous clearance, we refer to Micallef et al. (2006) and Hernandez and Sherman
(2011) who respectively reported rates of 26% and 10% for HCV mono-infected and HIV/HCV co-infected
individuals. No association between viral clearance and HCV genotype has been highlighted. However,
results were contradictory. Indeed, Lehmann et al. (2004) demonstrated a better spontaneous clearance
for genotype 3 HCV infected individuals while Grebely et al. (2014) demonstrated better viral clearance
for genotype 1 HCV infected individuals. In the following, we assume that there is no signiﬁcant impact
of genotype 3 on the clearance.
For the mortality rate related to decompensated cirrhosis, Pineda et al. (2005) estimated a median sur-
vival time for HCV/HIV co-infected and HCV mono-infected patients of 16 and 48 months, respectively.
Hence, one can compute the annual mortality rates:(
1 − 0.5(12/16)
)
= 0.4054 and
(
1 − 0.5(12/48)
)
= 0.1591. (4.13)
HCV genotype was not associated with survival of decompensated cirrhosis. Considering the mortality
rate related to HCC, Lewin et al. (2015) estimated a median survival time for HCV/HIV co-infected
and HCV mono-infected patients of 17.2 and 54.7 months, respectively. From (4.13), we obtain the fol-
lowing annual mortality rates 0.3834 and 0.1411 respectively. No information was available for genotype 3.
We now focus on the diﬀerent values of the treatment-related and transplantation-related parameters.
First, by referring to the economic model of McGarry et al. (2012), the values of 0.0310 and 0.1033 were
chosen for the annual transition rates of liver transplant initiation. Considering the mortality after liver
88
Chapter 4. Network model for the propagation of hepatitis C virus in France
transplantation, Terrault et al. (2012) reported a 3-year survival rate of 60% for HCV/HIV co-infected
patients and 79% for HCV mono-infected respectively. From (4.13), we easily deduce a mortality rate
of 0.1566 for HCV/HIV co-infected patients and 0.0756 for HCV mono-infected respectively. As no
information on genotype 3 is available, we assume that the mortality rate is higher for genotype 3 HCV
infected patients by a factor of 1.39 which corresponds to the mean ﬁbrosis progression acceleration factor
(see Section 4.5.1.2).
As for the SVR rates, Wyles et al. (2015) estimated those rates for HCV/HIV co-infected patients in
each ﬁbrosis stage. Based on a Daclatasvir + Sofosbuvir therapy during 12 weeks, SVR rates obtained
were 93.8%, 100%, 100%, 96.6% and 97.5% for patients in ﬁbrosis stage F0, F1, F2, F3 and F4 respectively.
Since it has been established that HIV co-infection has no statistically signiﬁcant impact on treatment
eﬀectiveness (odds ratio 1.07) (see Highleyman (2016)), we assume the exact same SVR rates for HCV
mono-infected patients. For patients in decompensated cirrhosis, Pol et al. (2016) reported a SVR rate
of 86% for an indication of Ledipasvir + Sofosbuvir during 12 weeks in genotype 1 and 4 HCV infected
patients.
Next, considering patients infected by genotype 3 HCV, we refer to Hézode (2016) who reported SVR
rates for diﬀerent indications. Indeed, an indication of Sofosbuvir + Daclatasvir during 12 weeks demon-
strated a SVR rate of 95% for patients without cirrhosis, an indication of Sofosbuvir + Daclatasvir +
Ribavirin during 12 weeks demonstrated a SVR rate of 90% for cirrhotic patients and an indication of
Sofosbuvir + Daclatasvir + Ribavirin during 24 weeks demonstrated a SVR rate of 78.5% for patients
with decompensated cirrhosis.
Let us now consider the annual cessation rate. We refer to Angelis et al. (2004) who used the values
5%, 9% and 12% in a back-calculation model of the incidence of opiate use/injecting drug use. Similarly,
Martin et al. (2011) used a cessation rate of 7.75% for their modeling study of the impact of antiviral
therapy on the prevalence of HCV in IDU. Hence, we choose the mean annual cessation rate of 8.44%.
As stated earlier, people leaving the population of IDU because of the cessation rate are tracked via
an alternative model with respect to their compartment (health state) of origin. Indeed, if one leaves the
original model in a given health state, say ﬁbrosis state F2, one will enter the alternative model in that
exact same health state. An illustration of this alternative model for genotype 1 HCV infected individuals
is displayed in Appendix D. Additionally, the annual number of HCV infections occurring in the non-IDU
population is integrated in the alternative model. Since HCV infections occurring in the population of
IDU represent 76.5% of the total number of new infections, the number of HCV infections occurring in
the non-IDU population will be computed such as:
# of HCV infections in
the population of non-IDU =
# of HCV infections in
the population of IDU ×
1 − 0.765
0.765 .
Finally, let us focus on the needle/syringe sharing frequency. Referring to Section 4.4.1, we previously
used the value of 5.33 for our simple HCV compartmental model. In order to give a more precise
estimation of the transmission risk of HCV, we now refer to Vickerman et al. (2007, 2008) where several
values have been estimated for the frequency of needle/syringe sharing in diﬀerent cities in England.
Reported frequencies were 2.85, 5.6 and 16 per month for Teesside, Bristol and London respectively.
However, the majority of PWID in Bristol and Teesside (49.7% and 76.2% respectively) were on opiate
substitution therapy (OST) and PWID on OST tend to lower their frequency of injecting and sharing.
In France, it has been estimated by the OEDT3 that around 50% of PWID were on OST (see Costes
et al. (2010)). Taking this into account, we retained the frequency of needle/syringe sharing observed
in Bristol, i.e 5.6 sharing events per month. To obtain a per-partner sharing frequency, we compute
5.6/3=1.87 where 3 corresponds to the mean number of partners.
Parameters are reported in Table 4.6 and Table 4.4. Table 4.5 gives the sources of the diﬀerent indices
used in Table 4.6. All other parameters were previously reported in Table 4.2. An illustration of the
ﬁnal model, for the particular case of genotype 1, is given in Figure 4.17. Each starred compartment or
rate is the HIV-infected counterpart of the non-starred quantities. For a better clarity, natural mortality,
cessation and initiation rates were not displayed. Full details of the complete set of diﬀerential equations
for the genotype 1 are available in Appendix C. We only focused on genotype 1 in Appendix C since the
diﬀerential equations of genotype 3 admit a similar formulation. the same reason holds for the alternative
model.
3Observatoire européen des drogues et des toxicomanies, the European monitoring centre for drugs & drug addiction.
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Table 4.4: Annual rates used in the model to simulate the spread of HCV
Parameter Notation Value Source
Annual risk of death
HCV mono-infected
With decompensated cirrhosis λh 0.1591 Pineda et al. (2005)
With hepatocellular carcinoma λH 0.1411 Lewin et al. (2015)
HCV/HIV co-infected
With decompensated cirrhosis λh 0.4054 Pineda et al. (2005)
With hepatocellular carcinoma λH 0.3834 Lewin et al. (2015)
Other parameters
Per-partner sharing frequency, per month ω 1.87 Vickerman et al. (2007, 2008)
Cessation of injecting drugs, % – 8.44 Angelis et al. (2004); Martin et al. (2011)
Table 4.5: Sources of the annual rates
Source Index
Bochud et al. (2009) [1]
Thein et al. (2008) [2]
Soto et al. (1997) [3]
Mohsen et al. (2003) [4]
Benhamou et al. (1999) [5]
Nkontchou et al. (2011) [6]
Kanwal et al. (2014) [7]
Lok et al. (2009) [8]
McGarry et al. (2012) [9]
Re et al. (2014) [10]
Kramer et al. (2015) [11]
Wyles et al. (2015) [12]
Hézode (2016) [13]
Pol et al. (2016) [14]
Terrault et al. (2012) [15]
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Table 4.6: Annual rates used in the model to simulate the spread of HCV (by genotype)
Genotype 1 Genotype 3
Parameter Notation Value Notation Value Source
Annual ﬁbrosis progression
HCV mono-infected
From F0 to F1 λ1 0.1170 κ1 0.1626 [1,2]
From F1 to F2 λ2 0.0850 κ2 0.1182 [1,2]
From F2 to F3 λ3 0.1200 κ3 0.1668 [1,2]
From F3 to F4 λ4 0.1160 κ4 0.1612 [1,2]
HCV/HIV co-infected
From F0 to F1 λ∗1 0.2340 κ∗1 0.3252 [1,2,3,4,5]
From F1 to F2 λ∗2 0.1700 κ∗2 0.2364 [1,2,3,4,5]
From F2 to F3 λ∗3 0.3120 κ∗3 0.4337 [1,2,3,4,5]
From F3 to F4 λ∗4 0.3016 κ∗4 0.4191 [1,2,3,4,5]
Annual progression to ESLD
HCV mono-infected
From F3 to HCC λh 0.0084 κh 0.0224 [6,7,8]
From F4 to HCC λH 0.0145 κH 0.0387 [6,7,8]
From F4 to DC λD 0.0300 – – [9]
From DC to HCC λDH 0.0790 – – [9]
From HCC to LT λL 0.1033 – – [9]
From DC to LT λDL 0.0310 – – [9]
HCV/HIV co-infected
From F3 to HCC λ∗h 0.0124 κ∗h 0.0332 [6,7,8,11]
From F4 to HCC λ∗H 0.0215 κ∗H 0.0573 [6,7,8,11]
From F4 to DC λ∗D 0.0501 – – [9,10]
From DC to HCC λ∗DH 0.1169 – – [9,11]
From HCC to LT λ∗L 0.1033 – – [9]
From DC to LT λ∗DL 0.0310 – – [9]
Treatment of HCV†
With ﬁbrosis state F0 ν0 0.9380 νˇ0 0.9500 [12,13]
With ﬁbrosis state F1 ν1 1.0000 νˇ1 0.9500 [12,13]
With ﬁbrosis state F2 ν2 1.0000 νˇ2 0.9500 [12,13]
With ﬁbrosis state F3 ν3 0.9660 νˇ3 0.9500 [12,13]
With ﬁbrosis state F4 ν4 0.9750 νˇ4 0.9000 [12,13]
With DC νD 0.8650 νˇD 0.7850 [13,14]
Mortality after liver transplant
HCV mono-infected λLD 0.0756 κLD 0.1051 [1,15]
HCV/HIV co-infected λ∗LD 0.1566 κ
∗
LD
0.2177 [1,15]
† Rates based on a treatment duration of 12 or 24 weeks. ESLD, end-stage liver disease; S, susceptible; A,
acute HCV infection; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant.
Starred compartments represent HIV infected individuals. Sources are given in Table 4.5.
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4.5.3 Migration crisis
Migrations, and more speciﬁcally human migrations, play a major role in the dissemination of diseases
all over the world. When the host country and the country of origin admit diﬀerent prevalence rates,
migrations ﬂows can interfere with the host country infected population and impact patient care. More-
over, as immigrants tend to be often more vulnerable to exposure to drugs than non-immigrant people
with a similar socio-economic background (see Carballo et al. (2011)), strong immigration ﬂows can have
a direct impact on the spread of HCV.
Currently, European countries are facing a major challenge in welcoming thousands of immigrants
ﬂeeing the Syrian civil war. Indeed, with an estimated prevalence of HCV reaching 1% (see Daw and
Dau (2012)) (with a genotype 3 HCV infection proportion of 1.6% (see Chemaitelly et al. (2015)) for the
Syrian population) and an estimated prevalence of HIV of 0.01% according to the Central Intelligence
Agency, the arrival of Syrian immigrants should be considered in the model with a great attention.
Today, the French government is planning to receive 30,000 immigrants in the next two years from
Syria and the neighboring regions. Thus, we will add 15,000 individuals per year for the ﬁrst two years
in the model distributed into 6 diﬀerent groups depending on their status (uninfected, HCV infected,
HCV/HIV co-infected, etc). Since obtaining reliable data is diﬃcult in the particular case of war refugees,
we will successively assume diﬀerent initiation-to-drugs rates for our simulations. Moreover, as no data
is available on the health state of refugees (ﬁbrosis stage, HCC, etc), we assume that every HCV infected
individual enters the model in stage ﬁbrosis F0. Every migrating individual is considered in the expression
Λk,A(t) of Equation 4.12.
4.5.4 Prevalence of HCV and initial conditions of the model
Let us now consider the proportions of patients infected by HCV and/or HIV in the French IDU popu-
lation. Those proportions will allow us to initiate the model.
As for the proportions of HCV infected patients and of HCV/HIV co-infected patients, we refer to the
French survey Coquelicot on the prevalence of HCV and HIV in the French population of IDU. Indeed,
in 2011 it was estimated that the proportion of HCV infected patients in the French IDU population
was 44% while the proportion of HIV infected patients was 10% (see Jauﬀret-Roustide et al. (2013)). No
indication was available on the proportion of HCV/HIV co-infected patients. However, in 2004, Larsen
et al. (2005) reported a value of 92.8% for the proportion of HCV/HIV co-infected individuals in the
French IDU population. Moreover, in the same French survey Coquelicot (see Jauﬀret-Roustide et al.
(2013)), values were available for the prevalence of HCV and HIV in some urban areas. Those values
are reported in Table 4.7. For all others urban areas, it is assumed a prevalence of HCV of 44% and a
prevalence of HIV of 10%. For the absolute number of PWID in each urban area, we refer to Section 4.4.3.
Table 4.7: HCV and HIV prevalence in IDU population of some urban areas in 2011
Urban area HCV prevalence HIV prevalence
Bordeaux 24% 4%
Lille 28% 0%
Marseille 56% 17%
Paris 44% 10%
Strasbourg 47% 3%
To determine the proportions of the diﬀerent genotypes in the French population, we refer to Laperche
et al. (2012) who reported in 2010 the approximated values 56%, 9%, 25%, 5%, 3% and 2% for genotypes
1, 2, 3, 4, 5, 6 respectively. However, since non-3 genotypes admit relatively similar SVR rates, we decide
to group them and stick to a proportion of non-3 genotype (75%) and a proportion of genotype 3 (25%).
Last, to consider the proportion of individuals in the diﬀerent health states, we refer to Razavi et al.
(2014) who proposed a model for the estimation of the present and future disease burden of HCV in
several countries. The model oﬀered an evolution of the diﬀerent quantities (F0-F4, DC, HCC, LT) from
1950 to 2030. Estimated values obtained for the year 2013 are reported in Table 4.8. As liver transplant
is not considered in our model for IDU, the proportion of individuals in the ’Liver transplant’ state has
been split up to decompensated cirrhosis and HCC according to their relative proportions.
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Thus, the proportion of individuals with decompensated cirrhosis used in our model is 0.52 + 0.60 ×
0.52 = 0.832 while the proportion of individuals with HCC used is 0.48+0.60×0.48 = 0.768. Proportions
used in the alternative model are the same as displayed in Table 4.8. Referring to Table 4.8, the total
number of HCV infected patients in the non-IDU population is estimated to 201, 627−112, 116 = 89, 511.
As no data was available for the acute phase of the disease, we assumed that no patient was in acute
phase at the initiation of the model.
Table 4.8: HCV prevalence by health state in France for the year 2013
Health state Number (%)
F0 51,387 (25.49)
F1 71,098 (35.26)
F2 31,586 (15.67)
F3 27,925 (13.85)
F4 16,408 (8.14)
DC 1,053 (0.52)
HCC 967 (0.48)
LT 1,203 (0.60)
Total 201,627 (100)
4.6 Results
The evolution of the HCV prevalence in France is presented in the following ﬁgures for diﬀerent assump-
tions. Those assumptions are directly related to the proportion of teated patients, the sharing frequency
between PWID and the rate of immigration. Each assumption is compared to the base case scenario
which is based on the values introduced in the previous sections, i.e a proportion of treated patients of
5.2%, a sharing frequency of 1.87 per partner per month and a rate of immigration of 15,000 people per
year for two successive years.
First, Figure 4.18 exhibits the evolution of both genotypes 3 and non-3 starting from the year 2013
to the year 2040. One can notice that the evolution of the proportions of both genotypes stay relatively
constant over time. Since genotype 3 tends to be more aggressive than other genotypes, we could have
expected a lower genotype 3 proportion over time due to a higher mortality. However, as 2nd-gen DAAs
admit very high SVR rates whatever the genotype, this could explain the fact that no sustained decline
in terms of proportion is observed.
Next, we focus on the proportion of treated patients in France. Since the proportion of treated
patients in France hardly reaches the value of 5.2%, we made some assumptions on higher proportions
to observe the potential impact of 2nd-gen DAAs on the prevalence of HCV in France. By referring to
Figure 4.19, one can observe that, as expected, the prevalence of HCV decreases with the proportion of
treated patients. Indeed, by assuming a proportion of treated patients of 50%, the prevalence of HCV
decreases below 50,000 infected individuals just in a few years. However, it has to be recalled that since
HCV is an asymptomatic disease, a large proportion of HCV infected individuals are still undiagnosed
and that 50% of treated patients might be unrealistic for now.
In Figure 4.20, we propose to study the impact of sharing frequencies in the IDU population. Indeed,
as sharing frequencies are directly related to the transmission of the virus, being able to limit the frequency
of syringe/needle sharing could have a positive impact on the total prevalence of HCV in France. Since
we calculated the number of transmissions occurring outside of the IDU population based on the number
of transmissions occurring in the IDU population (see Section 4.5.2), we made a modiﬁcation as follows:
# of HCV infections in
the population of non-IDU =
# of HCV infections in
the population of IDU ×
1 − 0.765/sf
0.765/sf
where sf is the sharing frequency reduction. With this modiﬁcation the reduction of sharing frequency
does not impact the number of new infections occurring outside the IDU population. One can observe on
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Figure 4.20 that the evolution of the prevalence slightly declines when the sharing frequency decreases.
This impact might not be as strong as the impact of 2nd-gen DAAs but the sharing frequency only aﬀect
the number of new infections and not the current prevalence.
Last, we study the potential eﬀect of immigration on the prevalence of HCV. By referring to Fig-
ure 4.21, one can see that immigration has a limited impact on the HCV prevalence and that immigration
rates have to last for several years to be signiﬁcant. However, those immigration rates are based on gov-
ernmental sources which do not reﬂect the the numbers of the clandestine immigration. Hence, despite
of the results exhibited by Figure 4.21, one can expect a greater impact of immigration on the HCV
prevalence.
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Figure 4.18: Mean evolution of the HCV prevalence in France by genotype.
The diﬀerent curves represent the mean quantities over 100 simulations. The blue area represents the
evolution of the prevalence of non-3 genotype while the orange area represents the evolution of the
prevalence of genotype 3.
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Figure 4.19: Mean evolution of the HCV prevalence in France for diﬀerent proportion of
treated patients.
The diﬀerent curves represent the mean quantities over 100 simulations. The blue curve represents the
base case with a proportion of treated patients of q = 5.2%. The three other curves (in green, red and
pink) represent the evolution of the prevalence of HCV in France for three diﬀerent values of q (10%, 30%
and 50% respectively).
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Figure 4.20: Mean evolution of the HCV prevalence in France for diﬀerent sharing frequen-
cies.
The diﬀerent curves represent the mean quantities over 100 simulations. The blue curve represents the
base case with a sharing frequency of 1.87× 12 per partner per month. The three other curves (in green,
red and pink) represent the evolution of the prevalence of HCV in France for a frequency reduced by
50%, 80% and 90% respectively.
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Figure 4.21: Mean evolution of the HCV prevalence in France for diﬀerent immigration
rates.
The diﬀerent curves represent the mean quantities over 100 simulations. The blue curve represents the
base case with 15,000 people immigrating in France each year for two successive years. The four other
curves (in green, red, pink and light blue) represent the evolution of the prevalence of HCV in France with
15,000 people immigrating in France each year for four, six, eight and ten successive years respectively.
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4.7 Discussion
In this chapter, we have introduced two compartmental models of the propagation of HCV in France to
estimate the impact of the new 2nd-gen DAAs on the size of the infected population. The ﬁrst part of the
chapter was meant to develop a simple compartmental model of the propagation of HCV on a network
of networks representing PWID populations in distinct but interconnected urban areas (metapopulation
model). The second part was entirely dedicated to the development of a more complex model taking into
account more in-depth mechanisms of the infection on the same network of interconnected urban areas.
The simple model allowed us to give a representation of the basic mechanisms of the HCV infection
by considering the heterogeneities of the PWID population. It was applied on a three-city network and
demonstrated, as expected, that the epidemic spread was correlated with the amount of interactions be-
tween the cities in this three-city system. Indeed, it has been showed that the epidemic was growing faster
and stronger when the amount of interactions between cities was high. Then, this model corroborated
this result on a network of 100 interconnected urban areas where two epidemic starting points were set
in two diﬀerent urban areas, mainly diﬀering from each other by the amount of interactions they have
with other urban areas, and where very diﬀerent outcomes in terms of prevalence and propagation speed
were observed.
In the second part of this chapter, we still considered our network of urban areas but largely focused
our attention on developing a much more complex HCV compartmental model. By considering the
diﬀerent ﬁbrosis stages and the main HCV genotypes, this second model was meant to describe at best
the future evolution of the HCV prevalence in France with the arrival on the market of new therapeutics.
Our results have shown that the new 2nd-gen DAAs have a strong impact on the prevalence of HCV
assuming that a suﬃcient number of patients has access to the treatment. Indeed, with the current
proportion of treated patients, the infection will not disappear before several decades. Needle sharing
frequencies and migrations rates seem to have a limited impact on the prevalence.
The main advantages of our approach come from the consideration of heterogeneities in the PWID
population to model the transmission process on the one hand, and on the other, the use of a metapop-
ulation model to model the infectious dynamics at a country scale. Indeed, the use of a metapopluation
model allowed us to divide the general PWID population into several PWID subpopulations in order to
better handle population heterogeneities with a contact network.
However, our approach presents some limitations. First, when dealing with the PWID population,
diﬃculties arise when trying to obtain reliable data. Indeed, whether it be the needle sharing behavior for
the estimation of HCV transmission or the degree of each individual for the establishment of a pertinent
contact network, the lack of data forced us to make strong assumptions. Moreover, no cessation of
treatment was assumed despite the fact that the rate of noncompliance among PWID might be signiﬁcant.
Second, as the number of annual HCV infections was diﬃcult to estimate, the number of HCV infections
occurring outside the PWID population was simply computed as a proportion of the number of HCV
infections occurring in the PWID population. Third, for the sake of simplicity, we only focused on the new
2nd-gen DAAs without considering other treatments. Fourth, as for immigration, more reliable numbers
should be considered.
To conclude, the methodology addressed in this chapter allows for an interesting way to deal with the
spread of an epidemic at a national scale. Moreover, by considering contact networks, one can relieve the
homogeneous mixing assumption and use classic compartmental models with population heterogeneities.
However, our model still needs to be applied on real datasets for validation. The diﬀerent limitations
stated above could be subject to further research.
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The work presented in this doctoral thesis answered to three diﬀerent epidemiology-related problematics
using mathematical modeling. Despite the fact that the main goal of this work was the assessment of the
new therapeutics’ impact on the HCV infected population, we explored several ways in the application of
mathematical models to epidemics. In a series of three papers, we investigated several statistical estima-
tion methods, some back-calculation models for the reconstruction of past incidence and the association
of two dynamic compartmental models on a contact network with a metapopulation model.
In the ﬁrst paper (Chapter 2), we studied diﬀerent statistical estimation technics for two parametric
models (RCS and NHRS). The estimation of the relative bias and the relative standard deviation showed
that the maximum likelihood estimator provided almost always better estimations than the least squares
estimator.
However, in presence of a high amount of censoring, it turned out that the least squares estimator was
performing better. The computation of the mean integrated squared error (MISE) corroborated those
results for both low and high amount of censoring. We ﬁnally applied those estimation methods to two
real datasets of the Code Red v2 worm propagation and of the spread of HIV in France. Considering the
Code Red v2 dataset, the diﬀerent estimation methods gave similar results for the RCS model. As for the
NHRS model, results were more contrasted with a fairly poor ﬁt for the least squares estimator. As for
the HIV dataset, both RCS and NHRS models were not suitable to this dataset since the results were not
as good as they were for the Code Red v2 dataset. Estimation methods studied in this part turned out
to be very eﬃcient tools to deal with the estimation of epidemic models parameters and could be applied
to much wider problems such as models of the propagation of communicable diseases in populations to
support health care decision makers.
However, some issues are still to be addressed. Indeed, the development of statistical methods to
assess whether the model is in line with the nature of the studied data should be considered. Moreover,
one could ﬁnd of interest to theoretically study the asymptotic properties of the diﬀerent estimators.
In the second paper (Chapter 3), in order to estimate the past incidence of HCV, we compared several
back-calculation methods based on either the maximum likelihood method (logistic and exponentially
modiﬁed Gaussian models) or the EMS algorithm with the approach of reference in France which is
based on the weighted least squares method.
Similar trends were exhibited on the evolution of incidence and prevalence of HCV for the diﬀerent
models and results were consistent with the prevalence estimation reported by INVS for the year 2004. In
particular, the method based on the EMS algorithm oﬀered better performances in terms of mean squared
error compared with the other methods and allowed us to reduce the bias induced by an arbitrary choice
of a given parametric model. This latter advantage was precisely highlighted by the poor performances
exhibited by the parametric models (particularly the logistic model). Moreover, by assuming that the
random variables Xij (the unobserved number of people infected in year i who died of HCC in year j)
were realizations of independent Poisson variables, we were able to easily compute a conﬁdence interval
for our results thanks to the bootstrap method. However, our approach has some limitations. Indeed,
due to the long term progression of HCV, our approach is not able to provide reliable estimation for
the recent HCV incidence. Regarding the population, only sex was consider as a covariate while other
covariates such as age or alcohol consumption should be considered. Last, no treatment was considered
in this study.
As for further research, our recommendations would be to focus on the points raised in the limita-
tions and to obtain more reliable date even if a large work was undertaken about this aspect in this study.
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In the last paper (Chapter 4), we focused our attention on two compartmental models of HCV
propagation and on a metapopulation model representing the network of the 100 largest French urban
areas. The main objective was to estimate the impact of new anti-HCV therapeutics by focusing on the
PWID population and its role in the spread of the infection.
Hence, a two-level network was built to deal with the interactions between the urban areas on the
one hand, and on the other, to model the interactions between individuals inside each sub-population
(urban area). Then, the two compartmental models were applied on these sub-populations. The ﬁrst
compartmental model, the simplest one, was mainly set as an example to test the suitability of the
metapopulation model to deal with the spread of an epidemic at a country scale. Numerical simulations
exhibited sensible stylized facts in terms of the extent and speed of propagation of an epidemic in France.
The second compartmental model presented more in-depth features related to the infection such as
ﬁbrosis, cirrhosis or genotype. Our main results showed that the new 2nd-gen DAAs had a signiﬁcant
impact on the prevalence of HCV even if a greater proportion of patients should be treated in order
to achieve an eradication of HCV in France in the future decades. The main advantage of our work
is the fact that it presents an easy way to deal with social and spatial heterogeneities. Moreover, we
built an advanced model of HCV propagation which considers several essential components of the disease
mechanisms. However, with more advanced models comes more complexity and more assumptions.
Indeed, by focusing on such a marginal population (PWID), some data were not available and numerous
assumptions had to be made. Mathematically, we witnessed a general increase of the complexity as each
new compartment leads to a new diﬀerential equation. Moreover, as no data was available to validate the
model on such a country scale, it makes sense to remain cautious about the interpretation of the results.
Last, we did not consider any treatments other than the new 2nd-gen DAAs in our models.
To conclude, the methodology addressed in this chapter allows for an interesting way to deal with the
spread of an epidemic at a national scale. However, our model still needs to be applied on real datasets
for validation. The diﬀerent limitations stated above could be subject to further research.
Français
Le travail présenté dans cette thèse de doctorat répond à trois problématiques épidémiologiques dif-
férentes, toutes liées à la modélisation mathématique. Bien que l’objectif principal de cette thèse soit
d’évaluer l’impact des nouvelles thérapeutiques anti-VHC sur la population infectée, nous avons exploré
plusieurs manières d’utiliser des modèles mathématiques pour l’étude des épidémies. Dans cette série de
trois papiers, nous avons abordé quelques méthodes d’estimation statistique, plusieurs modèles de rétro-
calcul dans le cadre de l’estimation de l’incidence passée d’une maladie et l’association de deux modèles
dynamiques compartimentaux basés sur un réseau de contacts à un modèle de métapopulation.
Dans le premier papier (Chapitre 2), nous avons étudié diﬀérentes méthodes d’estimation statistique
appliquées à deux modèles paramétriques (RCS et NHRS). Les estimations du biais relatif et de l’écart-
type relatif ont montré que l’estimateur du maximum de vraisemblanceprésentait presque toujours de
meilleures estimations que l’estimateur des moindres carrés.
Cependant, en présence d’un grand nombre de données censurées, il s’est avéré que c’est l’estimateur
des moindres carrés qui démontrait de meilleures performances. Le calcul du "mean integrated squared
error (MISE) a d’ailleurs permis de corroborer ces résultats pour diﬀérents niveaux de censure. Enﬁn,
nous avons appliqué ces méthodes d’estimation à deux jeux de données sur la propagation du ver Code
Red v2 et sur la propagation du VIH en France. En ce qui concerne le jeu de données sur le ver Code
Red v2, les diﬀérentes méthodes d’estimation ont donné des résultats similaires pour le modèle RCS.
Pour le modèle NHRS, les résultats ont été plus contrastés puisque l’estimateur des moindres carrés a
démontré de moins bonnes performances. Concernant le jeu de données sur le VIH, les deux modèles RCS
et NHRS se sont révélés peu adaptés puisque les résultats n’étaient clairement pas aussi bons que pour
le jeu de données sur le ver Code Red v2. Les méthodes d’estimation étudiées dans cette partie se sont
avérées être des outils eﬃcaces pour l’estimation des paramètres de modèles épidémiques et pourraient
être appliquées à des problématiques plus larges telles que la propagation d’une épidémie au sein d’une
population aﬁn de venir en aide aux preneurs de décision du milieu de la santé.
Cependant, quelques problèmes nécessitent toujours d’être résolus comme par exemple le dévelop-
pement de méthodes statistiques permettant d’évaluer si le modèle est en adéquation avec les données
étudiées. De plus, d’un point de vue théorique, il pourrait être intéressant de s’intéresser aux propriétés
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asymptotiques des diﬀérents estimateurs.
Dans ce deuxième papier (Chapitre 3), et dans le but d’estimer l’incidence passée du VHC, nous avons
comparé avec l’approche de référence en France, basée sur la méthode des moindres carrés pondérés,
plusieurs méthodes de rétro-calcul basées, d’une part, sur la méthode du maximum de vraisemblance
(modèle logistique et exponentiel gaussien) et, d’autre part, sur l’algorithme EMS.
Des tendances similaires ont été observées pour les diﬀérents modèles en ce qui concerne l’évolution de
l’incidence et de la prévalence du VHC. Les résultats se sont d’ailleurs avérés cohérents avec l’estimation
de la prévalence eﬀectuée par l’INVS pour l’année 2004. En particulier, la méthode basée sur l’algorithme
EMS a démontré de meilleures performances en termes d’erreur des moindres carrés, comparativement
aux autres méthodes. Cette méthode a également permis de réduire le biais inhérent au choix d’un
modèle paramétrique. Ce second avantage a notamment été souligné par les moins bonnes performances
obtenues avec les modèles paramétriques (particulièrement le modèle logistique). De plus, en se basant
sur l’hypothèse selon laquelle les Xij (le nombre non-observé de personnes infectées l’année i qui meurt de
CHC l’année j) étaient des réalisations indépendantes de loi de Poisson, nous avons été facilement capable
de générer des intervalles de conﬁance grâce à la méthode du bootstrap. Cependant, notre approche
présente des limitations. En eﬀet, le VHC étant une maladie à progression lente, notre approche n’est
pas capable de fournir des estimations suﬃsamment précises sur l’incidence récente du VHC. Concernant
la population, seul le sexe a été retenu en tant que covariable alors que d’autres covariables toutes
aussi pertinentes telles que l’âge ou la consommation d’alcool aurait pu l’être également. Enﬁn, aucun
traitement n’a été pris en compte dans ce travail.
Aﬁn de prolonger ces travaux au cours de futures recherches, nos recommandations se focaliseraient
sur les points soulevés plus haut et sur l’obtention de données plus ﬁables même si un grand travail a
déjà été fait dans ce cadre-là au sein de ce papier.
Dans le dernier papier (Chapitre 4), nous avons focalisé notre attention sur deux modèles comparti-
mentaux de propagation du VHC et sur un modèle de métapopulation représentant les 100 plus grandes
aires urbaines françaises. L’objectif principal a été d’estimer l’impact des nouvelles thérapeutiques anti-
VHC en se concentrant sur la population toxicomane et son rôle dans la propagation de l’infection.
Ainsi, un réseau à deux niveaux a été construit pour prendre en compte les interactions entre les aires
urbaines d’une part, et d’autre part, pour modéliser les interactions entre individus au sein de chaque
sous-population (aire urbaine). Puis les deux modèles compartimentaux ont été appliqué sur ces sous-
populations. Le premier modèle compartimental, le plus simple des deux, a principalement été développé
pour tester l’adéquation du modèle de métapopulation à une problématique de type propagation d’une
épidémie à l’échelle d’un pays. Des simulations numériques ont permis de mettre en avant des résultats
tangibles en termes d’ampleur et de vitesse de propagation d’une épidémie en France. Le second modèle
compartimental qui a été développé, s’est principalement axé sur une description plus en profondeur du
VHC prenant en compte les états de ﬁbrose, la cirrhose ou le génotype. Nos principaux résultats ont
montré que les antiviraux à action directe de seconde génération avaient un impact signiﬁcatif sur la
prévalence du VHC même si une proportion plus grande de patients traités serait nécessaire pour éra-
diquer le VHC en France dans les prochaines décennies. Le principal avantage de notre travail est qu’il
constitue une manière simple de modéliser les hétérogénéités sociales et spatiales. De plus, nous avons
construit un modèle de propagation du VHC plus avancé, prenant en compte bien plus de mécanismes
essentiels de la maladie. Cependant, ce modèle plus avancé entraîne un accroissement de la complexité
et du nombre d’hypothèses. En eﬀet, en se focalisant sur une population aussi marginale que la popu-
lation toxicomane, on se retrouve confronté à une quantité de données disponibles limitée nécessitant
de faire de nombreuses hypothèses. Mathématiquement, nous témoignons d’un accroissement général de
la complexité puisque chaque nouveau compartiment conduit à une nouvelle équation diﬀérentielle. De
plus, aucune donnée n’étant disponible pour la validation du modèle à cette échelle, il convient de rester
prudent sur l’interprétation des résultats. Enﬁn, aucun autre traitement n’a été pris en compte dans nos
modèles.
En conclusion, la méthodologie abordée dans ce chapitre permet de modéliser de façon originale la
propagation d’une épidémie à l’échelle d’un pays. Cependant, notre modèle nécessite d’être validé sur
des jeux de données réelles. Enﬁn, les diﬀérentes limitations abordées plus haut peuvent être sujettes à
de futurs travaux de recherche.
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Appendix A. Diﬀerential equations
A Diﬀerential equations
dsk,·(t)
dt = Λ − kβsk,·(t)θk,·(t) − kβ
∗sk,·(t)θ∗k,·(t) − kβ†sk,·(t)θ∗∗k,·(t) − μsk,·(t)
−sk,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
aΦ(t) + cΦ(t) + a∗Φ(t) + c∗Φ(t)
)
+β∗
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
+ β†
(
a∗Φ(t) + c∗Φ(t)
)]
+ pσak,·(t) + γck,·(t),
ds∗k,·(t)
dt = −kβs
∗
k,·(t)θk,·(t) + kβ∗sk,·(t)θ∗k,·(t) + p∗σa∗k,·(t) + γ∗c∗k,·(t) − μ∗s∗k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗sk,·(t)
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
− βs∗k,·(t)
(
aΦ(t) + cΦ(t) + a∗Φ(t) + c∗Φ(t)
)]
,
dak,·(t)
dt = kβsk,·(t)θk,·(t) − (σ + μ)ak,·(t) − kβ
∗ak,·(t)θ∗k,·(t)
+βsk,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
aΦ(t) + cΦ(t) + a∗Φ(t) + c∗Φ(t)
)
,
da∗k,·(t)
dt = kβs
∗
k,·(t)θk,·(t) + kβ†sk,·(t)θ∗∗k,·(t) + kβ∗ak,·(t)θ∗k,·(t) − (σ + μ∗)a∗k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗k,·(t)
(
aΦ(t) + cΦ(t) + a∗Φ(t) + c∗Φ(t)
)
+β∗ak,·(t)
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
+ β†sk,·(t)
(
a∗Φ(t) + c∗Φ(t)
)]
,
dck,·(t)
dt = (1 − p)σak,·(t) − kβ
∗ck,·(t)θ∗k,·(t) − (γ + δ + μ)ck,·(t)
−β∗(ak,·(t) + ck,·(t))
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
,
dc∗k,·(t)
dt = (1 − p
∗)σa∗k,·(t) + kβ∗ck,·(t)θ∗k,·(t) − (γ∗ + δ∗ + μ∗)c∗k,·(t)
+β∗ck,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + a∗Φ(t) + c∗Φ(t)
)
.
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B The main French urban areas
Urban area Population Urban area Population
Paris 12,341,418 Saint-Brieuc 171,721
Lyon 2,214,068 Béziers 165,498
Marseille - Aix-en-Provence 1,727,070 Montbéliard 162,326
Toulouse 1,270,760 Niort 152,721
Lille† 1,166,452 Vannes 150,860
Bordeaux 1,158,431 Chartres 145,735
Nice 1,004,914 Bourges 139,968
Nantes 897,713 Thionville 135,627
Strasbourg† 768,868 Chalon-sur-Saône 133,557
Rennes 690,467 Boulogne-sur-Mer 133,062
Grenoble 679,863 Maubeuge 129,931
Rouen 658,285 Arras 128,784
Toulon 611,237 Colmar 127,625
Montpellier 569,956 Blois 127,053
Douai - Lens 540,981 Calais 126,266
Avignon 515,536 Quimper 125,487
Saint-Etienne 512,830 Beauvais 125,095
Tours 483,744 Bourg-en-Bresse 122,806
Clermont-Ferrand 469,922 Laval 121,399
Nancy 434,479 La Roche-sur-Yon 117,965
Orléans 423,123 Creil 117,654
Angers 403,633 Cherbourg-Octeville 116,517
Caen 403,765 Tarbes 115,557
Metz 389,700 Belfort 114,077
Dijon 377,590 Alès 113,769
Béthune 368,633 Vienne 112,334
Valenciennes† 367,094 Agen 111,663
Le Mans 344,893 Saint-Quentin 111,474
Reims 317,611 Evreux 111,449
Brest 314,844 Roanne 107,209
Perpignan 309,962 Charleville-Mézières 106,835
Amiens 293,671 Montauban 105,654
Genève - Annemasse† 292,180 Cholet 104,917
Le Havre 290,890 Périgueux 102,417
Bayonne† 288,359 Sarrebruck - Forbach† 101,806
Mulhouse 284,739 Nevers 101,586
Limoges 282,971 Brive-la-Gaillarde 101,435
Nîmes 259,348 Ajaccio 100,643
Dunkerque 257,773 Mâcon 99,873
Poitiers 255,831 Carcassonne 97,801
Besançon 246,841 Albi 97,667
Pau 240,857 Compiègne 97,502
Annecy 221,111 Bastia 93,971
Chambéry 217,356 Epinal 93,891
Lorient 215,591 Fréjus 93,562
Saint-Nazaire 213,083 Bâle - Saint-Louis† 93,018
La Rochelle 207,211 Châteauroux 92,723
Troyes 191,505 Auxerre 92,307
Angoulême 180,593 Sète 91,101
Valence 175,636 Cluses 90,872
Table B.1: Population of the French urban areas based on census data for the year 2012.
† Only the French part is considered.
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C Diﬀerential equations - Enhanced model -Genotype 1
dsk,·(t)
dt = Λk,·(t) − kβsk,·(t)θk,·(t) − kβ
∗sk,·(t)θ∗k,·(t) − kβ†sk,·(t)θ∗∗k,·(t)
−sk,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(ak,·(t) + aˇk,·(t))
+λS0f0,k,·(t) + κS0 fˇ0,k,·(t) − (τ + μ)sk,·(t)
ds∗k,·(t)
dt = −kβs
∗
k,·(t)θk,·(t) + kβ∗sk,·(t)θ∗k,·(t) + p∗σ(a∗k,·(t) + aˇ∗k,·(t)) − (τ + μ∗)s∗k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗sk,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λS0f∗0,k,·(t) + κS0 fˇ∗0,k,·(t)
dak,·(t)
dt = kβsk,·(t)θk,·(t) − kβ
∗ak,·(t)θ∗k,·(t) − (σ + τ + μ)ak,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βsk,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗ak,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗k,·(t)
dt = kβs
∗
k,·(t)θk,·(t) + kβ∗ak,·(t)θ∗k,·(t) + kβ†sk,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗ak,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†sk,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
df0,k,·(t)
dt = (1 − p)σak,·(t) − λ1(1 − λS0)f0,k,·(t) − λS0f0,k,·(t) − kβ
∗f0,k,·(t)θ∗k,·(t)
−β∗f0,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)f0,k,·(t)
df∗0,k,·(t)
dt = (1 − p
∗)σa∗k,·(t) − λ∗1(1 − λS0)f∗0,k,·(t) − λS0f∗0,k,·(t) + kβ∗f0,k,·(t)θ∗k,·(t)
+β∗f0,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)f∗0,k,·(t)
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ds1,k,·(t)
dt = −kβs1,k,·(t)θk,·(t) − kβ
∗s1,k,·(t)θ∗k,·(t) − kβ†s1,k,·(t)θ∗∗k,·(t)
−s1,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(a1,k,·(t) + aˇ1,k,·(t))
+λS1f1,k,·(t) + κS1 fˇ1,k,·(t) − (τ + μ)s1,k,·(t)
ds∗1,k,·(t)
dt = −kβs
∗
1,k,·(t)θk,·(t) + kβ∗s1,k,·(t)θ∗k,·(t) + p∗σ(a∗1,k,·(t) + aˇ∗1,k,·(t)) − (τ + μ∗)s∗1,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗s1,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗1,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λS1f∗1,k,·(t) + κS1 fˇ∗1,k,·(t)
da1,k,·(t)
dt = kβs1,k,·(t)θk,·(t) − kβ
∗a1,k,·(t)θ∗k,·(t) − (σ + τ + μ)a1,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs1,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗a1,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗1,k,·(t)
dt = kβs
∗
1,k,·(t)θk,·(t) + kβ∗a1,k,·(t)θ∗k,·(t) + kβ†s1,k,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗1,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗1,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗a1,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†s1,k,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
df1,k,·(t)
dt = (1 − p)σa1,k,·(t) + λ1(1 − λS0)f0,k,·(t) − λ2(1 − λS1)f1,k,·(t) − λS1f1,k,·(t) − kβ
∗f1,k,·(t)θ∗k,·(t)
−β∗f1,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)f1,k,·(t)
df∗1,k,·(t)
dt = (1 − p
∗)σa∗1,k,·(t) + λ∗1(1 − λS0)f∗0,k,·(t) − λ∗2(1 − λS1)f∗1,k,·(t) − λS1f∗1,k,·(t) + kβ∗f1,k,·(t)θ∗k,·(t)
+β∗f1,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)f∗1,k,·(t)
ds2,k,·(t)
dt = −kβs2,k,·(t)θk,·(t) − kβ
∗s2,k,·(t)θ∗k,·(t) − kβ†s2,k,·(t)θ∗∗k,·(t)
−s2,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(a2,k,·(t) + aˇ2,k,·(t))
+λS2f2,k,·(t) + κS2 fˇ2,k,·(t) − (τ + μ)s2,k,·(t)
ds∗2,k,·(t)
dt = −kβs
∗
2,k,·(t)θk,·(t) + kβ∗s2,k,·(t)θ∗k,·(t) + p∗σ(a∗2,k,·(t) + aˇ∗2,k,·(t)) − (τ + μ∗)s∗2,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗s2,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗2,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λS2f∗2,k,·(t) + κS2 fˇ∗2,k,·(t)
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da2,k,·(t)
dt = kβs2,k,·(t)θk,·(t) − kβ
∗a2,k,·(t)θ∗k,·(t) − (σ + τ + μ)a2,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs2,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗a2,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗2,k,·(t)
dt = kβs
∗
2,k,·(t)θk,·(t) + kβ∗a2,k,·(t)θ∗k,·(t) + kβ†s2,k,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗2,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗2,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗a2,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†s2,k,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
df2,k,·(t)
dt = (1 − p)σa2,k,·(t) + λ2(1 − λS1)f1,k,·(t) − λ3(1 − λS2)f2,k,·(t) − λS2f2,k,·(t) − kβ
∗f2,k,·(t)θ∗k,·(t)
−β∗f2,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)f2,k,·(t)
df∗2,k,·(t)
dt = (1 − p
∗)σa∗2,k,·(t) + λ∗2(1 − λS1)f∗1,k,·(t) − λ∗3(1 − λS2)f∗2,k,·(t) − λS2f∗2,k,·(t) + kβ∗f2,k,·(t)θ∗k,·(t)
+β∗f2,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)f∗2,k,·(t)
ds3,k,·(t)
dt = −kβs3,k,·(t)θk,·(t) − kβ
∗s3,k,·(t)θ∗k,·(t) − kβ†s3,k,·(t)θ∗∗k,·(t)
−s3,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(a3,k,·(t) + aˇ3,k,·(t))
+λS3f3,k,·(t) + κS3 fˇ3,k,·(t) − (τ + μ)s3,k,·(t)
ds∗3,k,·(t)
dt = −kβs
∗
3,k,·(t)θk,·(t) + kβ∗s3,k,·(t)θ∗k,·(t) + p∗σ(a∗3,k,·(t) + aˇ∗3,k,·(t)) − (τ + μ∗)s∗3,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗s3,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗3,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λS3f∗3,k,·(t) + κS3 fˇ∗3,k,·(t)
da3,k,·(t)
dt = kβs3,k,·(t)θk,·(t) − kβ
∗a3,k,·(t)θ∗k,·(t) − (σ + τ + μ)a3,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs3,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗a3,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗3,k,·(t)
dt = kβs
∗
3,k,·(t)θk,·(t) + kβ∗a3,k,·(t)θ∗k,·(t) + kβ†s3,k,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗3,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗3,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗a3,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†s3,k,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
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df3,k,·(t)
dt = (1 − p)σa3,k,·(t) + λ3(1 − λS2)f2,k,·(t) − λ4(1 − λS3)f3,k,·(t) − λS3f3,k,·(t) − λh(1 − λS3)f3,k,·(t)
−β∗f3,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)f3,k,·(t) − kβ∗f3,k,·(t)θ∗k,·(t)
df∗3,k,·(t)
dt = (1 − p
∗)σa∗3,k,·(t) + λ∗3(1 − λS2)f∗2,k,·(t) − λ∗4(1 − λS3)f∗3,k,·(t) − λS3f∗3,k,·(t) − λ∗h(1 − λS3)f∗3,k,·(t)
+β∗f3,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)f∗3,k,·(t) + kβ∗f3,k,·(t)θ∗k,·(t)
ds4,k,·(t)
dt = −kβs4,k,·(t)θk,·(t) − kβ
∗s4,k,·(t)θ∗k,·(t) − kβ†s4,k,·(t)θ∗∗k,·(t)
−s4,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(a4,k,·(t) + aˇ4,k,·(t))
+λS4f4,k,·(t) + κS4 fˇ4,k,·(t) − (τ + μ)s4,k,·(t)
ds∗4,k,·(t)
dt = −kβs
∗
4,k,·(t)θk,·(t) + kβ∗s4,k,·(t)θ∗k,·(t) + p∗σ(a∗4,k,·(t) + aˇ∗4,k,·(t)) − (τ + μ∗)s∗4,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗s4,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗4,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λS4f∗4,k,·(t) + κS4 fˇ∗4,k,·(t)
da4,k,·(t)
dt = kβs4,k,·(t)θk,·(t) − kβ
∗a4,k,·(t)θ∗k,·(t) − (σ + τ + μ)a4,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs4,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗a4,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗4,k,·(t)
dt = kβs
∗
4,k,·(t)θk,·(t) + kβ∗a4,k,·(t)θ∗k,·(t) + kβ†s4,k,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗4,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗4,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗a4,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†s4,k,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
df4,k,·(t)
dt = (1 − p)σa4,k,·(t) + λ4(1 − λS3)f3,k,·(t) − λH(1 − λS4)f4,k,·(t) − λS4f4,k,·(t) − λD(1 − λS4)f4,k,·(t)
−β∗f4,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)f4,k,·(t) − kβ∗f4,k,·(t)θ∗k,·(t)
df∗4,k,·(t)
dt = (1 − p
∗)σa∗4,k,·(t) + λ∗4(1 − λS3)f∗3,k,·(t) − λ∗H(1 − λS4)f∗4,k,·(t) − λS4f∗4,k,·(t) − λ∗D(1 − λS4)f∗4,k,·(t)
+β∗f4,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)f∗4,k,·(t) + kβ∗f4,k,·(t)θ∗k,·(t)
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Appendix C. Diﬀerential equations - Enhanced model - Genotype 1
dsD,k,·(t)
dt = −kβsD,k,·(t)θk,·(t) − kβ
∗sD,k,·(t)θ∗k,·(t) − kβ†sD,k,·(t)θ∗∗k,·(t)
−sD,k,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+β∗
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†
(
φ∗Φ(t) + ψ∗Φ(t)
)]
+ pσ(aD,k,·(t) + aˇD,k,·(t))
+λSDdck,·(t) + κSD dˇck,·(t) − (τ + μ)sD,k,·(t)
ds∗D,k,·(t)
dt = −kβs
∗
D,k,·(t)θk,·(t) + kβ∗sD,k,·(t)θ∗k,·(t) + p∗σ(a∗D,k,·(t) + aˇ∗D,k,·(t)) − (τ + μ∗)s∗D,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
β∗sD,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− βs∗D,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)]
+ λSDdc∗k,·(t) + κSD dˇc
∗
k,·(t)
daD,k,·(t)
dt = kβsD,k,·(t)θk,·(t) − kβ
∗aD,k,·(t)θ∗k,·(t) − (σ + τ + μ)aD,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βsD,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
− β∗aD,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)]
da∗D,k,·(t)
dt = kβs
∗
D,k,·(t)θk,·(t) + kβ∗aD,k,·(t)θ∗k,·(t) + kβ†sD,k,·(t)θ∗∗k,·(t) − (σ + τ + μ∗)a∗D,k,·(t)
+
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
[
βs∗D,k,·(t)
(
φΦ(t) + φ∗Φ(t) + ψΦ(t) + ψ∗Φ(t)
)
+ β∗aD,k,·(t)
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
+ β†sD,k,·(t)
(
φ∗Φ(t) + ψ∗Φ(t)
)]
ddck,·(t)
dt = (1 − p)σaD,k,·(t) + λD(1 − λS4)f4,k,·(t) − λDD (1 − λSD )dck,·(t) − λSDdck,·(t) − λDH (1 − λSD )dck,·(t)
−β∗dck,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)dck,·(t) − kβ∗dck,·(t)θ∗k,·(t)
ddc∗k,·(t)
dt = (1 − p
∗)σa∗D,k,·(t) + λ∗D(1 − λS4)f∗4,k,·(t) − λ∗DD (1 − λSD )dc∗k,·(t) − λSDdc∗k,·(t) − λ∗DH (1 − λSD )dc∗k,·(t)
+β∗dck,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)dc∗k,·(t) + kβ∗dck,·(t)θ∗k,·(t)
dhcck,·(t)
dt = λH(1 − λS4)f4,k,·(t) + λDH (1 − λSD )dck,·(t) − λHDhcck,·(t) − kβ
∗hcck,·(t)θ∗k,·(t)
−β∗hcck,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ)hcck,·(t)
dhcc∗k,·(t)
dt = λ
∗
H(1 − λS4)f∗4,k,·(t) + λ∗DH (1 − λSD )dc∗k,·(t) − λ∗HDhcc∗k,·(t) + kβ∗hcck,·(t)θ∗k,·(t)
+β∗hcck,·(t)
∑
Φ
(
τΦ,·
n· +
∑
Φ τΦ,·
)
·
(
s∗Φ(t) + φ∗Φ(t) + ψ∗Φ(t)
)
− (τ + μ∗)hcc∗k,·(t)
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Appendix D. Alternative model
D Alternative model
A F0 F1 F2 F3 F4
· · ·· · ·
A∗ F∗0 F∗1 F∗2 F∗3 F∗4
· · ·· · ·
HCC
HCC∗
DC
DC∗
LT
LT∗
D
Figure D.1: Alternative model of the patients infected by HCV (Genotype 1).
The diﬀerent transmission rates do not appear for the sake of clarity. For full details on the transmission
rates, one can refer to Figure 4.17. A, acute infection; F, stage of the ﬁbrosis; HCC, hepatocellular
carcinoma; DC, decompensated cirrhosis; LT, liver transplant; D, death due to HCV. The subscript i,
for i ∈ {0, 1, 2, 3, 4}, corresponds to the stage of the ﬁbrosis progression. Starred compartments represent
HIV infected individuals.
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